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Abstract  
Norovirus is a leading cause of gastroenteritis worldwide, causing self-limited vomiting 
and diarrhoea in immunocompetent people and chronic infections with significant 
morbidity in immunocompromised patients.  
Data presented in this thesis uses deep sequencing to increase our understanding of 
norovirus in a hospital paediatric population with a large proportion of 
immunocompromised patients.  
Real-time PCR reveals that norovirus is the most prevalent gastrointestinal virus in this 
population, causing infection with a higher viral titre than other gastrointestinal viruses. 
Norovirus is most common in immunocompromised patients and is the virus most 
commonly associated with chronic infections, which occur primarily in 
immunocompromised patients.  
The performance of a novel method for deep sequencing norovirus full genomes is 
described; this overcomes the limitations of previously published methods and 
achieves full genomes with >12000-fold read depth regardless of genotype or viral titre. 
This method is applied to sequence the complete genomes of every new norovirus 
case at Great Ormond Street Hospital (GOSH) over a 19 month period. Full genomes 
reveal a broad range of circulating genotypes, more akin to genotypes circulating in the 
community than those typically seen in hospitals. Phylogenetic analysis shows that the 
majority (69%) of cases are not acquired from another patient. This suggests multiple 
introductions of different norovirus strains, with limited nosocomial transmission. 
Full genome sequencing of longitudinally collected samples shows that chronic 
norovirus infections may involve super- or re-infection with a different genotype, 
although this does not affect the duration of infection.  
Deep sequencing is used to investigate changes in the norovirus intra-host mutation 
frequency in chronically infected immunosuppressed patients who were and were not 
treated with oral ribavirin, revealing a possible role for ribavirin in the treatment of 
chronic norovirus infections. However interpretation of in vivo data is confounded by 
fluctuating mutation frequencies observed over time in all patients. 
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INTRODUCTION 
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 NOROVIRUS BASIC VIROLOGY 1.1
1.1.1  Norovirus history and classification 
Epidemic nonbacterial gastroenteritis was described as “Winter vomiting disease” in 
1929 [1] however an aetiological agent could not be cultivated or identified. In 1972 
immune electron microscopy, which involves the direct observation of antigen-antibody 
complexes, was for the first time used to analyse stool specimens obtained from an 
outbreak of acute gastroenteritis in Norwalk, Ohio (USA) that occurred in 1968. A small 
27-nm particle with distinct surface morphology, including the now characteristic cup-
like depressions on the surface of the virions (Figure 1.1), was identified. This virus was 
determined to be the cause of the outbreak by replicating symptoms in healthy 
volunteers experimentally infected with rectal swab filtrate taken from a patient linked to 
the 1968 outbreak [2]. The aetiological agent was termed Norwalk agent, and later 
Norwalk-like virus; in 2002 the genus was renamed as Norovirus, species  Norwalk 
virus [3]. Norovirus was the first virus to be identified as a cause of diarrhoea. 
 
Noroviruses are a small non-enveloped virus with an icosahedral capsid measuring 27-
40 nm in diameter belonging to the Norovirus genus in the family Caliciviridae. The 
Caliciviridae family comprises five phylogenetically distinct genera; Norovirus, 
Sapovirus, Vesivivirus, Lagovirus and Nebovirus [4]. The major human pathogens in 
this family are the norovirus and sapoviruses; other important pathogens in the family 
are veterinary pathogens, namely feline calicivirus (FCV) in the Vesivirus genus and 
rabbit haemorrhagic disease (RHDV) in the Lagovirus genus. FCV and RHDV cause 
respiratory disease in cats and haemorrhagic disease in rabbits, respectively.  
Figure 1.1 First image of “Norwalk agent” by electron microscopy, 1972. Image reproduced, with 
permission, from Kapikian et al. (1972) 
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1.1.2 Genome and structure 
Noroviruses have a linear, positive-sense single-stranded RNA genome. The 7.5 kb 
genome, first described by Jiang et al. in 1990 and characterised in 1993 [5, 6], 
comprises three open reading frames (ORF) with a polyadenylated 3’ end (Figure 1.2). 
The 5’ end of the genome is covalently attached to a virus-encoded protein, VPg (5’ 
cap), which recruits host cell transcription initiation factors. The un-translated regions 
(UTRs) are typically very short, with 5 and 48 nucleotides at the 5’ and 3’ ends, 
respectively.  
 
 
ORF 1 codes for a non-structural polyprotein which is cleaved post-translation by a 
virus-encoded proteinase (Pro) into six non-structural proteins involved in viral 
replication, including the RNA dependant RNA polymerase (RdRp) [7]. ORFs 2 and 3 
are translated from sub-genomic RNA produced during virus replication; ORF 2 codes 
for the major capsid protein (VP1) and ORF 3 for a minor capsid protein (VP2). The 
role of VP2 is poorly understood, but is most likely involved in capsid assembly and 
genome encapsidation [8]. Murine norovirus is the only norovirus that has a fourth 
ORF, overlapping the 5’ end of ORF 2, which codes for a protein involved in the 
regulation of the innate immune response in mice.  
The RNA-dependent RNA polymerase (RdRp) protein has a “right hand” structure with 
finger, thumb and palm domains. The finger and palm domains, bridged by an N-
terminal domain, form a rigid unit; the thumb domain is flexible, assuming either a 
“closed” or “open” conformation. The C-terminal end of the protein lies within the 
active-site cleft when the polymerase is not bound to a template. The C-terminal tail is 
Figure 1.2 Schematic of norovirus genome, with genotyping regions highlighted. Nucleotide numbering 
is based on a GII.4 genome (p48, replication complex formation; NTPase, NTP binding and hydrolysis of 
NTP; p22, replication complex formation; 5’ cap, viral genome-linked protein (VPg)involved in initiation 
of translation; Pro, cysteine proteinase, poly-protein cleavage; RdRp, RNA dependent RNA polymerase; 
S, shell domain; P1, protruding domain 1; P2, protruding domain 2). 
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displaced from the active site to allow binding of the primer–template RNA duplex and 
thus initiation of RNA synthesis [4]. 
The norovirus capsid consists of the N-terminal shell (S) domain and the protruding (P) 
domain. The S domain surrounds the viral RNA whilst the P domain, linked to the S 
domain through a flexible hinge, is the surface-exposed region of the capsid. The P 
domain has two subdomains, P1 and P2. P2 is the most exposed antigenic site and a 
receptor-binding region; consequently it has the greatest sequence variation. 
The major capsid protein (VP1) can self-assemble into virus-like particles (VLPs) 
without the requirement of RNA or VP2. This allows recombinant VLPs to be expressed 
in baculovirus systems, thus serving as a surrogate for full virions in the absence of a 
cell culture system.  
1.1.3 Nomenclature 
The Norovirus genus is composed of six genogroups (GI to GVI) based on genetic 
relatedness (Figure 1.3); GI and GII, and to a lesser extent GIV, cause infections in 
humans. The remaining genogroups cause diarrhoeal infections in pigs, cows, sheep, 
cats, dogs and rats, and sub-clinical infections in mice [9-15]; however there is no 
evidence of zoonotic transmission of animal noroviruses to humans [16, 17]. Genome 
sequences between the genogroups are highly diverse with, on average, 32-35% 
amino acid differences between genotype capsid sequences [18].  
Figure 1.3 Norovirus nomenclature. Variant types only apply to GII.4 noroviruses 
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Genogroups GI and GII are categorised into 9 and 22 genotypes, respectively (GI.1–
GI.9 and GII.1–GII.22). Due to recombination between genotypes at the ORF1/ORF2 
junction, norovirus has a dual typing system based on the polymerase (ORF1) and 
capsid (ORF2) sequences. Thus a norovirus with a genogroup II, genotype 4 
polymerase and capsid type will be designated GII.P4_GII.4, whereas a recombinant 
sequence with a GII.3 polymerase and a GII.4 capsid type will be designated 
GII.P3_GII.4. Orphan polymerase sequences, which are novel polymerase types that 
have only been seen in combination with established ORF2 genotypes instead of a 
unique ORF2 genotype, are designated a letter such as GII.Pc or GII.Pe, for example 
GII.Pe_GII.4. Despite the occurrence of recombination and the recommendation of a 
dual typing system involving both capsid and polymerase sequences [18], norovirus 
genotyping is routinely often still based on capsid typing alone. 
Diversity among noroviruses is maintained through two principle mechanisms. The first 
is recombination between norovirus genotypes, with a break-point at the ORF1–ORF2 
junction [19, 20]. The second, which is responsible for within-genotype diversity, is the 
accumulation of point mutations associated with error-prone replication by the RNA-
dependent RNA polymerase, which lacks a proof-reading mechanism [21]. The error-
prone template copying by RNA polymerase can lead to point mutations, either silent or 
resulting in amino acid substitutions, which in turn can lead to genotype diversity, 
antigenic variation and immune escape [22]. 
1.1.4 Norovirus biology 
Understanding of the norovirus life cycle has been limited due to the inability to culture 
human norovirus in vitro [23]. In 2014, Jones et al. published the first report of 
successful cultivation of human norovirus in a B cell line [24] however this was not 
replicated by other laboratories [25] therefore the challenge remained.  
Based on clinical features, the primary site of human norovirus infection and replication 
is assumed to be the small intestine; however cell types infected by norovirus are not 
defined. A failure to cultivate norovirus in transformed epithelial cell lines [23, 26-30] 
and a failure to observe viral particles in enterocytes from intestinal biopsies from 
infected volunteers [31, 32] suggested enterocytes were not the primary site of 
norovirus infection and replication. However, histopathological analysis of intestinal 
biopsies from chronically infected immunocompromised patients demonstrated the 
presence of structural and non-structural viral proteins in duodenal and jejunal 
enterocytes [33], suggesting enterocytes may be a permissive cell type for human 
norovirus replication after all, perhaps necessitating a primary culture system derived 
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from intestinal cells. The reason why norovirus was not originally detected in the 
enterocytes of infected volunteers [31, 32] is unclear; it may be due to differences in 
the primary site of replication between acute and chronically infected patients. However 
the original studies were conducted in 1973 and 1975 using electron microscopy, 
whereas the study reporting norovirus proteins in the enterocytes of a chronically 
infected patient [33] was conducted in 2016 using antigen-specific immunofluorescence 
to detect viral proteins. Therefore it is plausible that the discrepancy in the studies’ 
results is attributable to differences in the sensitivity of the detection methods 
employed, rather than differences in the site of replication.  
In 2016 Ettayebi et al. successfully cultured human norovirus in an intestinal primary 
culture system, known as human intestinal enteroids (HIEs) [34]. HIEs are generated 
from stem cells isolated from intestinal crypts in human intestinal tissues. They are 
multicellular, differentiated, non-transformed physiologically active cultures that 
recapitulate the natural intestinal epithelium. HIEs contain multiple intestinal epithelial 
cells; namely enterocytes, goblet, enteroendocrine and Paneth cells. They exist as 
either three dimensional or monolayer cultures. Ettayebi et al. successfully infected HIE 
monolayers with human norovirus GII.4, resulting in a 2.5 log increase in viral copies, 
cytopathic effect (CPE) with cell rounding and destruction of the monolayer and 
progeny virus that could be passaged. The authors demonstrated that despite cultures 
containing multiple cells types only enterocytes were infected, leading to the 
suggestion that enterocytes are the likely primary site of replication in vivo. HIEs were 
also successfully infected with GII.3, GII.17 and GI.I norovirus strains, however with 
lower levels of replication. Replication of non-GII.4 strains required the addition of bile, 
which was essential for virus adsorption. The active component in bile has not yet been 
characterised, however it is expected to be non-proteinaceous as heat or trypsin 
treatment did not alter its activity.  
Noroviruses are known to recognize and interact with human blood group antigens 
(HBGAs) [35], which are carbohydrate epitopes present on the surface of red blood 
cells, mucosal epithelia or as free antigens in biological fluids such as saliva and 
intestinal contents [36]. The human population can be divided into two broad groups; 
“secretors” and “non-secretors”. An estimated 70-80% of the human population are 
considered “secretors” [37], in whom fucosyltransferase 2 (FUT2) gene expression 
controls the expression of HBGA on mucosal epithelium, including in the gut. In the 
remaining 20–30%, referred to as “non-secretors”, FUT2 expression is inactivated by a 
single nucleotide polymorphism (SNP), therefore there is no HBGA expression on the 
intestinal epithelium. Challenge studies have demonstrated that FUT2 non-secretors 
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are inherently resistant to infection with GI.1 and GII.4 noroviruses [38-40], which is 
backed up by epidemiological studies in which infection with GII.4 noroviruses is only 
observed in secretors [41]. However non-secretor status is not protective against non-
GII.4 norovirus infections [42, 43]; this extends to in vitro infection, for which Ettayebi et 
al. demonstrated that whilst GII.4 norovirus cannot infect HIEs generated from non-
secretors, GII.3 infected HIEs from secretor and non-secretors. It is already known that 
the specific HBGAs to which norovirus binds varies with genotype, with epidemic GII.4 
noroviruses binding A, B and O antigens [44], however the full extent to which secretor 
or non-secretor status protects against infection with different genotypes is not known.  
HBGAs, as well as being expressed in human hosts, are expressed by certain bacteria 
[45-47]. Jones et al. reported that in vitro infection of a B cell line was only enabled by 
the addition of enteric bacteria expressing HBGA [24]; as such norovirus infection of 
the cell line could only be achieved from unfiltered stool that contained bacteria or with 
the addition of synthetic H-type HBGA. The role of enteric bacteria was further 
confirmed  in vivo in murine infections, which demonstrated reduced norovirus titres in 
mice treated with antibiotics to deplete their intestinal microbiota [48]. These data 
suggests the role of HBGA binding, rather than direct viral attachment to the intestinal 
wall, may be to attach to enteric bacteria which stimulates infection of permissive cells 
[49]. However in Ettayebi et al.’s HIE primary culture system, infection was achieved 
using norovirus positive stool filtrates, which do not contain HBGA-expressing bacteria 
[34]. Therefore the precise role of HBGA, enteric bacteria and co-factors for norovirus 
infection remain incompletely defined. 
Prior to the recent advances in human norovirus culture, the only norovirus that could 
be cultured in vitro was murine norovirus. Consequently the mouse model has been 
used to study norovirus biology and host responses to infection. However murine 
norovirus infection in immunocompetent mice causes a sub-clinical persistent infection 
without diarrhoea therefore is not truly representative of human norovirus infections.  
In the absence of an in vitro culture system, some human norovirus replication studies 
have been possible through the use of replicon bearing cells. RNA transcripts are 
derived from plasmid DNA containing a full length norovirus genome; these transcripts 
are then transfected into a stable cell line, creating replicon-bearing cells. Replicon-
bearing cells can maintain the RNA after multiple passages and express norovirus 
proteins, with the exception of the capsid structural protein VP1 [50].  
Replication in RNA viruses is characteristically error-prone, caused by a lack of proof-
reading mechanisms that result in limited replication fidelity. Consequently intra-host 
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viral populations exist as a quasispecies, with a degree of sequence heterogeneity 
within a host [51]. In immunocompetent individuals, the norovirus intra-host viral 
population is relatively homogeneous. Conversely, in immunodeficient individuals with 
chronic infection the intra-host viral population is highly heterogeneous, with no single 
dominant strain (Figure 1.4) [52]. The high diversity in these patients has led to the 
suggestion they may be a reservoir for the emergence of novel viral variants [52, 53]. 
Figure 1.4 Comparison of the intra-host distributions of norovirus variants in immunocompetent and 
immunocompromised subjects, determined by deep sequencing ORF2 (figure reproduced, with 
permission, from Bull et al. 2012 [52]). Each unique variant is represented by alternate grey shading; 
number on x-axis indicates day of sampling. Low-frequency variants (<2%) are indicated by black dotted 
lines. For the immunocompetent subject (Ac), only two variants were detected, with frequencies of 79% 
and 20%, respectively. These variants remained stable over the 9 days of infection. For the 
immunocompromised subject (Ch), no dominant variant was observed. Instead, a distribution of low-
frequency variants coexisted, and their prevalence varied over the course of the infection. 
 
1.1.5 Immunology 
Since norovirus infections in immunocompetent people typically resolve within days, 
the innate immune response is predicted to play a critical role in controlling infection. 
Nevertheless there is evidence to suggest that the adaptive and cell-mediated immune 
response also contributes to control of infection, including neutralizing antibodies, 
CD4+ T cells and CD8+ T cells [49]. The role of T cells in the control of infection has 
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been demonstrated in both animal models and human case reports, in which norovirus 
clearance in immunocompromised patients is associated with immune reconstitution 
and T cell recovery [54, 55]. Furthermore, in volunteer studies that involved oral 
immunization with recombinant virus-like particles (VLPs) the VLPs elicited a virus-
specific T-helper type 1 (Th-1)-dominated cell-mediated response [56]. 
Norovirus infection elicits mucosal and serum antibody responses, which in mouse 
models are protective against secondary norovirus infections [57, 58]. Furthermore, in 
human infections norovirus-specific mucosal and serum IgA correlates with protection 
[38, 59]. However, early human volunteer studies did not demonstrate cross-protective 
or long term protective immunity following infection [40, 60]. Infected volunteers were 
resistant to re-infection 6–14 weeks after the initial challenge, but only if re-challenged 
with the same genotype [61]. Two explanations are offered for the observed lack of 
protection. First, noroviruses are genetically diverse, with weak to no cross-protective 
immunity across genotypes. Second, protective immune responses are short-lived. 
Estimates from mathematical modelling suggest immunity to human norovirus lasts 4–9 
years [62], however a study showed that whilst volunteers were protected against 
homologous re-infection 6 months after initial exposure, immunity had waned by two 
years [60].  
 NOROVIRUS INFECTIONS 1.2
1.2.1 Clinical presentation  
Norovirus transmission occurs via the faecal-oral or vomit-oral route, either directly 
person-person (88% of 5036 outbreaks in Europe, 2001–2006), via faecally 
contaminated food or food contaminated by infected food handlers (10%) or 
contaminated water (1.5%) [63]. Transmission can also occur indirectly via 
contaminated surfaces or fomites [64]. Norovirus has a low infectious dose, estimated 
at only 18 virus particles [65]. 
Following a 12-36 hour incubation period, norovirus infections are typically associated 
with an acute onset, projectile vomiting lasting less than a day and watery diarrhoea 
lasting two to three days. In immunocompetent people infections are generally self-
limiting with limited morbidity besides dehydration.  
Virus shedding persists after resolution of symptoms; on average norovirus is detected 
in stool for up to 22.1 days in infants under one year old and 14.5 days (range 2–34) in 
immunocompetent adults and children over one year of age [66]. In the absence of an 
in vitro culture system or animal model for human norovirus, it is not known whether 
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virus shed following the resolution of symptoms is viable and therefore infectious. 
Although transmission is typically caused by symptomatic, rather than asymptomatic 
patients [67], there is no direct evidence to suggest asymptomatically shed virus is non-
infectious. It is possible that limited transmission following the resolution of symptoms 
is due to reduced faecal contamination of the environment in the absence of diarrhoea, 
as opposed to shed virus being non-viable; evidence of infectivity is required to confirm 
this.  
The pathological basis of diarrhoea in norovirus infections is not well understood, 
however infections are associated with broadening and blunting of villi and transient 
malabsorption of D-xylose, fat and lactose. The cause of diarrhoea is postulated to be 
an alteration of secretory and/or absorptive processes, rather than structural damage of 
the intestinal wall [49]. Typically there is only moderate intestinal inflammation, 
although severe infections may be associated with higher gut inflammation [68]. The 
underlying pathophysiology of vomiting is undefined.  
Based on a single outbreak study, norovirus is suggested to cause post-infectious 
irritable bowel syndrome in 34% of infected patients; however this is transient, having 
resolved by 6 months post-infection [69]. In patients with inflammatory bowel disease, 
norovirus infection can present with bloody diarrhoea [70]. In rare instances, norovirus 
has been reported as the cause of necrotizing enterocolitis of the large and small 
intestine in premature infants [71-73], benign infantile seizures [74, 75] and 
encephalopathy [76, 77].  
In immunocompromised patients, norovirus infection can cause a bi-phasic illness and 
is increasingly recognised as a significant cause of morbidity [78, 79]. The initial acute 
phase exhibits classical symptoms of vomiting and diarrhoea, however a second 
chronic phase may ensue with viral shedding and diarrhoea lasting weeks to years. 
Long-term shedding in immunocompromised patients in the literature ranges from 35-
898 days [66]. The consequence of chronic infection can be dehydration, malnutrition, 
dysfunction of intestinal barrier [80], dramatic weight loss [81] and a requirement for 
nutritional support [54]. Deaths attributed to chronic norovirus infections are rare but 
have been reported in immunocompromised patients [81, 82]. Since norovirus 
clearance in immunocompromised patients is associated with immune reconstitution, 
cautious reduction of immunosuppression in chronically infected solid organ transplant 
patients may contribute to viral clearance, however this risks graft rejection or graft 
versus host disease (GHVD). In the absence of full immune reconstitution there is a 
need for specific antiviral therapy to clear chronic norovirus infections and recover gut 
function.  
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Norovirus can also cause asymptomatic infections, in which viral genomes are 
detected in stool but there are no accompanying gastrointestinal symptoms. The 
overall prevalence of sub-clinical infections in England is estimated to be 12% across 
all age groups, with the greatest burden of asymptomatic  infection falling to under five-
year olds, in whom prevalence exceeds 25% [83]. In a small cohort of children in 
France with inherited immunodeficiencies 11.6% (5/43) of asymptomatic children had 
detectable norovirus in stool, thus were presumed to have sub-clinical infections [84]. 
Asymptomatic patients are less likely than symptomatic patients to transmit norovirus 
to others [67], presumably due to reduced environmental spread in the absence of 
vomiting or diarrhoea. The viral load and duration of norovirus shedding in stool has 
been shown to be comparable in symptomatic and asymptomatic cases [85].  
1.2.2 Diagnosis of infection 
Before the advent of molecular techniques in diagnostic settings, norovirus diagnosis 
relied on electron microscopy of stool. However this lacked both specificity and 
sensitivity; structurally similar gastroenteric viruses, such as Sapovirus also in the 
Caliciviridae family, could be misidentified as norovirus. In addition a tendency for 
norovirus virions to clump together means they are not homogenously distributed in 
stool therefore may be missed. Consequently electron microscopy is no longer widely 
used in diagnostic laboratories.  
Immunochromatographic (ICG) lateral flow tests can provide a rapid result (15 minutes) 
and be performed by persons without technical or laboratory expertise, therefore have 
a potential role in bed-side diagnostics. However, the sensitivity of these tests has 
been shown to be very poor, only 35–52%, and highly genogroup dependent [86]. The 
sensitivity of enzyme immunoassays (EIA) to detect norovirus antigen is also reportedly 
very low (<70%) therefore they are not recommended for diagnosis of norovirus 
infection [87]. 
The gold standard of diagnosis for norovirus and other viral infections in the majority of 
diagnostic laboratories is reverse-transcription real-time PCR (RT-qPCR). Real-time 
PCR uses primers and a fluorescently-labelled probe specifically targeting the virus of 
interest, in this case norovirus. The fluorescent signal emitted by the probe increases 
exponentially with amplification of the target DNA or cDNA (Figure 1.5).
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Figure 1.5 (a) Amplification and (b) fluorescent signal emission in a real-time PCR reaction. F, 
fluorophore; Q, quencher. Separation of the fluorophore and quencher during probe hydrolysis emits a 
fluorescent signal, which is detected during each cycle of PCR 
(a) 
 
(b) 
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The PCR cycle at which the fluorescent signal crosses a pre-defined threshold (set 
above background noise) is known as the Cycle Threshold (Ct); this is the semi-
quantitative value with which we report a positive result (Figure 1.6). High viral loads 
will result in an amplification signal crossing the threshold earlier in the PCR cycles, 
thus an earlier Ct value, and vice-versa. There is a linear relationship between viral 
load and Ct value; a difference in 3 Ct values is equivalent to an approximate 10-fold 
difference in viral load, and a difference in 1 Ct value approximately a two-fold 
difference in viral load. 
Figure 1.6 Positive (detection) and negative (no detection) real-time PCR amplification curves 
 
1.2.3 Control of infection in hospitals 
In the absence of a vaccine or therapeutic options, control of norovirus outbreaks in 
hospital is achieved with strict infection control practices to interrupt transmission, as 
recommended by the Public Health England (PHE) guidance for managing norovirus 
outbreaks in acute and community health and social care settings [88].  
Good hand hygiene should be actively encouraged in patients, staff and visitors. Due to 
a lack of viral envelope, norovirus is resistant to common disinfectants, including 
alcohol-based hand sanitizers [89-92]; therefore hand washing must include soap and 
running water.  
Norovirus can be detected in the majority of vomit samples from infected patients [64] 
and droplets and spray from projectile vomiting can reach a 7.8 m2 area, therefore 
vomiting is likely to be an important mode of norovirus transmission. Given that 
norovirus remains stable in the environment for weeks to months [93], daily 
environmental cleaning with a bleach solution, followed by a terminal clean after patient 
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discharge or after resolution of symptoms, is an important aspect to control and prevent 
the spread of norovirus [94]. The difficulty in eliminating norovirus from the environment 
was demonstrated by Morter  et al., who detected norovirus by PCR in 31% of 
environmental swabs after cleaning bays or wards that had accommodated norovirus 
infected patients; norovirus was detected in the environment surrounding the bedside, 
furniture, toilet and shower room fixtures and fittings as well as notes trolleys, 
keyboards and soap and alcohol dispensers [95].    
Control of norovirus outbreaks is more difficult in hospitals with nightingale-style wards, 
as these are often associated with high patient density, limited hand washing facilities 
and minimal or no barriers between patients. Fewer norovirus outbreaks are observed 
in hospitals with small bays or a high proportion of side-rooms for patient isolation 
compared to those with nightingale-style wards and limited isolation facilities [96]. 
Isolation and cohorting is a major part of norovirus infection control practices; this 
includes exclusion, isolation or cohorting of infected patients and exclusion of infected 
staff for 48 hours after symptom resolution [88]. Exclusion of infected staff members 
can reduce transmission to patients [97], however exclusion can also involve excluding 
new admissions onto wards affected by a norovirus outbreak by closing the ward; in 
2015 PHE reported bay or ward closures in 94% (611/653) of nosocomial outbreaks 
[98]. Closure of affected hospital wards to new patient admissions during a norovirus 
outbreak can be an effective method to limit transmission; most data suggest that ward 
closures are effective in terms of the number of cases and duration of outbreak [94]. In 
Avon, UK, the closure of units within four days resulted in outbreak containment within 
one week, compared to two weeks without rapid unit closure; however this came at a 
cost of £635,000 per 1,000 beds [99]. Owing to the cost and disruption to patient care 
associated with ward closure, UK guidelines are shifting away from ward closure 
recommendations [88]. A recent UK analysis of ward closure cost effectiveness in 
norovirus outbreaks concluded that whilst ward closures are highly likely to avert cases 
of nosocomial infections, it is also highly likely to increase costs to the hospital; there is 
therefore a very low probability that ward closure saves costs. Closing a ward on the 
third day of an outbreak will result in a third fewer subsequent cases and outbreaks but 
is likely to incur a loss of £14,000 [100]. However if a hospital is willing to pay £5,000 to 
avoid an additional nosocomial case then, assuming ≥25% efficacy at preventing 
transmission to other wards, ward closure becomes cost-effective. For ward closure to 
be cost-effective in preventing an outbreak the hospital must be willing to pay £35,000 
and, additionally, the efficacy of the ward closure must exceed 50% [100]. 
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Norovirus vaccination studies for the prevention of norovirus infection are underway 
[101]. Phase I and II norovirus vaccine trials, using non-replicating virus-like particles 
(VLP), have shown promise for the prevention of norovirus infection; the incidence and 
disease severity is significantly reduced in vaccinated compared to placebo groups 
[102, 103]. However re-infection challenges were only within weeks of vaccination, 
therefore the duration of protection is unclear. Moreover, human vaccine studies which 
included a re-infection challenge did not involve a heterologous genotype, therefore 
cross-genotype protection is unknown  [101]. 
1.2.4 Disease burden 
Diarrhoeal disease constitutes the second greatest burden of all infectious diseases in 
respect of disability adjusted life years and deaths worldwide each year, second only to 
lower respiratory infections and preceding HIV [104, 105], causing an estimated four 
episodes of diarrhoea per year in a child under 5 years in Europe [106]. With an 
estimated prevalence of 20% in cases of acute gastroenteritis in developed countries 
[107] norovirus is considered the leading cause of outbreaks of acute gastroenteritis 
[108, 109].  In countries where rotavirus vaccine has been introduced, norovirus is now 
the most common cause of medically-attended gastroenteritis in children [110, 111]. 
The majority of the global population will encounter norovirus before adulthood [4]; in a 
study of Finnish children aged 0–14 years, antibody prevalence against norovirus GII.4 
reached 91.2% after 5 years of age [112].  
The annual cost to the NHS of infectious gastroenteritis from bed days lost and staff 
absences is estimated at £115 million, of which 63% is attributable to norovirus 
outbreaks [99]. The global economic burden of norovirus has recently been estimated 
at US$4.2 billion in direct healthcare costs. However since the majority of infections are 
short and self-limiting without need to present to healthcare services, norovirus 
infections seen in healthcare institutions are only the tip of the iceberg. For every 
norovirus case reported to national surveillance, there are an estimated 147 additional 
cases in the community which are unreported [113]. Consequently the global societal 
costs from norovirus infections, primarily attributed to loss of productivity, are estimated 
at US$60.3 billion per year, with disease in under 5-year olds accounting for the 
biggest portion of economic burden (US$39.8 billion) [114]. 
Diarrhoea is a common complication in transplant recipients, with up to 80% of 
hematopoietic stem cell transplant (HSCT) patients suffering from gastroenteritis [115]. 
There are several possible causes, including conditioning therapy, graft versus host 
disease (GVHD), drugs or an infectious agent. The prevalence of norovirus infection in 
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immunocompromised patients has not been determined; however in case series of 
immunocompromised patients it has been shown to be 17-23% [54, 116-118].  
1.2.5 Norovirus epidemiology 
 Global epidemiology 1.2.5.1
Norovirus causes sporadic cases of gastroenteritis in the community, occurring in 
individuals or small family clusters. Causing an estimated 3 million sporadic cases of 
gastroenteritis annually in the UK [113], it is estimated that for every case of norovirus 
reported to national surveillance there are 147 community cases and 10 general 
practice (GP) consultations [113]. Sporadic community cases of norovirus occur year-
round with no distinct seasonality [119], as is the case for infections in 
immunocompromised hosts [82, 120]. 
In addition to sporadic infections, norovirus is characterised by outbreaks occurring 
each year with a winter-time peak [121] (Figure 1.7); for this reason norovirus is often 
referred to as “winter vomiting disease”. Norovirus outbreaks typically occur in semi-
enclosed settings such as hospitals, long-term care facilities, schools, military bases 
and cruise ships [122].  
Figure 1.7 Seasonal comparison of laboratory reports of norovirus (England and Wales). 2009/2010 and 
2012/2013 are epidemic years with heightened and early seasons, respectively, caused by the 
emergence of novel GII.4 variants. Figure reproduced from PHE national norovirus surveillance report 
available at https://www.gov.uk/government/statistics/norovirus-national-update (accessed 
22/09/2016) 
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Norovirus epidemiology is punctuated by epidemic years, in which there is heightened 
norovirus activity or an increase in cases outside of the typical winter season, as 
observed in 2009/2010 and 2012/2013, respectively, in Figure 1.7. These are caused 
by the emergence and rapid global spread of a novel GII.4 variant, which replaces the 
previously dominant variant. Since 1995 norovirus pandemics have occurred every 2–3 
years, as listed in Table 1.1. The current circulating GII.4 variant worldwide is 
Sydney_2012, which replaced New Orleans_2009 in 2012–2013. 
Table 1.1 Norovirus GII.4 epidemic variants 
 
The emergence of novel GII.4 variants is associated with amino acid residue changes 
in three surface-exposed epitopes of the hyper-variable capsid P2 domain, listed in 
Table 1.2. Changes in these epitopes are predicted to create antibody-escape mutants 
to which the population has little or no cross-protective immunity. The ability of pre-
existing immunity to neutralize the novel virus is limited, resulting in emergence of a 
new pandemic strain [123, 124]. Homologous substitutions at these immunogenic sites 
do not change the properties of virus binding or immunogenicity of the virus epitopes 
[125].  
Table 1.2 Norovirus immunogenic epitopes associated with shifts in GII.4 antigenicity and emergence of 
new epidemic strains. 
Epitope Capsid amino acids involved 
Epitope A [123] 294, 296–298 (Site A)*, 368, 372 
Epitope D [124] 393–395 (Site B)* 
Epitope E [124] 407, 412, 413 
* Site A and Site B initially described by Allen et al. (2008) [125]; superseded by Epitope A and D in later 
publications 
As part of national outbreak control in the UK, Public Health England (PHE) undertakes 
continuous surveillance of norovirus activity via the following means [88]: Calls to the 
Variant Name Year first emerged 
US95_96 1995 
Farmington_Hills_2002 2002 
Asia_2003 2003 
Hunter_2004 2004 
Yerseke_2006a 2006 
Den Haag_2006b 2006 
New Orleans_2009 2009 
Sydney_2012 2012 
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National Health Service (NHS) telephone service, NHS Direct, are monitored as an 
early warning sign; an increase in vomiting in the community can indicate the beginning 
of the norovirus “season” and can give a four week warning of impending norovirus 
pressures on the health service [126]. Voluntary weekly reporting of suspected and 
laboratory-confirmed norovirus hospital outbreaks to PHE via the online Hospital 
Norovirus Outbreak Reporting Tool (http://bioinformatics.phe.org.uk/noroOBK) to 
identify norovirus epidemics in a timely manner. Lastly, surveillance of norovirus 
outbreak strains to identify the emergence of new strains, which is a predictor of the 
impact of outbreaks.  
 Circulating genotypes  1.2.5.2
Since the mid-1990s norovirus outbreaks globally have been dominated by the 
genotype GII.4 [127], implicated in more than 90% of outbreaks [128]. The genotypes 
causing the non-GII.4 proportion of outbreaks vary between season, with GII.2, GII.3, 
GII.6 and GII.7 detected most frequently [129, 130].  
For the first time in almost 20 years, GII.4 has been outcompeted by an emerging 
genotype, GII.17 Kawasaki 2014, in China and Japan [131]. During the winter of 2014–
2015 GII.17 caused 66% of hospitalized norovirus cases in Hong Kong, compared to 
19% caused by GII.4. GII.17 reportedly causes more infections in elderly people, 
causing infection in only 16% of children under five and in 37% of over 65-year olds; in 
contrast to 70% and 11%, respectively, caused by GII.4. GII.17 is reported to be an 
immune-escape variant with a high evolutionary rate (4.4 x10-2 nucleotide substitutions 
per site per year; 10-fold higher than GII.4), which could account for its rapid 
emergence in Asia [132]. It is yet to be seen whether GII.17 will replace GII.4 globally; 
nevertheless early detection of GII.17, facilitated by genotyping, will allow public health 
bodies to prepare for potential heightened norovirus activity in coming seasons.  
GII.4 outbreaks are likely to represent person-person transmission [133]; conversely its 
association with person-borne transmission means that only 10% of foodborne 
outbreaks are associated with GII.4 [134]. GI noroviruses on the other hand are rarely 
detected in hospital settings; associated with only 2% of hospital infections in Denmark 
between 2002 and 2010 [130]. Instead GIs are more frequently detected in, and 
therefore more likely to indicate, foodborne outbreaks [133]. In the USA GI.3, GI.6, 
GI.7, GII.3, GII.6 and GII.12 are two to seven times more likely to be detected in food-
borne rather than person-to-person transmission [135]. 
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Even though only 14% of all norovirus outbreaks globally are foodborne, 37% of 
outbreaks involving mixed genotypes are considered foodborne [134]; a diversity of 
genotypes is likely to indicate contamination at source with sewage [136-138].  
The detection of mixed genotypes in sewage suggests that there is a far greater 
diversity of norovirus genotypes circulating in the community than in hospital settings. 
Community acquired infections (CAIs) which are detected in hospitalised patients show 
a broader range of genotypes than those which are hospital acquired (HAI), with 17% 
compared to 6% non-GII.4 infections, respectively [130]. However CAIs which are 
detected in hospital are not a true reflection of the norovirus genotypes circulating in 
the community as they signify a presentation bias; they do not represent acute sporadic 
infections in patients without co-morbidities. Therefore the true distribution of norovirus 
genotypes in the community is not known.  
 MOLECULAR METHODS 1.3
1.3.1 The clinical application of molecular epidemiology 
To establish transmission events, classical epidemiology relies on linking norovirus 
cases in time and place; i.e. occurring physically near each other (such as the same 
ward) and at a similar time (within the incubation period; up to 2-3 days). Molecular 
epidemiology, on the other hand, compares genomic sequences of the virus, be it 
partial or full genomes, to determine whether they are similar enough to be linked 
cases.  
A full understanding of transmission dynamics is critical for prevention and control of 
norovirus transmission, both in food-borne and healthcare settings. Classical 
epidemiology, which links cases in time and place, is important in identifying outbreaks 
and, based on circumstantial evidence, may give an indication of the source of 
transmission. Nevertheless circumstantial evidence may incorrectly link cases or, 
conversely, not identify transmission between cases that are not traditionally linked in 
time or place. The implication of these scenarios is potential miss-allocation of infection 
control resources in the former or unrecognised transmission, potentially leading to a 
wider outbreak, in the latter.  
Knowledge of the viral genome in the context of transmission and outbreaks, termed 
molecular epidemiology, may provide an evidence base for outbreak investigations, 
and thus the implementation of interventions. Classical genotyping techniques provide 
useful information, in particular to identify the genotypes causing infection, however the 
technique is time-consuming and only provides a snapshot of information; in particular 
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genotyping is of limited use when a predominant genotype is in circulation, as is the 
case with norovirus GII.4 globally. Full genome sequences, on the other hand, provide 
us with greater resolution; in addition to the known regions of interest used in 
conventional genotyping, such as the RNA polymerase and capsid sequences, full 
genomes allow us to identify recombination events and to analyse minority variants in 
the intra-host viral population. The data generated from full genome sequencing has 
the potential to unequivocally include or exclude cases from an outbreak and, 
especially in food-borne point source outbreaks, confirm the source of infection.  
Norovirus is best known for causing large outbreaks in enclosed settings such as 
schools, cruise ships, healthcare and military facilities; these are usually caused by a 
point-source contamination and/or person-to-person transmission. However foodborne 
outbreaks can sometimes affect several towns, states or countries. In the case of multi-
region food-borne outbreaks caused by the same contaminated food-stuff, cases may 
not be recognized as part of a wider outbreak using classical epidemiology alone.  
In instances where foodborne outbreaks are dominated by a single, rare, genotype, 
genotyping can be used to link cases across geographical regions. For instance a peak 
in norovirus cases in Denmark over a three month period in 2010/2011 was initially 
attributed to six independent outbreaks. However genotyping using partial polymerase 
and capsid sequences across these outbreaks revealed a shared genotype, 
GI.Pb_GI.6, which was also detected in a batch of imported frozen raspberries; thus 
linking the outbreaks and implicating the raspberries as the common source [139]. 
In a healthcare setting, molecular epidemiology allows us to compare viral genome 
sequences between cases, thus excluding cases from an outbreak or linking previously 
unrecognised transmission events. The application of molecular epidemiology to 
elucidate nosocomial transmission was elegantly demonstrated in a Dutch hospital, in 
which the comparison of capsid P2 sequences from patients infected with norovirus 
revealed that outpatients, who visit the hospital for short appointments therefore were 
assumed to have infections from the community, were shown in fact to be linked to 
outbreaks within the hospital. This consequently allowed targeting of infection control 
practices in outpatient departments, which were previously not recognised as a risk for 
nosocomial transmission [140]. 
1.3.2 Sequencing methods: Capillary and deep sequencing 
Capillary (Sanger) sequencing uses chain-terminating ddNTPs followed by capillary 
electrophoresis to produce a single consensus sequence from a PCR amplicon. Mixed 
sequences cannot be resolved (Figure 1.8).  
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Conversely deep sequencing, also known as next generation sequencing (NGS), 
generates a single sequence from each fragment of DNA present in the sequencing 
library. This means mixed sequences can be resolved. Read depth refers to the 
number of sequencing reads at each position, be it across a genome or PCR amplicon. 
Whilst Sanger sequencing effectively has a read depth of one (i.e. the consensus 
sequence only), deep sequencing can have up to several thousand reads per position. 
A consensus sequence can be derived from deep sequencing reads by determining the 
nucleotide that is present in the majority of reads at that position. Conversely a minority 
variant is a nucleotide that is present in a minority of reads at that position (Figure 1.8).  
Figure 1.8 Schematic demonstrating the difference between capillary (Sanger) and deep sequencing 
 
1.3.3 Norovirus genotyping  
Conventional genotyping for norovirus is based on PCR amplification and capillary 
sequencing of 330–650 nt fragments of the norovirus polymerase or capsid genes, as 
illustrated in Figure 1.2 on page 33. Capsid genotyping is achieved by PCR 
amplification of the shell domain using genogroup-specific primers. The broad-range 
nature of these primers, necessary due to sequence variation between genotypes, 
results in limited sensitivity therefore a nested PCR approach is often required. 
Following capillary sequencing of the capsid shell domain amplicon, the genotype is 
determined by reconstructing a phylogeny of the unknown sequence with reference 
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sequences of known genotypes. The genotype is assigned based on clustering with a 
known reference with bootstrap support >70 [18]. The same PCR and phylogeny 
approach is taken for polymerase typing. Both analyses can be done using the web-
based Norovirus Genotyping Tool [141], which is a publically available online repository 
of norovirus sequences, to which one submits the polymerase and/or capsid 
consensus sequence of an unknown sample, which automatically re-constructs a 
phylogeny for each and reports the genotype.   
Once the capsid genotype is determined, genotype-specific primers are used to amplify 
the variable P2 region. Universal GI and GII primers to amplify P2 have been reported 
[138], negating the need for different primer sets to amplify each of the 31 known 
norovirus GI and GII genotypes; these broad-range primers can successfully amplify 
the P2 region of several genotypes however with only a 71% success rate. 
Consequently a separate primer set for each genotype is common. The draw-back of 
this approach is that multiple primer sets are required (31 for all genotypes), the 
genotype must be known and, even so, primer mismatches due to sequence diversity 
within genotypes may still cause the PCR to fail. 
Once sequenced, the P2 region can be used in two ways. First, to determine the 
variant type in GII.4 sequences using the online Norovirus Genotyping tool. Similarly to 
the polymerase and shell domain sequences, the P2 sequence from a GII.4 norovirus 
can be compared to known reference sequences in a phylogeny to determine the GII.4 
variant type, for example Sydney_2012 or New Orleans_2009. 
Second, the sequence identity of the P2 region (approx. 430 nt) from samples of 
interest can be compared and used in phylogenetic analysis to determine if several 
norovirus episodes are linked. This can be useful in an immunocompetent population in 
whom linked episodes are expected to have identical P2 regions [138, 142, 143], but of 
limited use in immunocompromised populations in whom there is extensive intra-host 
diversity [52] and therefore P2 regions may not be identical between linked episodes 
[144]. In the context of an immunocompromised population full genome sequences 
may provide added resolution and thus be more informative to recognise transmission. 
1.3.4 Utility of whole genome sequencing 
Traditional polymerase and capsid genotyping by PCR and additional sequencing of 
the P2 region for outbreak investigations is a labour intensive process requiring several 
rounds of PCR and sequencing, each requiring genogroup or genotype specific 
primers, which only yields partial genome sequences at the end.  Moreover whilst the 
P2 domain can identify linked outbreak events with 64–73% specificity (assuming 
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bootstrap support >70 or <70, respectively), the full capsid sequence can identify linked 
outbreak events with 100% specificity [145] thus is more informative.  
Whole genome sequencing simplifies investigation of norovirus molecular epidemiology 
by generating all the regions of interest in one step, thus allowing identification of the 
genotype, variant type, and full capsid sequence; negating the need for sequential PCR 
and sequencing reactions.  
By increasing the sequence data available, whole genome sequencing for molecular 
epidemiology has the potential to increase our understanding of the transmission 
dynamics of norovirus. This can be applied to develop evidence-based interventions 
and target infection control practices; thus minimising transmission and reducing the 
burden of norovirus disease. 
 Full genomes reveal inter- and intra-genotype recombination 1.3.4.1
Whole genome sequencing generates a full capsid sequence but, crucially, also the full 
ORF 1 sequence. This is important because recombination between norovirus 
genomes occurs with a breakpoint in or near the ORF1/ORF2 overlap region [19, 20] 
therefore to get a full picture of norovirus epidemiology both ORF1 and ORF2 must be 
analysed, which is facilitated by whole genome sequencing. Recombination is 
particularly important in the emergence of new GII.4 variants. It has been proposed that 
inter- and intra-genotype recombination is likely to be an important force in driving the 
evolution and emergence of novel GII.4 variants, by affecting the antigenic properties 
of a variant (via acquisition of a different ORF2/3 sequence) or by altering the balance 
of replication and mutation rates, thus increasing viral fitness (via acquisition of a 
different ORF1).  All of the GII.4 variants since Farmington Hills_2002 have been 
influenced by recombination, either as the parent of a new recombinant or as a 
recombinant itself; the current dominant variant GII.Pe_GII.4 Sydney_2012 is a 
recombinant of Osaka_2007 (ORF1) and Apeldoorn_2008 (ORF 2/3) [146]. 
The utility of whole genome sequencing to identify recombinant strains was 
demonstrated by Wong et al. [147] who sequenced 32 stool samples from patients 
infected with norovirus GII.4 in England during the 2012/2013 winter season, achieving 
full genome sequences in 23 of the 32 samples. The winter season of 2012/2013 saw 
the GII.4 variant Sydney_2012 replace the previously circulating variant New 
Orleans_2009; Wong and colleagues used full genome sequences to identify two stool 
samples with New Orleans_2009/Sydney_2012 recombinant sequences, suggesting 
that during co-circulation of the two variants co-infection and recombination had 
occurred. Wong et al. identified the recombination breakpoint in the ORF1/ORF2 
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overlap region, which confirms the breakpoint previously identified using partial 
genome sequences by Bull et al [19].  
Detection of recombination is important for local epidemiology, as well as global. An 
outbreak investigation that utilises capsid sequences alone will not identify recombinant 
sequences; patients infected with recombinant virus will be miss-identified as belonging 
to one transmission cluster, when in fact they are linked to more than one. 
 Intra-host minority variants suggest direction of transmission 1.3.4.2
One additional utility of generating full genome sequences using deep sequencing 
methods is that it allows analysis of minority variants. 
RNA viruses lack proof-reading enzymes, resulting in a high mutation frequency of 10−3 
to 10−5 substitution per nucleotide per replication cycle [21, 51]. Intra-host viral 
populations consequently exist as a heterogeneous population with a consensus 
sequence and minority variant sequences, known as quasispecies. During a norovirus 
transmission event between an infected donor and an uninfected recipient, only some 
of those variants will establish a new infection in the recipient [52]. By comparing the 
consensus sequence and minority variants between two linked patients, it may be 
possible to infer the direction of transmission (i.e. which is the donor and which is the 
recipient) by demonstrating that minority variant sequences in one patient (the donor) 
are seen as the consensus sequence in the other patient (the recipient), as illustrated 
in Figure 1.9. Full genomes are required for this kind of analysis as the minority variant 
sites can be spread across the genome [148]. 
Whilst molecular data can be highly suggestive of transmission, including the direction 
of transmission [148], it cannot unequivocally prove direct transmission between two 
individuals since an unidentified intermediary may be involved in the transmission 
chain. Moreover one should not exclude the possibility that two individuals in whom the 
molecular evidence is suggestive of transmission may have independently acquired 
infections with similar, but not directly linked, norovirus strains.  
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Figure 1.9 Illustration of norovirus minority variant analysis and transmission dynamics. A minority 
variant from Patient A (orange) is transmitted to Patient B, in whom an infection is established. Deep 
sequencing of the quasi-species in each patient shows that the nucleotide sequence corresponding to 
the minority variant in Patient A is seen as the majority (consensus) sequence in Patient B 
 
 
 Estimates of norovirus evolutionary rate using full genomes 1.3.4.3
The largest number of norovirus whole genome sequences generated to date in a 
single study has allowed estimations of norovirus evolutionary rates [149]. More than 
100 whole genome sequences (n=112) from stool samples collected in Vietnam 
between 2009 and 2011 suggest the evolutionary rate across the whole genome is 
5.34 – 6.15 x10-3 substitutions per site per year, which supports previous estimates 
generated using partial genome sequences. Analysis of full genomes showed that ORF 
1, encoding a non-structural polyprotein including RNA-dependent RNA polymerase, 
exhibited a lower evolutionary rate than the major capsid protein encoding ORF 2. 
Moreover for the first time the evolutionary rate was calculated for ORF3, which is a 
minor capsid protein with poorly understood function; it was demonstrated that ORF 3 
was the region with the highest evolutionary rate across the genome (7.38–8.99 x10-3 
substitutions per site per year), although this difference was not statistically significant 
due to overlapping 95% confidence intervals. The authors propose ORF 3 could 
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therefore be a possible site of virus-host interaction under selective pressure. Without 
full genome sequences this would remain unrecognised. Additionally, whole genome 
sequencing of several genotypes in this study suggests similar evolutionary rates in 
GII.3 and GII.4 sequences. Infections with GII.4 are far more prevalent than GII.3; it 
has previously been suggested that this could be due to a higher evolutionary rate in 
GII.4 viruses [150]. A similar evolutionary rate in the two genotypes suggests the 
difference in prevalence could instead be a sampling bias caused by infections with 
GII.4 genotypes presenting more frequently to healthcare facilities, although there is 
currently not any genotyping data available from community cohorts to corroborate this.   
 
 AIMS AND OBJECTIVES 1.4
The primary aim of this thesis is to assess the utility of norovirus next generation 
sequencing in clinical practice, in the context of an immunocompromised paediatric 
population. This will be achieved via the following objectives. 
Objective 1: Determine the burden of norovirus infection in the study population, in 
the context of other gastrointestinal viral infections (Chapter 3) 
Objective 2:  Evaluate the performance of a novel method for sequencing norovirus 
full genomes, namely target enrichment using SureSelect [Agilent] 
(Chapter 4) 
Objective 3: Use norovirus full genome sequencing to investigate the molecular 
epidemiology of norovirus in a nosocomial paediatric population 
(Chapter 5) 
Objective 4: Use deep sequencing to evaluate the efficacy of a broad spectrum 
antiviral, Ribavirin, in the treatment of chronic norovirus infections 
(Chapter 6)
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  CHAPTER 2
 
GENERAL MATERIALS AND METHODS  
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 GREAT ORMOND STREET HOSPITAL FOR CHILDREN 2.1
(STUDY POPULATION) 
Great Ormond Street Hospital (GOSH) is a tertiary referral paediatric hospital in central 
London, UK, that receives over 268,000 patient visits per year. GOSH has 350 beds, 
60% of which are in isolation. Most of the children seen at the hospital are referred 
from other hospitals throughout the UK and overseas. There is no accident and 
emergency department therefore acute gastroenteritis is not the primary reason for 
admission. 
The hospital has more than 50 clinical specialties with a focus on highly specialist 
services, including those that involve patients with primary and secondary 
immunodeficiencies.   
GOSH is one of the largest centres for bone marrow transplant (BMT) for severe 
immunodeficiency worldwide and the largest paediatric/adolescent oncology centre in 
Europe, treating approximately 450 haematology/oncology patients each year.  
Each year GOSH performs over 100 hematopoietic stem cell transplants (HSCT), 
primarily for patients from oncology, haematology and immunology clinical specialties. 
In addition GOSH is a renal, cardiac and lung transplant centre. 
 ROUTINE DIAGNOSTIC TESTING FOR 2.2
GASTROINTESTINAL VIRUSES 
As part of the infection control screening policy at GOSH, all children are tested for 
gastrointestinal viruses on admission for inpatient stay, regardless of whether they are 
symptomatic or asymptomatic. Stool samples are tested by real-time PCR for the 
presence of norovirus, adenovirus, rotavirus sapovirus and astrovirus. Patients with a 
positive stool virus are followed up weekly until they become negative, however, 
patients with underlying immunodeficiency are tested weekly and thereafter at 
outpatient appointments irrespective of whether they have previously been positive for 
a stool virus.  Any child who develops gastrointestinal symptoms during their inpatient 
stay or in outpatients is also tested. Before 2010 stools were tested for the presence of 
viruses by electron microscopy. Since 2010 stools are tested by reverse transcription 
real-time PCR. 
Norovirus infections detected less than 48 hours after admission to hospital are 
considered positive on admission (POA); detection more than two days after admission 
is considered a hospital acquired infection (HAI). Since many of the patients at GOSH 
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have complex medical histories many of them have previously been admitted to local 
hospitals or had several outpatient visits prior to admission at GOSH; therefore earlier 
acquisition of infection in another healthcare facility cannot be excluded. 
Norovirus infections detected for longer than one month are considered chronic 
infections; less than one month are considered acute.  
 INFECTION CONTROL POLICY AT GOSH 2.3
At GOSH there is an Infection Prevention and Control (IPC) team who are responsible 
for coordinating the surveillance, investigation and prevention of infection in patients, 
staff and visitors. This team is led by the director of infection prevention and control 
(DIPC), typically a clinician, and additionally includes three IPC nurses and one IPC 
Clinical Scientist. 
On a daily basis the IPC team are informed by the diagnostic Virology laboratory of all 
new episodes of norovirus detected by real-time PCR. The IPC team reviews these 
results daily for any evidence of cross infection. In addition the IPC team are informed 
by ward staff of any patients with diarrhoea and/or vomiting. An outbreak of 
gastroenteritis is suspected of occurring when an epidemiologically linked group of 
patients, staff or visitors develop symptoms associated with gastroenteritis or an 
indistinguishable organism, such as norovirus, is detected from them. 
Once an outbreak is suspected an incident report is completed and an outbreak control 
group may be formed to coordinate actions. Any symptomatic staff are excluded from 
duty, leave the hospital and do not return until they are asymptomatic for 48 hours. 
Patients who are either symptomatic or have norovirus detected in stool are isolated if 
they are not already and if there is a room available. The decision to close units or 
wards or to restrict admissions is based on the risk to the patient population and the 
number of isolation facilities available. 
 RNA EXTRACTION FROM STOOL 2.4
A pea-sized amount of stool was mixed with 1 ml stool lysis buffer (Qiagen Buffer ASL), 
vortexed, and centrifuged for 5 minutes at 13,000 rpm to pellet cellular debris. The 
clarified stool suspension was used for RNA extraction. 
RNA was extracted from 200 µl of the clarified stool suspension using the Qiagen EZ1 
virus mini kit or Qiasymphony DSP Virus/Pathogen kit with a 90 µl elution volume. All 
purified RNA was stored at −80°C prior to cDNA synthesis. 
60 
 
 REAL-TIME PCR 2.5
Real-time PCR reactions for norovirus, rotavirus, astrovirus and sapovirus consisted of 
10 µl RNA, primers and probes as per Table 2.1, 12.5 µl Qiagen Quantifast RT PCR 
mastermix, 0.25 µl RT enzyme and water to make a total volume of 25 µl. One-Step 
PCR cycling consisted of 50 oC for 20 minutes (cDNA synthesis) and 95 oC for 5 
minutes (RT enzyme inactivation and activation of hot-start Taq polymerase), followed 
by 45 cycles of 95 oC for 15 seconds (denaturation) and 60 oC for 30 seconds (primer 
annealing and template extension). Real-time PCR reactions for adenovirus consisted 
of 10 µl DNA, primers and probe as per Table 2.1, 12.5 µl Qiagen Quantifast PCR 
mastermix and water to make a total volume of 25 µl. Cycling consisted of 95 oC for 5 
minutes followed by 45 cycles of 95 oC for 30 seconds and 60oC for 30 seconds. All 
PCR targets have a single copy in the genome. A positive and negative template 
control was included in every PCR run to ensure the reliability of results.  
The real-time PCR assay to detect norovirus GI and GII was developed by me shortly 
before the commencement of the work contributing to this thesis. The assay validation 
methods are described in section 2.5.1 on page 64 and a summary of the results are 
shown in section 3.3.1 on page 87. 
The real-time PCR assays to detect rotavirus, adenovirus, sapovirus and astrovirus 
were previously developed by the GOSH Virology Department. These assays, and the 
norovirus assay described above, are routinely used by the GOSH virology department 
for the diagnosis of gastrointestinal infections. The ongoing performance of each real-
time PCR assay is monitored by the GOSH Virology diagnostic laboratory through 
regular Internal Quality Assurance (IQA), annual External Quality Assurance (EQA) 
and daily monitoring of positive control Ct values (with strict acceptability criteria) to 
ensure they remain fit for purpose.  
IQA consists of blindly re-submitting specimens for diagnosis of infection to ensure the 
obtained results are reproducible. EQA consists of a commercially distributed panel of 
specimens containing target pathogens to ensure each pathogen is correctly identified, 
with no cross-reactivity, false positive or false negative results.  
The real-time PCR assays for detection of gastrointestinal viruses described here meet 
the quality and competence requirements for accreditation to the internationally 
recognised standard ISO:15189 (Medical Laboratory Accreditation), as assessed by 
the United Kingdom Accreditation Service (UKAS). 
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Table 2.1 Primer and probe sequences used for PCR assays 
Assay name 
[Reference] 
Primer/probe 
name [Reference] 
Oligonucleotide sequence 
Final 
conc. 
(µM) 
Target and amplicon size  
Lower limit of 
detection* (and 
assay validation**) 
Norovirus real-time 
RT-PCR  
COG-1F [151] 
COG-1R [151] 
RING-1a [151] 
RING-1b [151] 
QNIF2 [152] 
COG-2R [151] 
QNIFS [152] 
CGYTGGATGCGNTTYCATGA 
CTTAGACGCCATCATCATTYAC 
FAM-AGATYGCGATCYCCTGTCCA-BHQ1 
FAM-AGATCGCGGTCTCCTGTCCA-BHQ1 
ATGTTCAGRTGGATGAGRTTCTCWGA 
TCGACGCCATCTTCATTCACA 
Cy5-AGCACGTGGGAGGGCGATCG-BHQ2 
 
0.8 
0.8 
0.2 
0.1 
0.8 
0.8 
0.2 
ORF1/ORF2 junction, 86–89 nt GI: 5 copies/µl 
GII: 1 copy/µl 
(this study) 
Rotavirus real-time 
RT-PCR [153] 
Rota-F  
Rota-R  
Rota-Pr 
ACCATCTWCACRTRACCCTCTATGAG 
GGTCACATAACGCCCCTATAGC 
FAM-AGTTAAAAGCTAACACTGTCAAA-MGB 
1 
1 
0.5 
NSP3, 87 nt 5 copies/µl 
(GOSH Virology 
department) 
Sapovirus real-
time RT-PCR [154] 
SaV-F1  
SaV-F2  
SaV-F3  
SaV-R  
SaV-Pr1  
SaV-Pr2  
GAYCASGCTCTCGCYACCTAC 
TTGGCCCTCGCCACCTAC 
TTTGAACAAGCTGTGGCATGCTAC 
CCCTCCATYTCAAACACTA 
FAM-CCRCCTATRAACCA-MGB 
FAM-TGCCACCAATGTACCA-MGB 
 
 
0.4 
0.4 
0.4 
0.4 
0.2 
0.2 
ORF1/ORF2 junction, 103 nt 3 copies/µl 
(GOSH Virology 
department) 
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Assay name 
[Reference] 
Primer/probe 
name [Reference] 
Oligonucleotide sequence 
Final 
conc. 
(µM) 
Target and amplicon size  
Lower limit of 
detection* (and 
assay validation**) 
Astrovirus real-
time RT-PCR [155] 
Astro-F  
Astro-R  
Astro-Pr  
TCAACGTGTCCGTAAMATTGTCA 
GCWGGTTTTGGTCCTGTGA 
VIC-CAACTCAGGAAACARG-MGB 
0.8 
0.8 
0.5 
Capsid, 66 nt 1 copy/µl 
(GOSH Virology 
department) 
Adenovirus real-
time PCR 
AdenoUCL-F 
AdenoUCL-R 
AdenoUCL-Pr 
GCCACSGTGGGGTTTCTAAACTT 
GCCCCAGTGGKCTTACATGCACATC 
FAM-TGCACCAGACCCGGRCTCAGGTACTCCGA-BHQ1 
0.6 
0.6 
0.4 
Hexon gene, 132 nt 0.2 copies/µl 
(GOSH Virology 
department) 
Norovirus GI first 
round Genotyping 
PCR [129, 143]  
GIFF-1 
GIFF-2 
GIFF-3 
GISKR 
ATHGAACGYCAAATYTTCTGGAC 
ATHGAAAGACAAATCTACTGGAC 
ATHGARAGRCARCTNTGGTGGAC 
CCAACCCARCCATTRTACA 
0.5 
0.5 
0.5 
0.5 
Capsid shell domain, 597 nt (This study) 
Norovirus GI 
second round 
Genotyping PCR 
(semi-nested) [129, 
143] 
GIFFN 
GISKR 
GGAGATCGCAATCTCCTGCCC 
as above 
0.5 Capsid shell domain, 364 nt (This study) 
Norovirus GII first 
round Genotyping 
PCR [129, 143] 
GIIFB-1 
GIIFB-2 
GIIFB-3 
GIISKR 
GGHCCMBMDTTYTACAGCAA 
GGHCCMBMDTTYTACAAGAA 
GGHCCMBMDTTYTACARNAA 
CCRCCNGCATRHCCRTTRTACAT 
0.5 
0.5 
0.5 
0.5 
Capsid shell domain, 468 nt (This study) 
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Assay name 
[Reference] 
Primer/probe 
name [Reference] 
Oligonucleotide sequence 
Final 
conc. 
(µM) 
Target and amplicon size  
Lower limit of 
detection* (and 
assay validation**) 
Norovirus GII 
second round 
Genotyping PCR 
(semi-nested) [129, 
143] 
GIIFBN 
GIISKR 
TGGGAGGGCGATCGCAATCT 
as above 
0.5 Capsid shell domain, 343 nt (This study) 
NS7 PCR g2-4F4404 [156] 
g2-4R5115 [156]   
TCCTCAGAACCACATTTGGCTCAGGTAGTCGCAGAAG 
ACGAGGTTGGCTGTGGACCCATCAGATG 
 
0.2–0.5 
0.2–0.5 
RNA polymerase,  739 nt (This study) 
VP1 PCR g2-4F5686 [156] 
g2-4R6515 [156] 
ATGATGTCTTCACAGTCTCTTGTCG 
ACCCTACCTGTGTCTGGATTCACAAATC 
 
0.2–0.5 
0.2–0.5 
Major capsid protein, 857 nt (This study) 
Primers for reverse 
transcription 
UNP1-163 † 
UNP1-253 † 
UNP1-82 [149] 
UNP1-135 [149] 
UNP1-44 [149] 
UNP1-100 [149] 
CAGCCGTGTGGACTCCAA 
GGGTGGCACATATGACAGTGTT 
GACCTCTGGGACGAGGTTG 
CTCCACCAGGGGCTTGTAC 
GCACGGTTGAGACTGTGC 
GCCAGTCCAGGAGTCCAA 
0.03 
0.03 
0.03 
0.03 
0.03 
0.03 
n/a (This study) 
n/a, not applicable 
* For real-time PCR assays only 
** assay validation refers to assay design using published primer sequences, optimisation and validation of performance characterisation 
† unpublished; personal communication Paul Kellam (Sanger Institute) 
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2.5.1 Validation of performance characteristics for norovirus real-time 
PCR (RT-qPCR) 
The in silico specificity of the norovirus GI and GII primers and probes was verified by 
submitting each of the primer and probe sequences to NCBI nucleotide BLAST 
(https://www.ncbi.nlm.nih.gov/BLAST) to compare the primer and probe sequences to 
all sequences in the Genbank database. 
To determine specificity of the multiplex norovirus real-time PCR assay, targeting GI 
and GII, the assay was tested with stool samples known to be positive for rotavirus, 
adenovirus, astrovirus and sapovirus (one stool per pathogen).  
To determine the limit of detection, the RT-qPCR assay was tested on a ten-fold 
dilution series of plasmid containing the PCR target sequence. A separate plasmid was 
constructed for the GI and GII targets. Each plasmid was tested from 1–1x106 
copies/µl. Plasmids were prepared by cloning using the TOPO TA Cloning kit with 
chemically competent Escherichia coli cells [Invitrogen] and quantified by Nanodrop 
Spectrophotometer. 
To assess the sensitivity of the real-time assay, five GII, four GI and one GIV positive 
stool samples, supplied by Quality Control for Molecular Diagnostics (QCMD), were 
tested using the norovirus real-time assay. QCMD is an external quality assessment 
(EQA) programme used to monitor and improve the performance of diagnostic assays. 
The samples in each QCMD panel are designed to resemble clinically significant 
specimens. 
To test the reproducibility of the norovirus RT-qPCR and the relationship between Ct 
values and viral load, a ten-fold dilution series of norovirus GII plasmid from 3 to 3x106 
copies/µl was tested on four separate days.  
2.5.2 Viral load 
A 10-fold dilution series of the plasmid DNA containing the PCR target sequence, from 
3 to 3x106 copies/µl, was run in parallel to extracted stool samples to construct a 
standard curve. The viral load in copies/µl is determined by comparing the Ct value of 
the tested sample to the standard curve, as illustrated in Figure 2.1. 
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Figure 2.1 Viral load calculation using real-time PCR 
 
 PREPARATION OF cDNA  2.6
2.6.1 For gel-based capsid genotyping PCR (Chapter 3) 
cDNA was prepared using random primers and SuperScript III reverse transcriptase 
enzyme (Invitrogen). Briefly, reactions consisted of 18.5 ng/µl random primers, 0.77 µM 
each dNTP, 5 µl RNA and water to make volume up to 13 µl. Reactions were heated to 
65 oC for 5 minutes then cooled on ice. To each reaction 4 µl first-strand buffer and 1 µl 
each of 0.1M DTT, SuperScript III (Invitrogen) and RNase OUT (Invitrogen) was added. 
Reactions were incubated at 25 oC for 5 minutes, 50 oC for 1 hour and 70 oC for 15 
minutes. 0.6 µl RNase H (New England Biolabs) was added to each reaction prior to a 
final incubation of 37 oC and 65 oC for 20 minutes each to remove residual RNA. 
2.6.2 For SureSelect target enrichment and deep sequencing (Chapter 4) 
RNA extracts (90 µl) were concentrated to 11 µl using a vacuum centrifuge at 65oC 
prior to first strand cDNA synthesis. First strand cDNA was synthesised using random 
primers and SuperScript III (SS III, Life Technologies) as per manufacturer’s 
instructions. Briefly, 1 µl of 10mM (each) dNTP mix and 1 µl of 3 µg/ml random primers 
were incubated with 11 µl RNA for five minutes at 65 °C to anneal primers to RNA 
template, followed by incubation on ice for 1 minute. RNA–primer templates were 
mixed with 4 µl 5x first strand buffer, 1 µl 0.1M DTT, 1 µl RNase OUT and 1 µl SS III at 
25 °C for 5 minutes followed by cDNA synthesis at 50 °C for 1 hour and enzyme 
inactivation at 70 °C for 15 minutes. Second strand cDNA was synthesised using 
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Second Strand cDNA Synthesis kit (NEB) as per manufacturer’s instruction. Briefly, 20 
µl first strand cDNA was incubated with 48 µl water, 8 µl 10x 2nd strand buffer and 4 µl 
2nd strand enzyme mix at 16 °C for 2.5 hours. Double stranded cDNA was purified and 
concentrated with Genomic DNA Clean and Concentrator (Zymo Research), as per 
manufacturer’s instructions, with a 30 µl elution volume and quantified with Qubit 
dsDNA high sensitivity (HS) kit (Invitrogen). 
2.6.3 For gel-based NS7 and VP1 PCR (Chapter 6) 
cDNA was prepared using universal norovirus GII.4 primers (UNP1, Table 2.1) and 
SuperScript III reverse transcriptase enzyme (Invitrogen). Briefly, reactions consisted of 
0.03 µM each primer, 0.77 µM each dNTP,  20 µl RNA and water to make volume up to 
65 µl. Reactions were heated to 65 oC for 5 minutes then cooled on ice. To each 
reaction 20 µl first-strand buffer and 5 µl each of 0.1M DTT, SuperScript III (Invitrogen) 
and RNase OUT (Invitrogen) was added. Reactions were incubated at 25 oC for 5 
minutes, 50 oC for 1 hour and 70 oC for 15 minutes. 3 µl RNase H (New England 
Biolabs) was added to each reaction prior to a final incubation of 37 oC and 65 oC for 
20 minutes each. 
 GEL-BASED PCR 2.7
2.7.1 PCR for capsid genotyping (Chapter 3) 
A 468–597 nt fragment of the capsid shell domain was amplified by PCR using primers 
detailed in Table 2.1. Briefly, reactions consisted of 5 µl cDNA, 0.5 µM each primer, 2.5 
µl Accuprime Buffer I (Invitrogen), 0.5 µl Accuprime Taq polymerase and water to make 
volume to 20 µl. Denaturation at 94 °C for 2 minutes was followed by 40 cycles of 94 
°C for 30 seconds, primer annealing at 42°C for 60 seconds and template extension at 
68°C for 90 seconds. Samples that were negative by first round PCR were amplified by 
second round semi-nested PCR using primers as listed in Table 2.1 and the same 
cycling conditions as the first round. 
Amplified products were visualised by gel electrophoresis on a 2% agarose gel and 
capillary sequenced to generate a consensus sequence.  
2.7.2 PCR for NS7 and VP1 for cloning and deep sequencing comparison 
(Chapter 6) 
NS7 and VP1 PCR reactions consisted of 0.2 µM each primer, 0.25 µl GoTaq DNA 
Polymerase (Promega), 10 µl Green GoTaq Reaction Buffer, 2.5 mM MgCl2, 0.2mM 
each dNTP and water to make volume to 45 µl. Cycling conditions consisted of initial 
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denaturation at 95 °C for 2 minutes followed by 30 cycles of 95 °C for 30 seconds, 50 
°C for 30 seconds and 72 °C for 1 minute and a final extension at 72 °C for 5 minutes. 
PCR products were visualised on a 2% agarose gel. 
2.7.3 PCR for NS7 and VP1 mutation frequency in pre- and post-ribavirin 
samples (Chapter 6) 
NS7 and VP1 PCR conditions were optimised for sensitivity. The final PCR reactions 
consisted of 0.5 µM each primer, 0.4 µl Accuprime Pfx DNA Polymerase (Invitrogen), 5 
µl Accuprime Pfx reaction mix and water to make volume to 40 µl. Cycling conditions 
consisted of initial denaturation at 95 °C for two minutes followed by 35 cycles of 95 °C 
for 15 seconds, 52 °C for 30 seconds and 68 °C for 1 minute. PCR products were 
visualised on a 2% agarose gel. 
 GEL ELECTROPHORESIS 2.8
For a 2% gel, 1.2 g agarose was dissolved in 60 ml 1X TBE buffer. Once cooled, 7.5 µl 
ethidium bromide or Gel Red solution (Biotium) was added before casting.  
5 µl of PCR product was mixed with 1 µl loading dye (Invitrogen) prior to loading. Every 
gel was run with 5 µl of Hyperladder IV (Invitrogen) as a size marker. Gels were run at 
100 V for 20–30 minutes prior to visualising under UV light.  
 CAPILLARY (SANGER) SEQUENCING 2.9
Prior to capillary sequencing, PCR products were purified using Illustra MicroSpin 
columns (GE Healthcare) to remove unincorporated PCR primers and primer-dimer 
complexes smaller than 200 bp. The MicroSpin columns contain a resin of differing 
pore sizes; molecules larger than the largest pore size are excluded from the gel matrix 
and thus are eluted. Smaller molecules are retained by the gel matrix so are excluded 
from the purified DNA. 
All PCR amplicons were sequenced in the forward and reverse direction. Briefly, 
sequencing reactions consisted of 3 µl purified PCR product, 1.5 µl molecular grade 
water, 2.5 µl of 2 µM primer (forward or reverse), 1 µl sequencing buffer and 2 µl 
BigDye 3.1 reaction mix (Life Technologies). Cycling conditions consisted of initial 
denaturation at 96 °C for 1 minute followed by 25 cycles of 96 °C for 10 seconds, 50 °C 
for 5 seconds and 60 °C for 4 minutes. 
Sequencing products were purified by ethanol precipitation to remove unincorporated 
primers. The entire sequencing product (10 µl) was mixed with 5 µl 125 mM EDTA and 
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60 µl 96% ethanol and incubated at room temperature for 15 minutes to precipitate 
PCR amplicons. Following a 30 minute centrifugation at 2204 g, the pellets were 
washed with 60 µl 70% ethanol and re-pelleted with a 5 minute centrifugation at 2204 
g. Following an inverted pulse centrifugation at 180 g to remove residual ethanol and 
dry the pellet, pellets were re-suspended in 5 µl HiDi formamide. Sequencing products 
were denatured for 5 minutes at 95 °C prior to loading onto an ABI 3130 genetic 
analyser for capillary sequencing.  
Sequencing chromatograms were visualised and assembled using Seqman Pro v12 
(DNA Star). 
 NOROVIRUS GENOTYPING 2.10
Consensus sequences (either full genome or partial RNA polymerase/capsid 
sequences) were submitted to the web-based norovirus typing tool 
(www.rivm.nl/mpf/norovirus/typingtool) [141], which assigns a genotype based on 
phylogeny (as described on page 51 in Chapter 1). 
 WHOLE GENOME SEQUENCING BY SURESELECT 2.11
TARGET ENRICHMENT 
2.11.1 RNA bait design 
Overlapping 120-mer RNA baits complementary to and spanning the length of 622 
norovirus partial or complete genomes from Genbank were designed using an in-house 
PERL script. Briefly, a 120 nucleotide sliding window is scanned along each reference 
genome at intervals of 10 nucleotides. If the 120-mer is sufficiently different to other 
120-mer sequences in the bait set (as assessed by BLAT [157]), it is retained in the 
bait set; otherwise that 120-mer is discarded. In this way, the bait set spans the 
diversity in all of the included reference genomes. The reference genomes included 
polymerase genotypes GI.P1, GI.P2, GI.P3, GI.P4, GI.P6, GI.P8, GI.Pb, GI.Pc, GI.Pd, 
GI.Pf, GII.P1, GII.P2, GII.P3, GII.P4, GII.P5, GII.P6, GII.P7, GII.P8, GII.P11, GII.P12, 
GII.P15, GII.P16, GII.P17, GII.P18, GII.P21, GII.P22, GII.Pc, GII.Pe, GII.Pg, GII.Pp, 
GIII, GIV, GV and GVI and capsid genotypes GI.1, GI.2, GI.3, GI.4, GI.5, GI.6, GI.8, 
GII.2, GII.3, GII.4, GII.5, GII.6, GII.7, GII.8, GII.10, GII.11, GII.12, GII.13, GII.14, GII.15, 
GII.16, GII.17, GII.18, GII.21, GII.22, GIII, GIV, GV and GVI. The GII.4 reference 
genomes included all major GII.4 variants: CHDC1970s, Bristol_1993, 
Camberwell_1994, US95/96, Farmington Hills_2002, Lanzhou_2002, Asia_2003, 
Hunter_2004, Yerseke_2006a, Den Haag_2006b, Osaka_2007, Apeldoorn_2007, New 
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Orleans_2009 and Sydney_2012. The custom designed norovirus bait library was 
uploaded to Agilent SureDesign and synthesised by Agilent Biotechnologies.     
2.11.2 Library preparation, hybridisation and enrichment  
Norovirus cDNA samples were quantified and carrier G147 Human Genomic DNA: 
male (Promega) was added if necessary to obtain a total of 200ng.  
All DNA samples were mechanically sheared for 150 seconds using a Covaris E210 
focused-ultrasonicator (duty cycle 5%, PIP 175 and 200 cycles per burst) to yield a 
fragment size of approximately 270 bp. End-repair, non-templated addition of 3’ –A 
adapter ligation, hybridisation, enrichment PCR and all post-reaction clean-up steps 
were performed according to the SureSelect Illumina Paired-End Sequencing Library 
XT protocol. All recommended quality steps were performed between steps. 
2.11.3 Illumina sequencing of SureSelect enriched libraries 
Samples were multiplexed with 48 samples per run. Paired end sequencing was done 
on an Illumina MiSeq sequencing platform with the 500 cycle v2 Reagent Kit.  Base 
calling and sample demultiplexing were generated as standard on the MiSeq producing 
paired FASTQ files for each sample.  
 WHOLE GENOME ASSEMBLY OF SURESELECT DEEP 2.12
SEQUENCING DATA 
All assemblies were done in CLC genomics workbench v8, as summarised in Figure 
2.2. All reads were quality trimmed and adapter sequences removed. Trimmed reads 
were mapped to a curated reference list consisting of all norovirus complete genome 
and complete gene sequences in Genbank as of 14/07/2015 (n = 688). All paired reads 
mapping to the reference list (filtered reads) were taken forward to de novo assembly 
using workbench default parameters and a minimum contig length of 200 nucleotides. 
Contigs generated from the de novo assembly were aligned to a single Genbank 
reference sequence of the relevant genotype to check the orientation of the contig and, 
where multiple contig sequences were generated, the position of each contig relevant 
to the reference. Multiple contig sequences were joined based on overlapping 
nucleotide sequences or with a manually inserted gap. All trimmed reads (pre-filtering) 
were mapped to the full length contig sequence generated from the de novo assembly 
to generate a final consensus sequence. Areas of low coverage (<10) were assigned 
the ambiguity symbol N. 
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Figure 2.2 Schematic of norovirus de novo full genome assembly pipeline 
 
 Italics, workbench default settings 
Trim all reads 
Mapping to reference list            
(n = 688)  
De novo assembly 
Align contigs to single reference 
of appropriate genotype 
Join multiple contigs 
Check orientation of contigs 
relative to referencce 
Extract full length contig 
seququence (reverse 
complement if necessary) 
Mapping to full length contig (all 
trimmed reads) with local 
realignment and remove 
duplicate reads 
Extract consensus sequence 
Illumina adapter list 
Quality trim 
 
 
Trimmed reads 
Paired mapped reads 
(filtered reads) 
Contig list 
Length fraction: 0.5, similarity fraction 0.8 
Mismatch cost: 2, insertion/deletion cost: 3 
Map non-specific matches randomly 
Bubble size 50, word size 20 
Minimum contig length 200 
 
 
BLAST word size 20 
Minimum match size 100 
 
Automatically detect 
overlap or insert 
manual gap 
 
Length fraction: 0.5, similarity fraction 0.8 
Mismatch cost: 2, insertion/deletion cost: 3 
Map non-specific matches randomly 
Low coverage (<10): insert N 
Conflict resolution: vote 
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  IDENTIFICATION OF OPEN READING FRAMES 2.13
To verify correct genome assembly, open reading frames (ORF 1, ORF 2 and ORF 3) 
were identified for all genome sequences using the Find Open Reading Frames tool in 
CLC Genomics Workbench.  
  PHYLOGENETIC ANALYSIS  2.14
A phylogenetic tree infers the evolution of a set of taxa, in this instance between 
norovirus strains from infected patients. Internal nodes represent a common ancestor 
between two sequences; sequences with a shared common ancestor have a higher 
degree of relatedness than those that do not have a shared common ancestor. The 
branch length between nodes represents the genetic distance between two sequences, 
for instance the average number of nucleotide substitutions per site. The robustness of 
a tree, i.e. how reliable it is, is estimated using bootstrap values. A bootstrap value 
indicates the frequency of observing the same topology if the tree were to be 
reconstructed multiple times; for example if the tree were to be re-constructed 100 
times, how many of the resulting trees would have the same topology. Robust 
branches have high bootstrap values, whilst volatile branches have low values; a 
bootstrap value of 50 suggests the observed topology will only be replicated in 50% of 
trees. 
All phylogenetic analysis was carried out in CLC Genomics Workbench (v 9.0). 
Consensus sequences were aligned using the very accurate (slow) progressive 
alignment tool. Maximum Likelihood phylogenies were reconstructed using the general 
time reversible (GTR) nucleotide substitution model, including rate variation (+G), tree 
topology estimation (+T) and 200 bootstrap replicates. The GTR+G+T model was 
determined to be the best model for the data set by the Model Testing tool in CLC 
Genomics Workbench. The Model Testing tool applies statistical analysis to trees 
reconstructed using five different substitution models (see Table 2.2 for model details) 
to determine the most suitable for the data set.  
Details of all reconstructed phylogenies are summarised in Table 2.3. All nodes with 
bootstrap support <70 were collapsed.  
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Table 2.2 Summary of nucleotide substitution models tested by the CLC Genomics Workbench Model 
Testing tool, to determine the most suitable model for Maximum Likelihood phylogeny for a given data 
set 
Model name Model assumptions 
Jukes Cantor (JC) 
Equal rates of nucleotide substitution 
Equal rates of base frequencies 
Felsenstein 81 
Unequal base frequencies 
Equal rates of nucleotide substitution 
Kimura 80 
Transition/transversion substitution bias  
Equal rates of base frequencies 
HKY 
Transition/transversion bias 
Unequal base frequencies 
GTR 
Transition/transversion bias 
Unequal base frequencies 
Unequal rate for each pair of substitutions 
+G (applicable to HKY and 
GTR only) 
Site rate variation – i.e. variation is not equal across all sites in 
the genome 
+T 
Tree topology estimation to find the tree topology and branch 
lengths that best describe the sequences’ phylogenetic 
relationships 
 
  
 
7
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Table 2.3 Summary of phylogenetic trees reconstructed 
Tree details 
Number of 
sequences in 
tree* 
Phylogeny 
method 
Reference sequence Out-group sequence 
Figure 
No. 
GII.4 P2† † 
(GOSH) 
71 Maximum 
Likelihood 
GII.P4_GII.4 New Orleans_2009 JN595867 (USA 2010) 
GII.Pe_GII.4 Sydney_2012 JX459908 (Australia 2012) 
GII.P7_GII.7 KJ196295 (Japan 2010) Figure 
5.20 
GI.1 full 
genome 
1 None† N/A N/A N/A 
GI.2 full 
genome 
3 Maximum 
Likelihood 
GI.P2_GI.2 KF306212 (China 2013) GI.P1_GI.1 KF039736 (USA 2010) Figure 
5.11 
GI.3 full 
genome 
15 Maximum 
Likelihood 
GI.P3_GI.3 KJ196292 (Japan 2007) GI.P1_GI.1 KF039736 (USA 2010) 
 
Figure 
5.12 
GII.1 full 
genome 
1 None† N/A N/A N/A 
GII.2 full 
genome 
10 Maximum 
Likelihood 
GII.P16_GII.2 KJ407074 (USA 2011) GII.P17_GII.17 KT253245 (China 2015) Figure 
5.13 
GII.3** full 
genome 
61 Maximum 
Likelihood 
GII.P12_GII.3 GU980585 (Korea 2006) GII.P7_GII.7 KJ196295 (Japan 2010) Figure 
5.15 
GII.4*** full 
genome 
71 Maximum 
Likelihood 
GII.P4_GII.4 New Orleans_2009 JN595867 (USA 2010) 
GII.Pe_GII.4 Sydney_2012 JX459908 (Australia 2012) 
GII.P16_GII.4 Sydney_2012 LC175468 (Japan 2016) 
GII.P7_GII.7 KJ196295 (Japan 2010) Figure 
5.16 
  
 
7
4
 
Tree details 
Number of 
sequences in 
tree* 
Phylogeny 
method 
Reference sequence Out-group sequence 
Figure 
No. 
GII.6 full 
genome 
12 Maximum 
Likelihood 
GII.P7_GII.6 LN854568 (Netherlands 2014) GII.P17_GII.17 KT253245 (China 2015) Figure 
5.14 
GII.7 full 
genome 
3 Maximum 
Likelihood 
GII.P7_GII.7 KJ196295 (Japan 2010) GII.P12_GII.3 GU980585 (Korea 2006) Figure 
5.18 
GII.13 full 
genome 
1 None† N/A N/A N/A 
GII.17 full 
genome 
2 Maximum 
Likelihood 
GII.P17_GII.17 KT380915 (Shanghai 2014) 
GII.P17_GII.17 KP998539 (Hong Kong 2015) 
GII.P17_GII.17 LC037415 (Kawasaki 2015) 
GII.P17_GII.17 KT253245 (China 2015) 
GII.P16_GII.17 KJ196286 (Japan 2002) 
GII.P7_GII.6 LN854568 (Netherlands 2014) Figure 
5.17 
GII.4 P2† †  
(NNUH) 
60 Maximum 
Likelihood 
GII.P4_GII.4 New Orleans_2009 JN595867 (USA 2010) 
GII.Pe_GII.4 Sydney_2012 JX459908 (Australia 2012) 
GII.P12_GII.3 GU980585 (Korea 2006) Figure 
5.25 
GII.4 NNUH full 
genome 
60 Maximum 
Likelihood 
GII.P4_GII.4 New Orleans_2009 JN595867 (USA 2010) 
GII.Pe_GII.4 Sydney_2012 JX459908 (Australia 2012) 
GII.P12_GII.3 GU980585 (Korea 2006) Figure 
5.24 
GII.Pe ORF1 40 GII.Pe_II.4  
4 GII.Pe_II.2 
Maximum 
Likelihood 
GII.Pe_GII.4 Sydney_2012 JX459908 (Australia 2012) GII.P7_GII.7 KJ196295 (Japan 2010) Figure 5.5 
GII.P16 ORF1 1 GII.P16_II.17 
3 GII.P16_II.4 
Maximum 
Likelihood 
GII.P16_GII.2 KJ407074 (USA 2011) 
GII.P16_GII.17 KJ196286 (Japan 2002) 
GII.P7_GII.7 KJ196295 (Japan 2010)  
 
Figure 5.4 
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Tree details 
Number of 
sequences in 
tree* 
Phylogeny 
method 
Reference sequence Out-group sequence 
Figure 
No. 
GII.P21 ORF1 64 GII.P21_II.3 
1 GII.P21_II.13 
Maximum 
Likelihood 
GII.P21_GII.3 LN854569 (Netherlands 2014) GII.P7_GII.7 KJ196295 (Japan 2010) Figure 5.6 
GII.P7 ORF1 13 GII.P7_II.6 
3 GII.P7_II.7 
 
Maximum 
Likelihood 
GII.P7_GII.6 LN854568 (Netherlands 2014) 
GII.P7_GII.7 KJ196295 (Japan 2010) 
GII.P12_GII.3 GU980585 (Korea 2006) Figure 5.3 
Longitudinal 
samples**** full 
genome 
83 Maximum 
Likelihood 
GII.Pc_GII.2 JX846925 (Kuala Lumpur 1978) 
GII.P21_GII.3 LN854569 (Netherlands 2014) 
GII.P4_GII.4 New Orleans_2009 JN595867 (USA 2010) 
GII.Pe_GII.4 Sydney_2012 JX459908 (Australia 2012) 
GII.P16_GII.17 KJ196286 (Japan 2002) 
GII.P17_GII.17 LC037415 (Kawasaki 2015) 
GII.P7_GII.6 LN854568 (Netherlands 2014) 
GI.P3_GI.3 KJ196292 (Japan 2007) Figure 
5.26 
Ribavirin 
treated Patient 
A and B VP1 
6 Maximum 
Likelihood 
None GII.P.4_GII.4 Farmington Hills_2002 Figure 
6.10 
*  excluding reference sequences  
**  Two samples excluded from phylogeny due to mixed genotypes 
***  One sample excluded from phylogeny due to mixed genotypes 
**** Three samples excluded from phylogeny;  two due to mixed genotypes; one sample excluded (Px 101) as only one sample remaining once mixed sequence excluded 
†  Only 1 sample of this genotype, therefore phylogeny was not reconstructed 
† † P2; capsid protruding domain 2, nt 5910–6336 (numbering corresponds to GII.Pe_GII.4 Sydney_2012 JX459908 reference sequence) 
N/A  not applicable  
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 CLONING OF NS7 AND VP1 PCR AMPLICONS (CHAPTER 2.15
6) 
VP1 and NS7 amplicons were cloned using a pGEM-T Easy Vector System (Promega) 
and α-Select chemically competent cells (Bioline), according to manufacturer’s 
instructions. For each sample, 96 colonies were sub-cultured (into a 96-well plate, each 
well containing agar); DNA extraction and capillary sequencing of each sub-cultured 
colony was done by the GATC Biotech sequencing service.   
 DEEP SEQUENCING OF NS7 AND VP1 PCR AMPLICONS 2.16
(CHAPTER 6) 
NS7 and VP1 amplicons from each sample were pooled in equimolar quantities and 
mechanically sheared to 200 bp using a Covaris E210 focused-ultrasonicator (duty 
cycle 10%, Intensity 5 and 200 cycles per burst, 6 cycle repeats of 60 seconds). 
Sheared samples were prepared for deep sequencing using NEBNext DNA Library 
prep master mix set for Illumina and NEBNext Multiplex oligos for Illumina (New 
England Biolabs), according to manufacturer’s instructions. Prior to sequencing the 
library quality was assessed using Bioanalyser HS chips (Agilent). Indexed samples 
were multiplexed prior to 250 bp paired end sequencing on an Illumina MiSeq platform.  
 CALCULATION OF MUTATION FREQUENCY IN NS7 AND 2.17
VP1 AMPLICONS (CHAPTER 6) 
Reference guided assembly was performed with Seqman NGen version 11 (DNA Star) 
using default parameters and a simple percentage SNP calculation method. SNP 
reports were generated by Seqman Pro version 11.1 (DNA Star). The consensus 
sequence of the pre-ribavirin sample for each patient, obtained by capillary 
sequencing, was used as the assembly reference. SNPs with frequency <1% and sites 
with a consensus sequence change compared to the reference were excluded from 
analysis. 
Mutation frequencies of the total virus population were calculated as previously 
described [158], using the following equation; 
𝑁𝑜.  𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛𝑠 𝑝𝑒𝑟 10,000 𝑛𝑢𝑐𝑙𝑒𝑜𝑡𝑖𝑑𝑒𝑠 =
𝑁𝑜.  𝑆𝑁𝑃𝑠
𝑇𝑜𝑡𝑎𝑙 𝑁𝑜.  𝑏𝑎𝑠𝑒𝑠 𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒𝑑
× 10,000 
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 CALCULATION OF dN/dS RATIOS (CHAPTER 6) 2.18
The degenerate nature of the amino acid code means that multiple codon sequences 
can code for the same amino acid. Consequently nucleotide substitutions (or 
mutations) in protein-coding genes can either be synonymous, in which case they do 
not result in an amino acid change (also known as silent substitutions), or non-
synonymous, in which case they change the amino acid. 
Under purifying selection, changes in a protein are disadvantageous therefore are 
selected against. Conversely under positive selection, changes in a protein are 
advantageous therefore are selected for. Synonymous substitutions (dS) do not have 
any impact on the protein, therefore are unlikely to be subject to purifying or positive 
selection; they are considered to be under neutral selection. Synonymous substitutions 
(dS) are an indication of background genetic drift. 
The number of non-synonymous substitutions (dN) can be normalised against the 
number of synonymous substitutions to determine whether the protein sequence is 
under purifying, neutral of positive selection. This is known as the dN/dS ratio. The 
equation is laid out below, where dN is the number of non-synonymous substitutions 
and dS the number of synonymous substitutions. A dN/dS ratio of 1 indicates no 
selection is occurring (neutral), <1 suggests purifying selection and >1 suggests 
positive selection.  
𝑑𝑁/𝑑𝑆 𝑟𝑎𝑡𝑖𝑜 =
𝑑𝑁 
𝑑𝑆
 
 
 MAPPING AMINO ACID RESIDUES IN THE NOROVIRUS 2.19
PROTRUDING DOMAIN PROTEIN STRUCTURE (CHAPTER 
6) 
Amino acid sequences of interest were aligned with the P domain sequence of 
norovirus GII.4 VA387 (2OBT; P domain protomer and HBGA B trisaccharide complex 
[35]) using ClustalW in Megalign (DNA Star) v 12.2. The crystal structure was viewed in 
PyMol (v 1.7.4.4 Edu) and known epitopes identified as per Table 2.4). 
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Table 2.4 Known epitopes in the norovirus GII.4 protruding (P) domain 
Epitope Amino acids* Evidence Reference 
P1 subdomain 222–274, 418–539 Crystal structure† 
 
[35] 
P2 subdomain 275–417 
 
Crystal structure† [35] 
HBGA binding site 343–345, 374, 441–
443 †† 
 
Crystal structure† [35] 
Indirect role in HBGA 
binding (e.g. interaction 
with binding site) 
 
336, 338, 347 Crystal structure† [35] 
Open pocket, speculated to 
interact with and increase 
affinity between 
trisaccharide and P protein 
 
390–393, 395 Crystal structure† [35] 
Dimer interface 
 
231, 232, 238, 243, 
245, 274, 278–281, 
308, 333, 337, 344, 
346, 348, 384, 386, 
436, 440–442, 455, 
458, 459, 463 
 
Crystal structure† [35] 
Binding pocket 291, 300, 335, 368 Sequence modelling and VLP 
ELISAs (mutations in VLP affected 
binding to HBGAs from saliva) 
Doubtful significance as not seen 
in crystal structure [35] 
 
[159] 
Immunogenic epitope A 
 
294, 296–298, 368, 
372 
Changes correlate with shifts in 
GII.4 antigenicity 
 
[123] 
Immunogenic epitope D 393–395 Changes correlate with shifts in 
GII.4 antigenicity 
 
[124] 
Immunogenic Epitope E 407, 412–413 Changes correlate with shifts in 
GII.4 antigenicity 
 
[124] 
* amino acid position relative to GII.4 VA387 capsid sequence (Genbank accession number AAK84679);  
†Crystalized P domain protomer and HBGA trisaccharide complex (2OBT, www.rcsb.org); 
†† It is predicted there are additional interactions and binding sites with lower affinity not observed in 
complex crystals [35]. 
HBGA, human blood group antigen; VLP, virus like particle 
 STATISTICAL ANALYSIS 2.20
All statistical analysis was performed using IBM SPSS Statistics v23 using two-tailed 
tests at the 95% significance level.  
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2.20.1 Statistics for Chapter 3 
The difference in age and PCR Ct values between gastroenteric viruses and between 
norovirus genotypes was tested using Kruskal Wallis ANOVA. Significant outcomes 
from Kruskal Wallace ANOVA were further tested by Pairwise comparison; P values 
were adjusted for multiple comparisons.  The difference in age and PCR Ct values 
between norovirus genogroups and between healthcare/previously acquired infections 
(HAI/POA) was tested using a Mann Whitney U Test. The difference in proportion of 
each norovirus genotype between HAI/POAs and between clinical specialties was 
tested by Fishers Exact test. The relationship between new norovirus episodes per 
month and the number of admissions per month was tested by Pearson’s correlation 
and Poisson Regression analysis.  
The difference in proportion of norovirus chronically infected patients between clinical 
specialties and genotypes was tested by Fishers Exact test. The difference between 
duration of infection in chronically infected patients between clinical specialties and 
genotypes was tested using Kruskal Wallis ANOVA. 
2.20.2 Statistics for Chapter 4  
The difference in % on-target-reads (% OTR), read depth and % genome coverage 
between norovirus genotypes and in PCR Ct value between Pass/Sub-optimal/Failed 
samples  was tested by Kruskal-Wallis ANOVA, with pairwise multiple comparison of 
significant results and P values adjusted for multiple comparisons.  
The relationship between PCR Ct value and % OTR, read depth and % genome 
coverage was assessed by Spearman’s correlation.  
A simple linear regression model (independent variable, PCR Ct value; dependant 
variable, logit transformed %genome coverage) was fitted to generate prediction 
intervals for % genome coverage from the PCR Ct value. % genome coverage was 
transformed using the formula 𝑡𝑟_𝑔𝑒𝑛𝑜𝑚𝑒 =
%𝑔𝑒𝑛𝑜𝑚𝑒 𝑐𝑜𝑣𝑒𝑟𝑎𝑔𝑒 ×(𝑁−1)+0.5
𝑁
 to ensure there 
are no proportions of 0 or 1 (SPSS cannot logit transform values of 0 or 1) and then 
transformed again (to enable linear regression) using the logit function 
(𝑙𝑜𝑔𝑖𝑡 𝑡𝑟𝑎𝑛𝑠𝑓𝑜𝑟𝑚𝑒𝑑 %𝑔𝑒𝑛𝑜𝑚𝑒 𝑐𝑜𝑣𝑒𝑟𝑎𝑔𝑒 = log (
𝑡𝑟_𝑔𝑒𝑛𝑜𝑚𝑒
1−𝑡𝑟_𝑔𝑒𝑛𝑜𝑚𝑒
) where log is the natural 
logarithm with base ℯ.  
Twenty-one of 507 samples were considered outliers and therefore excluded from the 
linear regression model to predict % genome coverage. These samples were excluded 
following discussion with the ICH Statistical Support Service (support detailed in 
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section 4.5 on page 141); 3/21 were believed to be RNA extraction failures (detailed on 
page 126, Table 4.2 and circled in Figure 4.8) and 18/21 were believed to be cDNA 
synthesis failures from Run 30 and 31 (detailed on page 125–126). 
2.20.3 Statistics for Chapter 5 
The difference in duration of infection between chronically infected patients who were 
and were not re-infected with a different strain of norovirus was assessed using a two-
tailed Mann Whitney U Test with a 95% significance level. 
2.20.4 Statistics for Chapter 6 
The difference in mutation frequency between the capsid (VP1) and RdRp (NS7) 
regions in all patients was assessed using a Wilcoxon signed rank paired test, and the 
difference in mutation frequency between pre- and post-ribavirin samples in Patient A 
and Patient B was tested using a Mann Whitney U Test. All tests were two-tailed with a 
95% significance level, using transition frequencies only.
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  CHAPTER 3
 
PREVALENCE OF NOROVIRUS INFECTION AND 
GENOTYPES IN A PAEDIATRIC UK HOSPITAL WITH 
IMMUNOCOMPROMISED PATIENTS 
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 INTRODUCTION  3.1
Norovirus is a leading cause of viral gastroenteritis world-wide [107]; however acute 
gastroenteritis can also be caused by adenovirus, astrovirus, sapovirus and rotavirus.  
Adenoviruses are the only of the gastroenteric virus with a double stranded DNA 
genome, in the range of 33–45 kbp. Human adenoviruses (species names Human 
mastadenovirus A–F) belong to the genus Mastadenovirus in the Adenoviridae family. 
Adenoviruses are a broad group of viruses, both in terms of genome sequences and 
clinical syndromes. There are 47 serotypes described each with different disease 
associations; the most common being respiratory disease, conjunctivitis and 
gastroenteritis. Acute gastroenteritis is caused by only two serotypes, 40 and 41. In 
immunocompetent individuals adenovirus infections are mostly mild and self-limiting, 
however following primary infection they can persist in a latent state [160]. The 
predominant cause of adenovirus-associated disease in immunocompromised patients 
is from reactivation of latent infections, in which detection in stool can be used for early 
initiation of antiviral treatment to prevent progression to life-threatening invasive 
infection [161]. 
Astrovirus and sapoviruses are both small single stranded RNA viruses, with genome 
size of 6.2–7.8 and 7.1–7.7 kb, respectively. Sapoviruses (species Sapporo virus) are 
the most similar to norovirus; as they belong to the Sapovirus family in the genus 
Caliciviridae they have similar cupped surface morphology typical of the Caliciviridae. 
Human astrovirus belong to the Mamastrovirus genus in the family Astroviridae. 
Outbreaks caused by sapoviruses occur throughout the year, less frequently than for 
noroviruses [162]. Astrovirus infections typically only occur in children, with very few 
reports in adults.  
Rotaviruses, in the Rotavirus genus, belong in the family Reoviridae (sub-family 
Sedoreovirinae) and have a segmented double stranded RNA genome. The vast 
majority of human rotavirus infections are caused by Rotavirus A, with occasional 
episodes of gastroenteritis caused by Rotavirus B and Rotavirus C; consequently it is 
generally only Rotavirus A which is the target for diagnostic PCR assays. Rotavirus 
infections are typically the most clinically severe of the gastrointestinal viruses, 
accounting for 70% of hospitalisations for gastroenteritis during seasonal peaks [163]. 
Consequently in 2013 a two-dose live oral vaccine was introduced to the UK childhood 
immunisation schedule with a dose at 2 months and 3 months of age. In the UK 
rotavirus infections have reduced by 67% since the introduction of the vaccine [164], 
however it has been shown that 17% of children shed vaccine virus in their stool for up 
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to 8 months following vaccination [165]. The vaccine is contraindicated in 
immunosuppressed patients; in the event that a child is vaccinated before diagnosis of 
their immunodeficiency, vaccine virus can cause a symptomatic infection [166, 167]. 
In 2010 the prevalence of healthcare-associated viral gastroenteritis in a paediatric UK 
hospital was assessed by Cunliffe et al. [168], who detected a viral cause in 53% of 
patients. Of 576 episodes of laboratory confirmed gastroenteritis, the majority (31%) 
were caused by rotavirus, an equal number (16% and 15%) identified norovirus and 
adenovirus, respectively, and a minority (5% and 2%) of infections were caused by 
astrovirus and sapovirus, respectively. This study was conducted prior to the 
implementation of the rotavirus vaccine; it is not known whether the prevalence of non-
rotavirus gastrointestinal viruses has changed in the relative absence of rotavirus 
infections. 
Although GII.4 strains predominate in norovirus outbreaks, they do so in the context of 
co-circulating genotypes [129]. Earlier reports have suggested that some norovirus 
genotypes are more common in children than adults [169, 170]; anecdotally this is 
particularly the case for GII.3 norovirus however there is limited evidence of this in the 
literature. The distribution of genotypes in a UK nosocomial paediatric population has 
not previously been described. In addition, it is not known whether chronic norovirus 
infections in immunocompromised patients are associated with specific genotypes. 
The site of norovirus in vivo replication remains elusive. Recent data from Jones et 
al.[24] reported in vitro culture of human norovirus in B cell lines, suggesting that B 
cells could be a major target for norovirus replication in vivo. At GOSH we are involved 
in the management of between 40–50 children with severe combined 
immunodeficiency (SCID). These patients are born with genetic defects affecting T and 
B lymphocyte development and function, although the degree to which each lineage is 
affected varies by mutation. Some of these patients do not have B cells; one would 
expect that if B cells are the primary site of norovirus replication, these patients could 
be less susceptible to norovirus infection compared to patients with B cells.    
This chapter describes the prevalence of norovirus in a paediatric UK hospital, in the 
context of other gastrointestinal infections occurring in this population. It explores the 
relationship of different norovirus genotypes and other gastrointestinal viruses to 
seasonality and viral load.  Understanding the molecular epidemiology of viral 
gastroenteritis in children will contribute to improving infection control practices and 
vaccine development. In addition we evaluated children with and without B lymphocyte-
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deficient SCID to determine whether the former were protected against norovirus 
infection.  
 MATERIALS AND METHODS 3.2
3.2.1 Sampled population  
Between 1st July 2014 and 30th June 2015 a total of 4,786 stool samples from 1,393 
patients (8% outpatients) at GOSH were tested during routine diagnostic analyses for 
the presence of gastroenteric viruses (Table 3.1). Between 1 and 46 samples were 
tested per patient (median 1) (Figure 3.1). The norovirus PCR assay was developed 
as part of this study (all other real-time PCR assays were developed by the GOSH 
Virology department). Detailed methods are described in Chapter 2.  
Table 3.1 Demographics of 4,786 stool samples tested in this study between 1/07/2014 and 30/06/2015 
at GOSH, UK 
Clinical specialty 
Number of patients tested (% 
male) 
Median age (range), years 
Surgical 202 (55%) 1.5 (0–17) 
Medical* 803 (54%) 1.9 (0–18) 
Immunocompromised† 270 (56%) 2.7 (0–17) 
International and 
Private‡ 
118 (59%) 3.3 (0–15) 
TOTAL 1393 (55%) 2.1 (0–18) 
* Medical; respiratory medicine, cardiac medicine, renal medicine, intensive care, neurology, 
dermatology, rheumatology, ear nose and throat and ophthalmology 
† Profoundly immunocompromised; bone marrow transplant, oncology, haematology and immunology 
‡International and Private; range of clinical specialties 
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Figure 3.1 Number of stool samples tested per patient, July 2014–June 2015, for detection of 
gastrointestinal viruses at GOSH (UK) 
 
Diagnostic real-time PCR results and accompanying clinical data for this study were 
exported retrospectively from the laboratory information system. The vaccine status of 
individual patients is not known. Detection of more than one virus during the study 
period was treated as an independent episode in the analysis. 
3.2.2 Norovirus genotyping 
The first norovirus positive stool from each patient at GOSH between 1st July 2014 and 
30th June 2015 was prospectively genotyped by PCR amplification and capillary 
sequencing of the capsid shell domain, described in detail in Chapter 2. Eleven 
norovirus positive samples had insufficient residual volume for genotyping and were 
excluded from analysis. cDNA for genotyping was prepared from 133 samples. 
3.2.3 National norovirus genotyping data 
To compare norovirus seasonality and genotypes circulating at GOSH to those 
circulating nationally, the number of norovirus outbreaks reported nationally to Public 
Health England (PHE) and the proportion of each genotype in the laboratory-confirmed 
outbreaks was provided by the Virus Reference Department (VRD), PHE, from their 
national surveillance data (collected via the Hospital Norovirus Outbreak Reporting 
System and published monthly on https://www.gov.uk/government/statistics/norovirus-
national-update). 
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3.2.4 Rotavirus vaccine detection 
Rotavirus positive specimens were genotyped, and GIP8 positives confirmed as 
vaccine or wild-type by sequencing the genes encoding VP4 and VP7, by the PHE 
VRD.  
3.2.5 Categorisation of patients 
The clinical specialty of each patient was assigned based on the clinical specialty of the 
ward to which they were admitted at the time of specimen collection. Immunodeficiency 
patients consisted of specialties associated with profound immunodeficiency; bone 
marrow transplant, oncology, haematology and immunology specialties. Medical 
patients consisted of respiratory medicine, cardiac medicine, renal medicine, intensive 
care, neurology, dermatology, rheumatology, ear nose and throat and ophthalmology. It 
is possible that some patients in the medical category will have had some degree of 
suppressed immunity.  
3.2.6 Statistical analysis 
Statistical analysis was performed using IBM SPSS Statistics v23. Details are 
described in Chapter 2.  
3.2.7 Norovirus in B cell deficient patients 
SCID patients are a very rare cohort, therefore to maximise numbers we retrospectively 
reviewed the records from 2008 onwards for children with T−B−NK+ SCID in whom B 
and T cells were absent.  These included five with Rag-1 mutations resulting in 
deficiency of RAG 1 (recombination-activating gene type 1) protein (Px 1–4 and Px 6) 
and two with DCLRE1C mutations resulting in Artemis deficiency (Px 5 and Px 8).  We 
compared these with seven children designated T−B+NK− SCID in whom mutations in 
IL2RG resulted in complete absence of T cells and natural killer (NK) cells with present, 
albeit dysfunctional, B lymphocytes (Px 11–13 and Px 15–18), one T−B+NK+ child in 
whom mutations in IL7RA results in absence of T cells only (Px 10) and one each RAG 
1 (Px 14) and Artemis deficiency (Px 9) patients who had undergone hematopoietic 
stem cell transplant (HSCT) thus introducing B cells.    
The difference in norovirus viral titre between B− and B+ patients was assessed by 
comparing the Ct values of all norovirus positive samples from each patient using a 
two-sided two sample T-test, with a 95% significance level.  
B cell counts in whole blood are measured by the diagnostic Immunology department. 
Normal B cell counts in children 2 months to 15 years are 0.6–2.7 x109 cells/L [171]. 
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 RESULTS 3.3
3.3.1 Validation of performance characteristics of norovirus real-time 
PCR 
A nucleotide BLAST search of the norovirus GI and GII primers and probes only 
returned matches against norovirus GI or GII, respectively. Adenovirus, rotavirus, 
sapovirus and astrovirus were not amplified by the norovirus RT-qPCR assay when 
tested on stool samples known to be positive for one of the aforementioned viruses. 
These results confirm the primer and probes are specific to norovirus.  
The lowest concentration of norovirus plasmid detected, and therefore the limit of 
detection, was 5 and 1 copies/µl for GI and GII, respectively.  
All of the GI (4/4) and GII (5/5) positive samples from QCMD were amplified and 
correctly identified as GI or GII. The GIV positive sample was amplified by the GI 
primers and probe.  
A linear relationship is observed between norovirus viral load in copies/µl and Ct value, 
with a difference in 3.3 Ct values for every 10-fold change in viral load. The variability in 
Ct value between different runs was minimal (± 1 Ct, or 0.25 log10) (Figure 3.2).  
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Figure 3.2 Real-time PCR Ct values of known quantity plasmid containing norovirus GII target sequence, 
tested on multiple days. Red lines indicate mean Ct value 
 
Copies/µl 3 30 300 3000 30000 300000 3000000 
N 3 6 8 8 7 8 2 
Mean Ct 36.4 33.9 30.3 26.7 23.5 19.8 17.0 
Standard deviation 1.4 0.6 0.4 0.5 0.4 0.4 0.03 
Standard error 0.8 0.3 0.1 0.2 0.1 0.1 0.02 
 
3.3.2 Prevalence of gastroenteric viruses 
Twenty-four percent (329/1393) of all patients tested in the twelve month period were 
positive for a gastroenteric virus, among which norovirus and adenovirus predominated 
with 144 and 146 episodes each over the 12 month period, each constituting 44% of all 
viral gastrointestinal infections (Table 3.2). 
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Table 3.2 Number and proportion of real-time RT-PCR positive episodes at GOSH, a children’s tertiary 
referral hospital, UK, over 12 months (2014–2015) from 4,786 stool specimens 
  
Total 
number  
% of 
patients 
% of 
positive 
samples 
Mixed 
infections (% 
of positives) 
Chronic 
infections† (% of 
positive) 
Number of 
patients tested 
1,393       
Enteric virus 
detected 
329  24% 100% 44 (13%)  
Norovirus  144 10% 44% 24 (17%) 38/144 (26%) 
Adenovirus  146  10% 44% 28 (19%) 28/146 (19%) 
Rotavirus  
33 (8/29 
vaccine*) 
2% 10% 5 (15%) 6/33 (18%) 
Sapovirus  80  6% 24% 17 (21%) 12/80 (15%) 
Astrovirus  18  1% 5% 4 (22%) 1/18 (6%) 
*29/33 rotavirus positive samples were typed for vaccine/wild-type; 4/33 samples had no residual 
specimen for typing 
† Chronic infections based on PCR positive >1 month 
 
Forty-four of the 329 infections (13%) were mixed infections with more than one virus 
detected (Table 3.2). The predominant mixed infections (23 /44, 52%) were norovirus 
and adenovirus, followed by norovirus and sapovirus (7/44, 16%) and adenovirus and 
sapovirus (6/44, 14%). Rotavirus was least frequently detected as part of a mixed 
infection (5/44, 11%). An equal number of mixed infections were from medical and 
immunocompromised patients; 16/44 (36%) each. Given that only 19% of patients 
tested were in the 'immunocompromised' category, this suggests mixed infections are 
likely to be more frequently associated with immune dysfunction.  
The median age of patients with a rotavirus infection, 0.7 years, was significantly 
younger than other infections with a median age of 2–3 years (P ≤0.015, Figure 3.3). 
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Figure 3.3 Age range of children infected with gastroenteric viruses. Horizontal lines indicate median age 
(n = 329) 
 
Children with GI norovirus infections were on average older than GII infections (median 
age 3.7 and 1.7 years, respectively) however this difference did not reach significance 
(P = 0.061, Figure 3.4). 
Figure 3.4 Age range of norovirus GI and GII infections in children (n = 133). Horizontal lines indicate 
median age 
 
Norovirus infections had a significantly higher virus titre, median Ct 23, compared to 
other infections (P ≤ 0.03 Figure 3.5a). Sapovirus infections had the lowest viral titre; 
median Ct 35.  
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Figure 3.5 Real-time PCR Ct value range in children infected with (a) all gastrointestinal viruses (n = 329) 
and (b) norovirus GI or GII (n = 133). Horizontal lines indicate median PCR Ct value 
 (a)       
 
(b) 
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3.3.3 Rotavirus vaccine-derived infections 
Four rotavirus positive patients had insufficient residual specimen for genotyping, thus 
29 of 33 samples were genotyped.  28% (8/29) of rotavirus infections were identified as 
vaccine strain.  
3.3.4 Prevalence of norovirus genotypes 
Eighty-seven percent (117/133) of norovirus infections were genogroup II (GII), which 
had a significantly higher virus burden (median Ct 22) compared to genogroup I (GI) 
infections (median Ct 28) (P = 0.004, Figure 3.5b).  
The majority of genotyped norovirus infections were GII.4 and GII.3; 52% and 26%, 
respectively (63/122 and 32/122), with the remaining 22% (27/122) identified as GI.1, 
GI.2, GI.3, GI.4, GII.1, GII.2, GII.6 or GII.17 (Figure 3.6). Eleven samples (11/133, 8%) 
could not be amplified by the genotyping PCR; these had a significantly lower viral 
burden compared to other samples (median Ct 35 and 22 for failed versus successful 
typing, respectively, P ≤ 0.001).  
Figure 3.6 Proportion of norovirus genotypes detected in children over a 12 month period 2014–2015 (n 
= 122) 
                             
3.3.5 Norovirus seasonality 
The proportion of norovirus genotypes each month in our paediatric population is not 
the same as those seen in nationally reported outbreaks, primarily attributable to the 
increased proportion of GII.3 in our population (Figure 3.7). A peak in prevalence of 
GI.3 in nationally reported outbreaks from August to November 2014 is followed by a 
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similar peak in our paediatric population from September to December 2014. 
Conversely, a peak in GII.6 episodes in our population from March to June 2015 is not 
seen in nationally reported outbreaks (Figure 3.7).  
Figure 3.7 Proportion of norovirus genotypes by month in (a) children in a paediatric tertiary referral 
hospital (data from this study) and (b) nationally reported outbreaks, reproduced with permission from 
PHE norovirus surveillance report. Black lines indicate total number of outbreaks or cases per month 
(a) 
 
 
(b) 
 
 
 
The overall number of norovirus cases per month in our population does not follow the 
typical winter peak seen in national outbreaks (Figure 3.7). Instead it was noted that in 
our population the number of cases of norovirus per month follows a similar trend to the 
number of hospital admissions, including outpatient visits and transfer between wards 
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(Figure 3.8). There is a significant positive correlation between the number of 
admissions and number of norovirus cases per month (R = 0.703, P = 0.011). This 
suggests that the number of hospital admissions accounts for 50% of the variability in 
number of norovirus cases (R2 = 0.494). Based on the Poisson regression coefficient 
(𝑦 = −1.447 + 0.001𝑥) it is estimated that one case of norovirus occurs for every 100 
admissions (95% CI 0.000–0.002, P = 0.002). 
Figure 3.8 (a) Number of norovirus cases per month in paediatric tertiary referral hospital and number 
of hospital admissions during the same period. Admissions include outpatient appointments and 
transfers between wards; (b) Regression analysis of norovirus cases per month and number of hospital 
admissions (P = 0.006) 
(a)        
 
 
 (b) 
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3.3.6 Hospital and community acquired norovirus infections 
The proportion of GII.4 infections was 40% in infections acquired before admission 
(POA) and 68% in hospital acquired infections (HAI) (Figure 3.9); these were not 
significantly different (P = 0.062). 
Figure 3.9 Proportion of norovirus genotypes in positive-on-admission (POA) and hospital acquired (HAI) 
norovirus infections 
 
The average viral titre of norovirus hospital acquired infections (HAI) is significantly 
higher than for infections acquired before admission (POA), with a median Ct value of 
21 and 24, respectively (P = 0.009, Figure 3.10a). 
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Figure 3.10 Real-time PCR Ct value range of (a) positive on admission (POA) and hospital acquired (HAI) 
norovirus infections (n = 133) and (b) norovirus infections in immunocompromised and non-
immunocompromised patients. Horizontal lines indicate median Ct value 
(a) 
 
(b) 
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3.3.7 Norovirus in clinical specialties 
The prevalence of norovirus infection is higher in immunocompromised compared to 
surgical or medical patients; 19% (51/270) of immunocompromised patients tested 
were found to be norovirus positive compared to 5% (10/202) and 7% (57/803) of 
surgical and medical patients.   
There was no significant difference in the norovirus PCR Ct values between 
immunocompromised and non-immunocompromised patients (median Ct 23 and 24, 
respectively; P=0.226, Figure 3.10b). 
3.3.8 Chronic infections 
Norovirus had the highest rate of chronic infections (38/144, 25%); adenovirus, 
rotavirus and sapovirus had similar rates whilst astrovirus had the fewest (1/18, 6%) 
(Table 3.2, Figure 3.11a). With the exception of sapovirus, in which chronic infections 
occurred equally in immunocompromised and medical clinical specialties, the majority 
(67–100%) of chronic infections were in patients from immunocompromised clinical 
specialties (Figure 3.11b).
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Figure 3.11 (a) Proportion of acute and chronic (PCR positive >1 month) infections and (b) Proportion of 
chronic infections belonging to immunocompromised or medical & surgical clinical specialties (excluding 
International & Private patients for whom immune status is not known*) 
(a) 
 
(b) 
 
* Excluded chronically infected International & Private patients: norovirus 8/38; adenovirus 2/28; 
rotavirus 0/6; sapovirus 4/12; astrovirus 0/1 
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There was no difference in proportion of chronic patients between the different 
norovirus genotypes (Figure 3.12, P = 0.801). The median duration of infection in 
chronically infected patients was 5 months (range 1–21 months). 
Figure 3.12 Proportion of norovirus genotypes with chronic infections  
 
3.3.9 Norovirus in B cell deficient patients 
Of eight B− patients, five developed norovirus GII infection (63%), compared to 6 of 10 
B+ patients (60%) (Table 3.3). The duration of virus shedding could not be determined 
for the majority of patients, however for the nine patients who had been diagnosed with 
norovirus infections since 2010, we were able to use Ct values to analyse viral titre. 
The average viral titre for B+ patients (mean Ct 19, 95% CI 18, 20) was a log higher 
than for B− patients (mean Ct 22, 95% CI 21, 23); this difference is significant (P 
0.0001, Figure 3.13).
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Table 3.3 Summary of norovirus results in B cell deficient and non-deficient SCID patients at Great Ormond Street Hospital, UK 
Patient 
ID 
Diagnosis 
B cell 
status 
B cell count 
(x10
9
 cells/litre) 
Norovirus 
infection 
Median Ct† 
value 
Ct value range 
Number of positive 
samples detected 
Date range of 
positive samples** 
Px 1 RAG 1 − 0.04 yes 27 19-35 9 2.5 months 
Px 2 RAG 1 − 0.04 yes 18 single result 1 single result 
Px 3 RAG 1 − 0.01 yes 28 single result 1 single result 
Px 4 RAG 1 − 0.00 yes 21 18-25 27 5 months 
Px 5 Artemis deficiency − 0.04 yes 17 16-22 5 14 months 
Px 6 RAG 1 − 0.06 no 
  
  
Px 7 SCID RAG/Omenn − 0.00 no 
  
  
Px 8 Artemis deficiency − 0.01 no 
  
  
Px 9 Artemis deficiency +* 0.29 yes NA NA   
Px 10 IL7RA + 0.48 yes NA NA   
Px 11 X-SCID + 2.36 yes 19 15-28 27 12 months 
Px 12 X-SCID + 2.84 Yes 22 21-28 7 10 months 
Px 13 X-SCID + Not available yes 17 12 to 22 25 12 months 
Px 14 RAG 1 +* 0.69 yes 29 20-31 4 1 month 
Px 15 X-SCID + 1.52 no   
 
  
Px 16 X-SCID + 2.13 no   
 
  
Px 17 X-SCID + 1.03 no   
 
  
Px 18 X-SCID + 0.93 no   
 
  
B−, B cell deficient; B+, B cell non-deficient; *, post-HSCT; NA, norovirus diagnosis was by electron microscopy therefore Ct values are not available; †, PCR cycle threshold. There is 
an inverse relationship between Ct and viral titre, with smaller values indicating a higher virus titre. A difference in Ct value of 3 is equivalent to a ten-fold difference in virus titre; 
** date range of positive samples does not necessarily reflect duration of infection, as the dates of onset and end of infection were not known in all cases.  
 101 
 
Figure 3.13 Real-time RT-PCR Ct value of all norovirus positive samples from B cell deficient (B−) and 
non-deficient (B+) patients. Lines indicate mean Ct value in each group 
 
 DISCUSSION 3.4
3.4.1 Norovirus is the most prevalent cause of gastroenteritis 
This chapter presents the prevalence of viral gastrointestinal infections and the 
prevalence of norovirus genotypes in a large cohort of 1,393 paediatric patients in a 
tertiary referral hospital over a 12 month period, which is dominated by norovirus and 
adenovirus infections. This is similar to previous reports of UK hospitalised children in 
which norovirus and adenovirus were detected in 15–16% and 14–15% of cases, 
respectively [168]. 
The high prevalence of adenovirus can be explained by the broad-range nature of the 
adenovirus PCR. Adenovirus is a DNA virus with several serotypes, each causing 
different clinical presentations. The serotypes most commonly associated with 
gastroenteritis are 40 and 41; however the real-time PCR assay detects, but does not 
distinguish between, all adenovirus serotypes. Immunocompromised patients can 
experience endogenous reactivation of persistent adenovirus infection [160]; 
adenovirus is detected in the stool of more than one third of paediatric HSCT patients 
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without associated clinical symptoms of acute intestinal infection [161]. Therefore it is 
possible that virus shed in stool is a manifestation of a focus of infection elsewhere in 
the body or reactivation of endogenous non-serotype 40/41 adenovirus. Consequently 
a proportion of the adenovirus infections detected in this study may not be causing 
gastroenteritis. 
3.4.2 Norovirus in post-rotavirus vaccination era 
Following the introduction of the rotavirus vaccine to the UK childhood vaccination 
programme in July 2013 the prevalence of rotavirus infections has reduced by 67% 
[164], which is reflected in the low prevalence of 2% reported in this study; an earlier 
study of hospitalised UK children reported a 31% rotavirus positive rate [168]. Whilst 
the rate of rotavirus positive patients is reduced compared to the pre-vaccination UK 
study [168] the rate of detection of norovirus, adenovirus, sapovirus and astrovirus is 
unchanged; consequently the overall positivity rate for gastrointestinal viruses is lower 
than previously reported; 23% in this study compared to 53% reported previously [168]. 
This suggests that other gastrointestinal viruses, including norovirus, have not 
increased in prevalence to fill the ecological niche left by diminishing rotavirus 
infections. Presumably this is because rotavirus and the other gastroenteric viruses, in 
addition to being antigenically diverse, are not competing to fill the same ecological 
niche therefore infection with one gastrointestinal virus does not preclude infections 
with another, as demonstrated here by the detection of mixed infections.  
3.4.3 Viral titres 
The retrospective nature of this study does not allow comparison of viral genome copy 
numbers between patients, as this is not routinely determined for norovirus in a 
diagnostic laboratory. However the linear relationship between PCR cycle threshold 
(Ct) values and genome copy numbers, in which a difference in approximately three 
cycles (3 Cts) is equivalent to a log10 difference in copy number, makes Ct values a 
good semi-quantitative indicator of viral titre and so allows us to compare viral titres 
based on Ct values. Furthermore the inherent variability of Ct values between PCR 
runs is small, thus Ct values are reproducible and we can report log differences with 
confidence.  
Measuring viral loads in stool specimens is inherently difficult due to differences in 
consistency between specimens. The volume of stool added to an extraction is semi-
standardised by adding a pea-size amount of stool to a fixed volume of lysis buffer, 
however the actual amount will vary; a pea-size amount of liquid stool is difficult to 
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measure. Differences in stool consistency make the input variable which may falsely 
indicate a higher or lower viral titre when comparing samples. Accuracy of viral load 
measurements can be improved by weighing the amount of stool that is extracted, and 
either standardising the input weight between specimens or expressing a viral load in 
copies/gram. However weighing stools may still produce variable results since the 
weight of liquid and solid stools may not be comparable.  
The data presented in this chapter was exported, retrospectively, from the laboratory 
information system; since the results are from routine diagnostic specimen processing, 
stools were not weighed. Consequently viral titres should be interpreted with caution; 
the observations made, outlined below, should be verified in a prospective study that 
carefully controls the stool input prior to viral load measurement.     
The majority (87%) of norovirus infections were genogroup II (GII), which had a 
significantly higher viral titre than GI infections. The higher titre seen in GII is not biased 
by infections in immunocompromised patients since there was no significant difference 
in PCR Ct values between immunocompromised and non-immunocompromised 
patients. The ratio of GI:GII infections is the same as that reported in smaller paediatric 
cohorts in the US [170] and in Venezuela [172]. The difference in viral titre between 
genogroups has also been observed in the US [170].  
The average norovirus viral titre was higher in HAI compared to POA; the most 
parsimonious explanation for this is that HAIs are more likely to be detected nearer to 
the onset of symptoms, whereas POAs may be detected sometime after onset, thus a 
waning viral load is detected.  
Despite the equal number of norovirus and adenovirus infections, norovirus infections 
are associated with a significantly greater virus titre with a difference in median PCR Ct 
value of 9 cycles. The difference in virus titre is more pronounced between norovirus 
and sapovirus, in which the observed difference in median Ct values is suggestive of a 
10,000-fold difference in viral load. The lower limit of detection of the PCR assays used 
to detect each of the viruses is comparable (1–5 copies/µl for all except adenovirus 0.2 
copies/µl), suggesting the observed difference in viral titres is not an artefact of assay 
sensitivity. However the observed Ct values are from the first positive stool sample 
from each infected patient; it is possible that if longitudinal sampling were performed 
one would observe a peak in viral titre in the other viruses later than is seen for 
norovirus.  
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3.4.4 Norovirus seasonality and genotypes 
Unexpectedly, the overall prevalence of norovirus does not follow the characteristic 
seasonal trend seen in national outbreaks. Instead the number of infections per month 
strongly correlates with the number of hospital admissions, accounting for 50% of the 
variability in norovirus prevalence. It is possible that the increase in number of 
admissions is caused by heightened norovirus activity, rather than the other way 
around, however this is an unlikely scenario since GOSH has no A&E department 
therefore acute gastroenteritis is not the primary reason for admission. Moreover, the 
lack of wintertime seasonality does not reflect the national data from PHE suggesting 
admissions are not linked to heightened norovirus activity. Conversely, these results 
suggest that the prevalence of norovirus in a tertiary children’s hospital is driven by 
traffic through the hospital, rather than seasonal outbreaks. The breadth of genotypes 
seen in this study, more commonly seen in community cohorts compared to hospitals, 
backs this hypothesis; patients presenting to primary healthcare facilities, such as GP 
practices, reportedly have a lower proportion of GII.4 infections; 54% compared to 91% 
of hospital infections are GII.4 [173]. The true distribution of norovirus genotypes in the 
community is not known since all genotyping studies to date are based on patients 
presenting to healthcare facilities thus introducing a presentation bias. There have 
been some comprehensive, unbiased, community studies on norovirus prevalence; 
namely Infectious Intestinal Disease (IID) [174], the Second Study of IID in the UK 
(IID2) [113] and the Malnutrition and the Consequences for Child Health and 
Development  (MAL-ED) study [175]. IID was a population based community cohort 
study in England in 1995, with 9776 randomly selected community participants from 
1995 to 1996; IID2 was a UK multicentre longitudinal community cohort study 
conducted in 2008–2009, with 6836 participants; MAL-ED is a multi-country birth cohort 
of 1457 children across eight countries (South Africa, Tanzania, India, Pakistan, 
Bangladesh, Nepal, Brazil and Peru) describing norovirus epidemiology during the first 
two years of life, with specimens collected from 2009 to 2014. However, to date, none 
of the norovirus infections from these studies have been genotyped. Genotyping of 
norovirus infections in these unbiased community cohorts is needed in order to 
determine whether infections caused by a breadth of genotypes are a true reflection of 
the community. 
In this study cohort just over half (52%) of norovirus infections were identified as GII.4, 
which is the dominant norovirus genotype worldwide. A quarter (26%) of infections 
were caused by GII.3, which has previously been described in varying proportions in 
UK cohorts, from 0–35% early in the norovirus season (September/October) to 0–10% 
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late in the season (March/April) [129]. The high prevalence of GII.3 in our paediatric 
population is different to adult cohorts, in which outbreaks are largely dominated by 
GII.4 [173] but in line with Sukhrie et al.’s finding of an association between GII.3 and 
paediatric wards [140]. A peak of GI.3 from September to December 2014 mirrors a 
similar peak in GI.3 in national outbreaks reported to the PHE, suggesting that the virus 
circulating in the hospital is to some extent reflective of the national landscape. 
However this is not the case for GII.3 which is only reported sporadically in national 
outbreaks. The data in this study supports the notion that GII.3 is more frequently 
associated with children [140]; however the reason for this is unknown. Speculatively, 
the reason could be immunity to GII.3 in the adult population following childhood 
infection, lower transmissibility compared to GII.4 resulting in fewer associated 
outbreaks and reporting bias or differences in receptor binding between children and 
adults. The latter suggestion is of particular interest since recent success in culturing 
human norovirus in vitro demonstrated that GII.3 (and other non-GII.4 genotypes) 
require additional co-factors for cell entry that are not required by GII.4 viruses [34]. 
This warrants further investigation but is beyond the scope of this study.  
3.4.5 Norovirus in clinical specialties 
All patients in this study have been categorised by clinical specialty; this was based on 
the ward to which they were admitted at the time of specimen collection. It is clear that 
immunocompromised patients are over-represented among patients with norovirus 
infection; 19% of immunocompromised patients were found to be norovirus positive, 
compared to just 5% and 7% of surgical and medical patients, respectively.  Previous 
studies in smaller cohorts of 47, 61,78 and 116 immunocompromised patients have 
reported prevalence of norovirus as 23%, 21%, 17% and 22%, respectively [54, 116, 
117, 176] which suggests the categorisation of patients into clinical specialties in this 
study is reliable and that the larger cohort of 270 immunocompromised patients in this 
study corroborates earlier findings.  
There is no difference in age between immunocompromised and medical/surgical 
patients tested for viral pathogens in this study (P=0.972, 2-sample T-test). The 
duration of hospital stay for each patient is not known, however there is a sampling 
bias between immunocompromised and medical/surgical patients, with more stool 
specimens tested for norovirus from immunocompromised patients compared to 
medical/surgical patients (mean 5 and 3 specimens per patient, respectively, P<0.001, 
2-sample T-Test), which may falsely indicate a higher prevalence of norovirus in 
immunocompromised patients. Since this is an observational study using routine 
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clinical data, a prospective study without sampling bias is required to confirm the 
observed results.    
3.4.6 Chronic infections 
Norovirus caused the highest rate of chronic infections (26% PCR positive >1 month). 
Nonetheless all other viruses tested in this study were also shown to cause chronic 
infections; 15–19% in sapovirus, rotavirus and adenovirus infections and 6% in 
astrovirus infections. The vast majority of chronic infections were in 
immunocompromised patients.  
Chronic norovirus infections in immunocompromised patients is a recognised cause of 
morbidity, in whom a bi-phasic illness develops [177] with an initial acute phase 
followed by  a second chronic phase with viral shedding and diarrhoea lasting weeks to 
years. The consequence of chronic norovirus infection can be dehydration, 
malnutrition, dysfunction of intestinal barrier [80], dramatic weight loss [81], a 
requirement for nutritional support [54] and in extreme cases death [81, 82]. 
Immunocompromised patients in this study do not show a higher norovirus viral titre or 
difference in genotypes; suggesting the higher chronicity in immunocompromised 
patients is host, not virus, mediated. 
3.4.7 Norovirus in B cell deficient patients 
This study shows that susceptibility to norovirus infection between patients with and 
without B cells does not differ.  
The finding that the average viral titre (based on Ct values) in B cell deficient patients is 
significantly lower, albeit in a small cohort, is in agreement with Jones et al. who 
showed that B cell deficient mice had decreased viral titres compared to wild-type mice 
[24]. Nevertheless our finding of a mean norovirus Ct value of 22 in B cell deficient 
SCID patients indicates a very high viral titre, suggestive of millions of viral genome 
copies per ml. Therefore extensive viral replication must be occurring in host cells other 
than B lymphocytes. The finding presented here that B cells cannot be the primary site 
of norovirus replication in vivo has since been corroborated by Ettayebi et al. [34], who 
demonstrated in vitro that in human intestinal enteroids (HIEs), which contain multiple 
intestinal epithelial cell types, norovirus cell entry and replication is only supported in 
enterocytes. This, together with earlier histological data in intestinal biopsies from 
chronically infected immunosuppressed patients showing viral proteins in enterocytes 
[33], suggests that the primary site of human norovirus replication in vivo is 
enterocytes.  
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An alternative explanation of the results presented here is that the detection of 
norovirus in these patients represents repeated re-infection, rather than a single 
infection with on-going replication. However all patients were screened for the 
presence of norovirus on a weekly basis (with exception of Px 12 who was screened 
monthly). Residual specimens were not available to confirm on-going infection based 
on genome sequencing, however all samples from norovirus positive-patients were 
consecutively positive for norovirus with no negative samples in between; given the 
frequency of sampling it is unlikely that these infections represent repeated re-
infections. 
This unique B cell deficient patient cohort at GOSH provides data in humans to support 
the in vitro and animal findings reported by Jones et al.; the difference in viral titres 
suggests a potential role for B cells in norovirus replication. However the occurrence of 
norovirus infection in B cell deficient patients suggests there must be other primary 
sites for norovirus replication. This finding is supported by histopathological analysis of 
intestinal biopsies by Karandikar et al. (2016), which did not detect norovirus proteins in 
B cells but did detect viral proteins in enterocytes [33], and by Ettayebi et al. (2016) 
who successfully cultivated human norovirus in enterocytes generated from intestinal 
stem cells [34]. Together with norovirus infection of B cell deficient patients presented 
in this chapter, this suggests B cells are not the primary site of infection in vivo.  
3.4.8 Conclusions 
This chapter reports the prevalence of gastroenteric viruses in a large observational 
cohort of paediatric patients in a UK hospital following the implementation of routine 
rotavirus vaccination. There is no change in the prevalence of other viruses compared 
to pre-vaccination studies. All viruses, but most commonly norovirus, are shown to 
establish chronicity, primarily in immunocompromised patients. New norovirus 
infections are not driven by seasonal trends, which may be specific to this population 
but has been reported in community cohorts [119]. The high proportion of non-GII.4 
infections in children may have implications for vaccine development. 
The prevalence of norovirus infection does not differ between patients with and without 
B cells, signifying B cells are not the primary site of in vivo norovirus replication. 
Nonetheless a difference in viral titre between the two patient groups suggests B cells 
may play a secondary role in norovirus replication. 
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  CHAPTER 4
 
NOROVIRUS WHOLE GENOME SEQUENCING BY 
SURESELECT TARGET ENRICHMENT 
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 INTRODUCTION 4.1
Comparison of norovirus genetic sequences has the potential to allow linking of 
previously unrecognised transmission events or exclusion of cases from an outbreak. 
Traditionally, norovirus genotyping has involved polymerase chain reaction (PCR) 
amplification and capillary sequencing of partial regions of the polymerase and capsid 
sequences, followed by additional sequencing of the P2 region for outbreak 
investigations. This is a labour intensive process requiring several rounds of PCR and 
sequencing, each requiring genogroup or genotype specific primers and only yields 
partial genome sequences at the end. Whilst the P2 domain can identify linked 
outbreak events with 64–73% specificity (assuming bootstrap support >70 or <70, 
respectively), the full capsid sequence can identify linked outbreak events with 100% 
specificity [145] and thus is more informative.  
Whole genome sequencing simplifies investigation of norovirus molecular epidemiology 
by generating all the regions of interest in one step, thus allowing identification of the 
genotype, variant type and full capsid sequence; negating the need for sequential PCR 
and sequencing reactions. However, unlike bacteria, which can be isolated in pure 
culture, norovirus culture is difficult [25, 34].  Moreover, as norovirus replicates within 
the host cell, viral nucleic extracts from culture would be contaminated by host DNA, 
and if obtained from clinical specimens, by DNA and RNA from enteric bacteria and 
host cells.  
Two principle methods have been applied to sequence norovirus full genomes from 
clinical specimens to date; sequencing of overlapping polymerase chain reaction (PCR) 
fragments and direct sequencing of total RNA. A third method, target enrichment, is the 
subject of this chapter. The overlapping PCR generates pure viral template, which 
results in sequencing data that is all on-target, but requires multiple PCR 
amplifications.  Total RNA sequencing necessitates great depth of sequencing to 
generate the target norovirus genome.  All three methods are summarised in Figure 
4.1. The latter two methods, total RNA sequencing and target enrichment, have been 
achieved with the advent of next-generation deep sequencing. 
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Figure 4.1 Schematic overview of the three principle methods used to generate norovirus full genome sequences with summary of advantages and disadvantages for each method 
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Schematic overview of the three principle methods used to generate norovirus full genome sequences with summary of advantages and disadvantages for each 
method 
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4.1.1 Overlapping PCR amplicon sequencing 
The advantage of PCR for sequencing from clinical specimens is that over the course 
of 30 to 40 amplification cycles the target sequence, in this case norovirus, is amplified 
exponentially generating a high yield of DNA for sequencing. The non-target 
sequences become insignificant. The generated amplicons can then be sequenced 
either by capillary sequencing or with a next-generation sequencing (NGS) platform.  
The norovirus genome is 7.5kb. Since this is beyond the upper size limit of a PCR 
reaction, the genome must be amplified in several overlapping fragments, referred to 
as tiled PCR. PCR amplification works using specific primers that are designed to be 
complementary to a conserved region of the target sequence and will not amplify 
sequences that do not match both the forward and reverse primers.  This is 
problematic for norovirus due to the sequence heterogeneity both within and between 
genotypes.  
Smaller fragments (<1kb) amplify with greater efficiency than larger fragments, and 
thus was the approach we used to produce pilot data preceding this thesis to 
successfully amplify norovirus full genomes using 22 overlapping PCR fragments [148]. 
However not all of the primer sites are conserved between genotypes therefore this 
approach could only be used to amplify GII.4 sequences. Larger fragments (2–3 kb), 
whilst more difficult to amplify, require fewer primers thus are more likely to be 
successful across genotypes. Nonetheless due to sequence heterogeneity both 
between and within genotypes this approach retains a limited success rate, as 
demonstrated by Cotten et al. [149] who successfully amplified full genome sequences 
from 83%, 88%, 92% and 100% of GII.13, GII.6, GII.4 and GII.9 samples but only 20%, 
40%, 50% and 77% of GI, GII.2, GII.12 and GII.3 and 0% of GII.7 samples.  
Norovirus whole genome sequencing from a single 7.5 kb amplicon has been 
described and used to generate 25 full genome sequences [146]. Although the authors 
do no report the success rate using this approach, it is generally very difficult to amplify 
fragments of such a size. The long dwell times of the PCR cycling often result in non-
specific amplification and the technique relies on purifying intact full length RNA 
genomes; fragmented genomes are not amplified.  
4.1.2 Direct Sequencing of total RNA (RNASeq) 
The most straight forward method to sequence norovirus genomes direct from stool is 
whole transcriptome sequencing, or RNASeq. This involves purifying the total RNA 
content of a stool specimen and preparing a sequencing library with all of the RNA, 
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which is then sequenced on an NGS platform. To avoid unnecessary sequencing of 
host ribosomal RNA, library preparations can either remove ribosomal RNA 
(ribodepletion) or select polyA-tailed mRNA (the transcriptome) which will include 
polyA-tailed norovirus genomes. 
The advantage of RNASeq is that there is no requirement for PCR primers therefore it 
is completely unbiased. Although norovirus whole genomes generated by RNASeq 
reported to date are predominantly GII.4, it is theoretically possible to sequence all 
genotypes with equal success.  
The biggest limitation of RNASeq is the same as its very reason for success. The 
unbiased nature of RNASeq means that all RNA present in the sample, which will 
include host and bacterial RNA transcripts as well as norovirus RNA, will be 
sequenced. The proportion of norovirus to other RNA can be very low, therefore large 
sequencing capacity is required to capture the norovirus sequences in each sample. 
Since sequencing platforms generate an approximately fixed amount of data, which is 
shared among the number of samples sequenced on one run, to generate the read 
depth required to recover norovirus genomes the number of samples sequenced per 
run is very limited. For instance to generate norovirus full genomes Illumina’s bench-
top sequencing platform MiSeq, which generates approximately 15 Gb of data and 25 
million reads, can only accommodate 6 stool samples per run [178].  
The data generated by RNASeq is sufficient to generate almost complete norovirus 
genome sequences; 40–99% of reported samples achieved >90% genome coverage. 
However due to the low proportion of reads that belong to norovirus, median 2–3% 
across all reported samples, the average read depth per sample sequenced on a 
MiSeq is only 9–259 [147, 178, 179]. Whilst this read depth is, in most cases, sufficient 
for a reliable consensus sequence, it does not allow variant analysis. Sequencing on a 
higher-throughput platform, such as the Illumina HiSeq which generates up to 750 Gb 
and 2.5 billion reads, allows up to 96 samples to be sequenced on a single run. Whilst 
the proportion of reads generated that corresponds to norovirus is still only 3%, the 
increased sequencing output allows greater read depth per sample, in some cases up 
to 1000-fold. Nevertheless the median reported mean depth remains approximately 
100-fold [178]. 
Unbiased sequencing of non-target RNA results in low read depths but also has a 
financial implication; for instance the reagents for a single MiSeq or HiSeq sequencing 
run (not including library preparation) cost approximately £600 or £4000, respectively; 
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when shared between few samples this does not make whole genome sequencing 
cost-effective. 
4.1.3 Target enrichment 
The proportion of norovirus RNA in stool samples can be very low, resulting in low read 
depths when directly sequencing total RNA. The purpose of target enrichment is to 
purify the RNA of interest in the specimen, in this case norovirus, and discard the rest. 
Consequently the specimen is enriched for the genomes of interest and sequencing 
isn’t wasted on non-target genomes, such as host or bacteria.  
Enrichment makes use of a panel of custom-designed 120-mer RNA baits which are 
complementary to all publicly available target genome sequences, with multiple baits 
targeting each position of the genome. Baits are tiled across the genome so that every 
position in the genome has a complimentary bait. cDNA synthesised from total RNA is 
incubated with the biotinilated target-specific RNA baits, which will hybridise to target 
genomes present in the sample. Streptavidin coated magnetic beads will in turn bind to 
the hybridised baits, which can then be separated from all non-target cDNA using 
magnetic bead capture. The RNA baits are then digested, leaving an enriched library of 
target cDNA which can be sequenced on an NGS platform (Figure 4.2). Unlike PCR 
which introduces a bias for A to G and T to C substitutions, it has been demonstrated 
that target enrichment does not introduce nucleotide substitution bias [180]. The great 
advantage of this technique is that, unlike PCR which uses a single primer at each site, 
multiple baits are designed to cover each position, thus accounting for sequence 
variation between norovirus genomes. This has the potential for un-biased sequencing 
across genotypes in a single reaction, without prior knowledge of the genotype present 
in the specimen. Nonetheless, as with overlapping PCR, target enrichment does 
require pre-existing knowledge of norovirus sequence diversity for bait design. Should 
a novel genotype emerge which is not included in bait design, or an existing genotype 
evolve to the point where it is no longer enriched by existing baits, this will result in 
failure of target enrichment.   
SureSelect target enrichment was initially developed for human exome sequencing 
[181]. However it has since been translated to full genome sequencing of viruses or 
difficult to culture bacteria; the objective is to enrich for whole genomes of a specific 
pathogen in a background of other, non-target, genomes. Pathogens that have 
successfully been sequenced to date using target enrichment are varicella zoster virus 
[180], hepatitis C virus [182], human herpes virus 6 [183], human herpes virus 7 [184], 
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Mycobacterium tuberculosis [185] and Chlamydia trachomatis [186]. This is its first 
application for sequencing norovirus genomes. 
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cDNA hybridised to 120 nt biotin-labelled norovirus-specific 
RNA baits designed to cover entire genome. Multiple baits at 
each position in the genome accommodate sequence 
heterogeneity between genomes 
Magnetic beads bind biotin-labelled DNA-RNA fragments 
Norovirus cDNA is enriched and ready for deep sequencing 
cDNA synthesised from stool total RNA 
Target cDNA pulled out using magnet 
Figure 4.2 Schematic of SureSelect target enrichment workflow for norovirus whole genome sequencing. Image reproduced, with permission, from Agilent Technologies 
(www.agilent.com) 
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 MATERIALS AND METHODS 4.2
4.2.1 Samples 
507 norovirus positive stool samples from 382 patients in four UK healthcare 
institutions were processed for whole genome sequencing. Samples included 
genotypes GI.1, GI.2, GI.3, GI.6, GI.7, GII.1, GII.2, GII.3, GII.4, GII.5, GII.6, GII.7, 
GII.13, GII.14 and GII.17, as detailed in Table 4.1 on Page 121. The presence of 
norovirus was verified in all samples using a multiplex norovirus GI and GII-specific 
one-step reverse-transcription real-time PCR (RT-qPCR); the primer and probe 
sequences and cycling conditions are described in Chapter 2. For 78/507 samples 
provided by one of the centres, the presence of norovirus RNA was not verified in the 
re-extracted residual specimen; for these samples the RT-qPCR Ct value corresponds 
to the original extract used as part of diagnostic service. The RT-qPCR cycle threshold 
(Ct) value is used in this study as a semi-quantitative indicator of viral titre. 
All specimens were residual diagnostic specimens obtained from patients with 
confirmed norovirus infections. Specimens were submitted to the UCL Infection DNA 
Bank for use in this study. All samples were supplied to the study in an anonymised 
form; the use of these specimens for research was approved by the NRES Committee 
London – Fulham (REC reference:  12/LO/1089). All stool samples were stored at 
−80°C in between diagnostic testing and RNA extraction for full genome sequencing.   
164 stool samples were genotyped using capsid PCR and Sanger sequencing in 
parallel to SureSelect target enrichment whole genome sequencing. PCR primer 
sequences and cycling conditions for capsid genotyping are described in Chapter 2. 
Briefly, GI or GII-specific primers were used to amplify a 597 or 468 nt region of the 
norovirus capsid shell domain, respectively; amplicons were capillary sequenced in the 
forward and reverse direction. Generated sequences were submitted to the Norovirus 
genotyping tool to identify the capsid genotype [141].   
4.2.2 Specimen processing and sequencing 
The details for RNA extraction, cDNA synthesis, SureSelect bait design, target 
enrichment, sequencing library preparation and Illumina sequencing are described in 
detail in Chapter 2.  
4.2.3 Negative controls 
All RNA extraction batches included a negative extract control, consisting of sterile 
Qiagen Buffer ASL extracted with the Qiagen EZ1 virus mini kit alongside stool 
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samples. All negative extracts were tested by norovirus-specific RT-qPCR to verify the 
absence of contaminating RNA. 
To determine the level of contaminating norovirus RNA in the sequencing pipeline, two 
negative extracts were processed for sequencing.  
4.2.4 Sequence assembly 
All assemblies were done in CLC genomics workbench v8 using a de novo assembly 
pipeline, as described in detail in Chapter 2.  
4.2.5 Simulated mixed infection 
To assess whether a reliable consensus sequence can be generated from a mixed 
infection, the reads generated from two single infections (one GII.3 and one GII.4) were 
merged into a single assembly pipeline. The consensus sequences generated from the 
single infection (original) and the mixed (simulated) infection were aligned to identify 
the number of differences between the two consensus sequences.  
4.2.6 Sequencing outcomes and parameters 
For each sequence generated, the following outcomes were noted. First, the proportion 
of sequencing reads that map to a norovirus reference during the assembly filtering 
step referred to as the percent on-target reads (% OTR). Second, the proportion of the 
norovirus genome which the generated sequence covers referred to as the % genome 
coverage; this is based on the expected genome size for the relevant genotype (e.g. 
7560 nt for GII.4 genomes). Third, the average number of reads mapping at each 
position across the genome, referred to as the mean read depth. 
Parameters were set to determine sequence success. The cut-off for sequencing 
success was defined as >90% coverage of the full norovirus genome with >100-fold 
mean read depth. These parameters were chosen based on the requirement to 
generate complete genome sequences (>90% genome coverage) with robust 
consensus sequences (>100-fold read depth). A 100-fold minimum read depth was 
chosen because, although in bacterial genomes a 20-fold read depth is considered 
sufficient to overcome sequencing errors [187], since viral genomes exist as a 
quasispecies [51] a higher read depth was chosen to maximise accuracy at 
polymorphic sites. A minimum read depth of 100-fold has previously been used as the 
minimum read depth for identification of polymorphic loci in DNA viruses [180]. 
Samples that met only one of these criterions were categorised as “sub-optimal”, and 
those which did not meet either criteria were considered a “fail”.  
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4.2.7 Statistical analysis 
All statistical analysis was performed in SPSS v23 as described in Chapter 2.  
4.2.8 Evaluation of turn-around times 
To measure turn-around times for sequencing in a clinical setting, for five weeks 
(January–February 2016) all of the first-time norovirus positive stool specimens at 
GOSH were sequenced prospectively, in weekly batches. Each batch consisted of 1–
12 new norovirus specimens; to remain cost-effective batches were made up to 12 
using archived study samples. The 12 norovirus samples were sequenced in multiplex 
alongside other pathogen samples, in order to achieve 48–96 samples per MiSeq run.  
 RESULTS 4.3
4.3.1 Overall sequencing outcomes  
A median of 81% of the total sequencing reads generated for each sample mapped to 
the norovirus genome, referred to as the % on-target-reads (% OTR). On average, 
100% of the full genome was covered (% genome coverage) with median read depth of 
12,227-fold (Table 4.1).   
Of 507 samples across all sampled genotypes, 453 (89%) passed; i.e. had >90% 
genome coverage and >100-fold read depth. 93% of samples had a genome coverage 
of >90% at any depth. (Table 4.1, Figure 4.3).   
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Figure 4.3 (a) Number of samples sequenced according to norovirus genotype, classified by sequencing 
outcome; (b) Sequencing outcome proportions for each norovirus genotype. Pass, >90% genome 
coverage and >100-fold read depth; Sub-optimal, >90% genome coverage or >100-fold read depth; Fail, 
<90% genome coverage and <100-fold read. Genotype refers to capsid genotype only 
(a) 
 
(b) 
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Table 4.1 Metrics of norovirus whole genome sequencing for all samples (TOTAL) and for each genotype 
Pass, >90% genome coverage and >100-fold read depth; Sub-optimal, >90% genome coverage or >100-fold read depth; Fail, <90% genome coverage and <100-fold read depth; 
n/a, range not applicable due to single sample; % OTR, percent on target reads; Ct, real-time PCR cycle threshold; GI.ut, genogroup I untypable; GII.ut, genogroup II untypable; 
NegEx, negative control
 
Number of 
samples 
sequenced 
Number 
samples Pass 
(%) 
Number samples 
Sub-optimal (%) 
Number 
samples 
Fail (%) 
Median % OTR (min–
max) 
Median read depth (min–
max) 
Median % genome 
coverage (min–
max) 
Median Ct 
values (min–
max) 
GI.1 2 2 (100%) 0 (0%) 0 (0%) 63.05 (43.85-82.25) 11,194 (7,239–15,149) 100 (100–100) 31 (30–32) 
GI.2 4 4 (100%) 0 (0%) 0 (0%) 77.60 (2.17-94.70) 11,464 (379–21,843) 100 (99–100) 29 (24–33) 
GI.3 15 15 (100%) 0 (0%) 0 (0%) 74.13 (1.08-93.25) 13,157 (246–27,569) 100 (90–100) 27 (17–35) 
GI.6 1 1 (100%) 0 (0%) 0 (0%) 86.56 (n/a) 8,642 (n/a) 100 (n/a) 29 (n/a) 
GI.7 1 1 (100%) 0 (0%) 0 (0%) 83.88 (n/a) 18,414 (n/a) 100 (n/a) 21 (n/a) 
GI.ut 2 1 (50%) 0 (0%) 1 (50%) 40.34 (9.50-71.18) 7,000 (42–13,957) 91 (83–100) 29 (23–35) 
GII.1 3 3 (100%) 0 (0%) 0 (0%) 95.61 (20.06-97.04) 11,990 (4,365–16,506) 100 (99–100) 15 (14–31) 
GII.13 1 1 (100%) 0 (0%) 0 (0%) 77.44 (n/a) 10,043 (n/a) 100 (n/a) 21 (n/a) 
GII.14 6 6 (100%) 0 (0%) 0 (0%) 53.31 (4.20-81.60) 10,238 (1,081–15,215) 100 (100–100) 27 (21–32) 
GII.17 2 2 (100%) 0 (0%) 0 (0%) 63.30 (40.27-86.33) 13,204 (8,598–17,811) 100 (100–100) 24 (21–27) 
GII.2 24 21 (88%) 0 (0%) 3 (12.5%) 57.60 (0.60-99.47) 4,717 (7–23,889) 100 (64–100) 24 (18–32) 
GII.3 105 91 (87%) 3 (2.9%) 11 (10.5%) 85.00 (0.02-99.36) 16,034 (7–38,843) 100 (3–100) 21 (10–38) 
GII.4 281 250 (89%) 12 (4.3%) 19 (6.8%) 83.75 (0.02-99.63) 12,465 (1–46,996) 100 (5–100) 22 (12–43) 
GII.5 6 5 (83%) 0 (0%) 1 (16.7%) 70.21 (0.04-97.13) 16,468 (1–29,488) 100 (49–100) 19 (16–23) 
GII.6 40 38 (95%) 0 (0%) 2 (5%) 70.32 (0.45-98.23) 9,356 (3–31,643) 100 (22–100) 21 (13–33) 
GII.7 10 9 (90%) 0 (0%) 1 (10%) 53.14 (2.72-83.88) 12,779 (2,106–26,914) 100 (96–100) 25 (22–30) 
GII.ut 4 3 (75%) 1 (25%) 0 (0%) 49.02 (0.59-92.61) 11,356 (98–23,588) 100 (94–100) 25 (19–35) 
NegEx 2 0 (0%) 0 (0%) 2 (100%) 26.30 (16.18-36.42) 42 (3–81) 11 (9–12) Not detected 
TOTAL 509 453 (89%) 16 (3%) 40 (8%) 81.22 (0.02–99.63) 12,227 (1–46,996) 100 (3–100) 22 (10–43) 
Total excl. Run 
30 & 31 
413 381 (92%) 16 (4%) 16 (4%) 84.45 (0.02–99.63) 14,341 (1–46,996) 100 (13–100) 22 (10–40) 
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There was no significant difference in % OTR (P = 0.127), mean read depth (P = 
0.398) or % genome coverage (P = 0.203) between norovirus genotypes (Figure 4.4 
(a–c)). 
A significant correlation was found between % OTR and read depth (R = 0.757, P 
<0.001, Figure 4.5) and between PCR Ct value and (i) % OTR (R = −0.536, P <0.001), 
(ii) read depth (R = −0.468, P <0.001) and (iii) % genome coverage (R = −0.223, P 
<0.001) (Figure 4.4 (d–f)). It follows that there is a significant difference in PCR Ct 
value between samples that passed compared to those that were sub-optimal (P 
<0.001) or failed (P <0.001) with median Ct values of 22, 32 and 32, respectively 
(Figure 4.6). There is an inverse relationship between Ct value and viral load [188]; 
thus samples with a smaller Ct value (higher viral titre) resulted in higher %OTR, read 
depth and genome coverage. 
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Figure 4.4 Norovirus full genome sequencing outcome metrics according to (a–c) norovirus genotype and (d–f) RT-qPCR Ct value. Red lines indicate median value 
(a)                (b)           (c) 
 
(d)                (e)           (f) 
   
% OTR, % on-target-reads; Ct, cycle threshold  
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Figure 4.5 Correlation of read depth and % OTR across all samples (n = 507). R = 0.757, P <0.001 
 
 
Figure 4.6 RT-qPCR Ct value of all samples, excluding Run 30 and 31, (n = 413) sequenced by SureSelect. 
Pass, >90% genome coverage and >100-fold read depth; Sub-optimal, >90% genome coverage or >100-
fold read depth; Fail, <90% genome coverage and <100-fold read depth 
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4.3.2 Predicted genome coverage 
The estimated linear regression model is 𝑦 = 7.432 − 0.059𝑥 where the dependent 
variable y is the logit of transformed genome coverage proportion and the independent 
variable x is the PCR Ct value (n = 477, R2 = 0.058, P <0.001).  
Prediction intervals generated using the linear regression model predict that stool 
samples with a norovirus RT-qPCR Ct value <40 will generate 92–100% of the full 
genome sequence, with 95% certainty (Figure 4.7).  
Figure 4.7 Observed and predicted % genome coverage values with 95% prediction intervals, excluding 
outliers detailed in section 2.20.2). Fitted linear regression model: y=7.432-0.059x where the dependent 
variable y is the logit transformed genome coverage proportion 
 
4.3.3 Failed samples  
There were 22 (22/507) samples that achieved less than 80% genome coverage; 
including 15 with Ct values below 30 (suggesting a high viral titre) (Figure 4.4 (f)). 
Since all other samples (485/507) achieved greater than 80% genome coverage, 
including 414 samples with Ct below 30, these were considered to be outliers. These 
outliers are dominated by samples from two sequencing runs (#30 and 31; Figure 4.8), 
accounting for 18/22 of the outliers. Runs 30 and 31 had processing problems during 
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cDNA preparation. Specifically, cDNA for samples in Runs 30 and 31 was prepared in 
a 96-well plate; during RNA concentration in the vacuum centrifuge the rate of 
evaporation across the plate was unequal, resulting in slightly varied volumes for the 
next step of cDNA synthesis.  
Figure 4.8 % genome coverage and Ct value, with sequencing runs 30 and 31 highlighted. Green circles 
highlight outliers that cannot be explained by sequencing runs 30 and 31 
 
Three samples (highlighted in Figure 4.8, detailed in Table 4.2) generated 
unexpectedly low % genome coverage (49–73%) given the RT-qPCR Ct values (22–
29) but were not part of sequencing runs 30 or 31. Sequences from all three samples 
were fragmented throughout ORF 1, with ORF 2 absent downstream from the capsid 
protruding domains and absent ORF 3 (Figure 4.9). In all three cases, the % OTR 
(0.01, 2.53 and 6.76%) and average read depth (1-, 120- and 137-fold) was low for 
ORF 1 despite apparently good Ct values. Coverage of ORF 1 and the 5’ end of ORF 2 
was sufficient to confirm two samples as GII.4 and one as GII.5 using the norovirus 
genotyping tool; we have shown good sequencing outcomes for both genotypes in 
other samples (Table 4.1 on Page 121). It is not possible to exclude the possibility of a 
novel recombinant strain, with recombination at the P1/P2 junction in ORF 2, and 
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subsequent failure due to missing complementary baits in the enrichment; however if 
this were the case we would expect to see good coverage of the enriched region, in 
this case ORF 1, which we do not. Moreover all three samples had been re-extracted 
at referring centres and the Ct value supplied was obtained from PCRs carried out on 
the original diagnostic extracts. This, combined with the low coverage of ORF 1, 
suggests that extraction failure at the local hospital may explain the unexpected 
sequencing failure. It has not been possible to test either possibility, since none of the 
original sample remains.  
Table 4.2 Sequencing results of samples with RT-qPCR Ct value <30 and unexpectedly low % genome 
coverage (<80%), excluding samples from sequencing runs 30 and 31 (n = 3; highlighted in Figure 4.8) 
Sample 
name 
Genotype 
RT-qPCR  
Ct value 
% genome 
coverage 
% OTR* 
Average 
read depth 
NOR_2431 GII.5 22 49% 0.01% 1 
NOR_2488 GII.4 29 52% 6.76% 137 
NOR_2500 GII.4 22 73% 2.53% 120 
*% OTR, % on-target-reads 
 
Figure 4.9 Alignment of samples with RT-qPCR Ct value <30 and unexpectedly low % genome coverage 
(<80%), excluding samples from sequencing runs 30 and 31 (n = 3; highlighted in Figure 4.8 and detailed 
in Table 4.2) 
 
 
The outliers discussed above were assumed to have failed due to the aforementioned 
technical problems. Six of the samples from Runs 30 and 31 had sufficient residual 
specimen to be re-extracted and re-sequenced; all of these were successfully 
sequenced on repeat, which suggests the assumed reason for failure is correct. 
However, since there was no residual specimen to repeat the remaining outliers, the 
possibility that these were sequence failures due to other limitations with the 
sequencing pipeline, rather than the aforementioned technical problems, cannot be 
excluded. 
One remaining outlier had only 13% genome coverage with a PCR Ct value of 38. This 
sample was not part of Runs 30 or 31. The possibility that this sample had poor 
genome coverage due to low virus titre (a Ct value of 38 is near the limit of detection 
for PCR) cannot be excluded, therefore this sample was not considered an outlier and 
was included in the calculation of predicted genome coverage.  
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4.3.4 Low titre samples 
Seven samples generated full genome sequences in spite of low viral titres (PCR Ct 
≥36). To determine whether these samples had misleadingly late Ct values due to a 
mismatch in the RT-qPCR primer target region, the seven genome sequences were 
aligned to the RT-qPCR primer and probe sequences used to generate the Ct value. 
There were no mismatches in the primer or probe sites (Figure 4.10), suggesting they 
are genuinely low titre samples and confirming the sensitivity of the method for low titre 
samples. 
Figure 4.10 Nucleotide alignment of all samples with real-time PCR Ct value ≥36 (i.e. apparently low 
titre) but >80% genome coverage (n = 7) by SureSelect target enrichment sequencing 
Degenerate nucleotide code: R, A/G; W, A/T 
 
4.3.5 Comparison to capsid genotyping 
96% (158/164) and 100% (164/164) of samples processed in parallel were successfully 
genotyped by PCR of the capsid shell domain with Sanger sequencing and by our 
method (SureSelect target enrichment), respectively (Table 4.3). For the 158 samples 
typed by both methods, there was 100% agreement in the respective genotypes. Of the 
6 samples that failed capsid typing by PCR, four were GII.4, one GII.7 and one GI.3 
(Table 4.4). 
Table 4.3 Genotyping success of samples processed in parallel by SureSelect target enrichment for full 
genome sequencing and PCR amplification of capsid shell domain followed by Sanger sequencing 
 Full genome sequenced Full genome failed** Total 
PCR amplified 158 0 158 (96%) 
PCR failed* 6 0 6 
Total 164 (100%) 0 164 
* no amplification by PCR 
** <90% genome coverage and <100-fold read depth
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Table 4.4 Sequencing results of samples that failed to amplify the capsid shell domain by PCR for 
genotyping, but were successfully sequenced by SureSelect target enrichment (n=6) 
Sample 
name 
Genotype 
RT-qPCR 
Ct value 
% genome 
coverage 
% OTR* 
Average 
read depth 
NOR_2266 GI.3 20 100% 70% 13,957 
NOR_2568 GII.7 31 99% 83% 11,235 
NOR_2567 GII.4 27 100% 91% 23,068 
NOR_2360 GII.4 33 100% 15% 3,995 
NOR_2359 GII.4 33 100% 8% 2,281 
NOR_2358 GII.4 37 99% 55% 11,740 
*% OTR, % on-target reads 
 
 
Two of the failed samples, with Ct values 20 and 27, had mismatches at the genotyping 
PCR primer sites (Figure 4.11) which accounts for genotyping failure in these 
instances.  
The remaining four of the six samples that failed genotyping had Ct values >30 (range 
31–37), which suggests the genotyping PCR is less sensitive than sequencing by 
target enrichment.
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Figure 4.11 Nucleotide alignment of all GII (n=5) and GI (n =1) samples that failed to amplify the capsid 
shell domain by PCR for genotyping, but were successfully sequenced (>99% genome coverage) by 
SureSelect target enrichment. Additional sequences (labelled with genotype) that were genotyped 
successfully are included for comparison. Mismatches predicted to cause genotyping PCR amplification 
failure are circled. (a) GII forward; (b) GII nested forward; (c) GII reverse; (d) GI forward; (e) GI nested 
forward; (f) GI reverse 
(a)                (b) 
       
(c) 
 
(d)              (e) 
    
(f) 
 
Degenerate nucleotide code: H, A/C/T; M, A/C; B, G/T/C; D, G/A/T; Y, C/T; R, A/G; N, G/C/A/T 
 
4.3.6 Contamination 
Two “negative extract” samples, consisting of Buffer ASL that was treated in the same 
way as, and alongside, stool samples, were negative for norovirus RNA by RT–qPCR. 
Nonetheless target enrichment and sequencing generated 16–36% OTR with 3–81-fold 
read depth (Figure 4.12 a). The genome coverage for each sample was only 9 and 
12% (Figure 4.12 b), with reads fragmented across the genome (Figure 4.13). The 
mapped regions do not correspond to PCR amplicon sites. 
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Figure 4.12 Distribution of (a) mean read depth and (b) % genome coverage for stool samples and 
negative extracts. Red lines indicate median values 
(a) 
 
(b) 
 
 
Figure 4.13 Contigs generated from Negative Extract mapping to norovirus full genome 
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4.3.7 Mixed infections 
Three (3/507) samples were identified as having sequences from more than one 
genotype during the assembly pipeline (Table 4.5). For two of the samples, the mixed 
infections were evident during the “mapping to reference list” step of the de novo 
pipeline (Figure 2.2 on Page 70 in General Methods), in which reads mapped to 
reference sequences corresponding to multiple norovirus genotypes, as per Table 4.5. 
For the third sample, mixed infection was evident during the “align contigs to single 
reference of appropriate genotype” step, in which a full length contig mapped to the 
reference sequence at ORF 1 but not at ORF 2 and ORF 3.  
Table 4.5 Mixed infections in clinical specimens identified during assembly pipeline 
Sample 
name 
Genotypes 
present 
Step in assembly pipeline that 
identified mixed infection 
Number of reads mapping to 
each genotype in filtering step 
NOR_2565 GII.3, GII.4 and 
GII.2 
Filtering step (mapping to 
reference list) 
GII.3: 792,264 
GII.4: 113,068 
GII.2: 859,899 
 
NOR_2276 GII.3 and GII.6 Filtering step (mapping to 
reference list) 
GII.3: 425,961 
GII.6: 373,439 
 
13V35152 GII.3 and GII.4 Align contigs to reference GII.4: 470,377 
GII.3: 1,155 
 
Comparison of the consensus sequences generated from a single infection and from a 
simulated mixed infection showed 178–332 single nucleotide polymorphisms (SNPs) 
and 95.53–97.61% sequence identity between the consensus sequences from the 
single and mixed datasets (Table 4.6).  
Table 4.6 Comparison of consensus sequences generated from de novo assembly in single infections 
(original) and a simulated mixed infection (mixed) 
  Samples data 
originates 
from 
Number 
of reads 
mapping 
Read 
depth 
Consensus 
sequence 
length 
% identity 
between 
consensus 
sequences 
SNP 
difference 
between 
consensus 
sequences 
SNPs in 
ORF1 
SNPs in 
ORF2 
SNPs in 
ORF3 
GII.3 
original  
Noro-14069 413,812 3,154 7,555 
97.61 178 
163 
/178 
15 
/178 
0 
/178 
GII.3 
mixed  
Noro-14069 
& -28464 
630,742 3,850 7,459 
GII.4 
original  
Noro-28464 431,263 2,917 7,489 
95.53 332 
284 
/332 
22 
/332 
26 
/332 
GII.4 
mixed  
Noro-14069 
& -28464 
676,523 4,017 7,426 
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4.3.8 Turn-around times and costs 
During a 5 week trial of sequencing in real-time at GOSH, actual turn-around times, 
from specimen receipt in the laboratory to sequencing result, were three weeks. This is 
based on weekly batching of specimens. The first week comprised batched RNA 
extraction of all norovirus positive specimens for that week, the second week cDNA 
synthesis and the third week SureSelect library preparation and sequencing. For library 
preparation reagents to remain cost effective samples must be sequenced in batches 
of 12 samples all with the same target pathogen; during the five weeks of prospectively 
sequencing in real-time this was only achieved in two of the five weeks, with one, five 
and eight samples in the other three weeks. 
If one assumes no delays for batching, the best possible turn-around times associated 
with full genome sequencing by SureSelect target enrichment from RNA to sequencing 
result is 6 days; three days longer than genotyping (RNA-dependent RNA polymerase 
and capsid regions) by PCR and Sanger sequencing. SureSelect target enrichment 
incurs an extra cost of £54 when reagents are purchased in bulk (Table 4.7). 
Table 4.7 Turn-around times and costs associated with norovirus genotyping by PCR and Sanger 
sequencing compared to SureSelect target enrichment full genome sequencing 
Genotyping method Hands on time 
Total turn-around 
time 
Reagent costs per 
sample 
PCR and Sanger 
sequencing* 
7 hours 3 days £32 
Full genome 
sequencing by 
SureSelect target 
enrichment 
11 hours 30 minutes 6 days £86–£93**  
* PCR amplification of three sites of interest for norovirus genotyping; RNA-dependent RNA polymerase 
(RdRp), capsid shell domain and capsid P2 domain, including one round of nested PCR, assuming RdRp 
and capsid shell domain targets are amplified and sequenced simultaneously 
** Cost based on batches of 96 or 48 samples and sequencing on an Illumina MiSeq. 
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 DISCUSSION 4.4
Target enrichment is an effective method for sequencing norovirus full genomes across 
genotypes with a high read depth averaging over 12,000-fold and complete or almost 
complete genomes in 89% of samples. Target enrichment achieved median genome 
coverage of 100% across all sequenced samples and, once outliers were accounted 
for, over 80% genome coverage regardless of the viral titre.  
4.4.1 Analysis of mixed infections 
The de novo assembly pipeline developed as part of this study identified mixed 
genotype infections in three samples. However with as many as 332 SNPs between 
the consensus sequences generated from a single and simulated mixed infection, a 
reliable consensus sequence cannot be generated using this assembly pipeline. This is 
due to miss-mapping of reads in relatively conserved regions, as evidenced by the 
majority of SNPs being found in ORF1 (163/178 and 284/332 in the GII.3 and GII.4 
consensus sequences respectively). Thus whilst this pipeline can identify infections 
with a mixture of genotypes, an alternative approach is required for assembly and 
generating the consensus sequence, possibly involving the use of minority variants and 
haplotype reconstruction.  
It is possible that samples identified as mixed infections during the assembly pipeline, 
due to reads mapping to multiple genotypes, are sequencing artefact rather than true 
mixed infections. Given that contaminating norovirus reads were detected in the two 
“negative extracts”, it is possible that contaminating reads from other samples mimic a 
mixed infection, when there is not one. This may be the case for sample 13V35152 
(Table 4.5) in which only 1,155 reads mapped to GII.3 compared to 470,377 reads 
mapping to GII.4; however the GII.3 reads generated a 3,000 nucleotide contig 
mapping to ORF 2, ORF 3 and the 5’ end of ORF 1 whereas the contaminating reads 
in the negative extracts were fragmented across the genome (Figure 4.13). 
Nonetheless in this instance further evidence is required to conclude there is a true 
mixed infection, such as re-extracting and re-sequencing the sample to replicate the 
results. This was not possible as there was no residual specimen for repeat 
processing.  
4.4.2 Comparison to other methods for whole genome sequencing 
Previous reports have described whole norovirus genome sequencing with overlapping 
PCR amplicons or using RNASeq, the findings of which are summarised in Table 4.9. 
PCR- based methods yield high read depth; however, due to sequence heterogeneity 
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between genotypes, primers generally need to be genotype specific [148]. Broad-range 
primers have been reported by Cotton et al. [149] nonetheless this approach retains a 
limited success rate; full genome sequences were amplified from a comparable 
proportion of samples of GII.13, GII.6 and GII.4. However PCR fared worse, recovering 
fewer full genomes from GII.2, GII.3, GII.7 and GI (Table 4.8). It may be possible to 
design broad-range primers that have greater sequencing success across genotypes; 
however there are currently no alternatives published in the literature. Norovirus whole 
genome sequencing from a single 7.5 kb amplicon has also been described and used 
to generate 25 full genome sequences [146] however the authors do not report the 
success rate using this approach; it is generally very difficult to amplify fragments of 
such a size. Conversely this chapter reports complete or nearly-complete genome 
sequences in 93% of processed samples. In target enrichment, baits are designed 
using all publically available norovirus sequences, across all GI and GII genotypes; 
unlike PCR which uses a single primer at each target site,  multiple baits are designed 
to cover each position in the genome thus accounting for sequence variation between 
norovirus genomes. This potentially allows un-biased sequencing across known 
genotypes in a single reaction. A disadvantage of the method is that it may fail to 
generate sequences for a newly emerging genotype where the existing baits are a poor 
match.   
Table 4.8 Percentage of samples belonging to each genotype for which full genomes were achieved in 
this study, using target enrichment, and by Cotton et al. [149] using PCR 
Genotype This study  Cotton et al. (2015) 
GII.13 100% 83% 
GII.6 95% 88% 
GII.4 89% (93% irrespective of read depth) 92% 
GII.2 88% 40% 
GII.3 87% (90% irrespective of read depth) 77% 
GII.7 90% 0% 
GI 100% 20% 
 
Whole transcriptome sequencing, or direct sequencing of total RNA (RNASeq), 
involves sequencing the total RNA or mRNA content of a stool specimen. The 
advantage of RNASeq is that there is no requirement for PCR primers therefore it is 
completely unbiased. Although whole genomes by RNASeq reported to date are 
predominantly GII.4, it is theoretically possible to sequence all genotypes with equal 
success as evidenced by Bavelaar et al who successfully sequenced five non-GII.4 
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genomes [189]. The data generated by RNASeq is sufficient to generate almost 
complete norovirus genome sequences; 40–100% of reported samples achieved >90% 
genome coverage [147, 178, 179, 189] (summarised in Table 4.9). However the 
median % OTR across all reported samples is only 2–3% using a MiSeq or HiSeq [178, 
179] and 28% using an Ion Torrent PGM [189], compared to 81% OTR by SureSelect 
target enrichment. The proportion of on-target reads using target enrichment is not 
100% meaning that, as with RNASeq, non-target sequences are generated; however 
the % OTR of target enrichment is, with the exception of PCR-based methods, superior 
to other methods that are currently published in the literature. The high proportion of 
non-target data using RNASeq makes the technique uneconomical and, critically, 
results in low read depth; on average only 9–259-fold using a MiSeq or HiSeq [147, 
178, 179] and 1,309 using an Ion Torrent PGM [189]. Conversely, the median read 
depth using target enrichment is over 12,000-fold which allows large batches of 
samples to be sequenced on a single MiSeq run and downstream analysis of minority 
variants.  
  
 
1
3
7
 
Table 4.9 Summary of norovirus whole genome sequencing reports in the literature 
Author Country Method 
Sequencing 
platform 
Assembly 
Number of 
samples 
Genotypes (% 
success*) 
% OTR 
Genome 
coverage 
Read depth 
Chhabra 
(2010) 
[190] 
India Overlapping PCR 
(9 amplicons) 
Sanger 
sequencing 
Not stated 3 GII.4 and 
GII.b_GII.3† 
n/a** 100% n/a†† 
Won (2013) 
[191] 
South Korea Overlapping PCR 
(10 amplicons) 
Sanger 
sequencing 
Not stated 1 GII.P12_GII.13† n/a** 100% n/a†† 
Eden 
(2013) 
[146]  
Australia Long PCR (7.6kb) Sanger 
sequencing 
Not 
applicable 
25 GII.4† n/a** 100% n/a†† 
Kundu 
(2013) 
[148] 
 
UK Overlapping PCR 
(22 amplicons) 
 
Roche 454 De novo 13 GII.4 † n/a** 86–99% Median 580 
(423–951) 
Cotten 
(2014) 
[149] 
Vietnam Overlapping PCR 
(3 amplicons) 
Illumina 
MiSeq 
De novo 265 GI (20%) 
GII.2 (40%) 
GII.3 (77%) 
GII.4 (92%) 
GII.6 (88%) 
GII.7 (0%) 
GII.9 (100%) 
GII.12 (50%) 
GII.13 (83%) 
Overall success 
78% 
 
n/a** 100% Not stated 
Botha et al. 
(2016) 
[192] 
South Africa Overlapping PCR 
(3–5 amplicons) 
Sanger 
sequencing 
 
Not stated 11 GII.4 n/a** 100% n/a†† 
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Author Country Method 
Sequencing 
platform 
Assembly 
Number of 
samples 
Genotypes (% 
success*) 
% OTR 
Genome 
coverage 
Read depth 
 
Nakamura 
(2012) 
[179] 
Japan Whole 
transcriptome 
amplification kit 
(70 cycles PCR) 
 
 
Roche 454 Reference 
mapping 
5 GII.4 (40%) Median 3% 
(0.05–60%) 
Median 84.5% 
(2.1–98%) 
9–259 
Batty 
(2013) 
[178] 
UK mRNA RNASeq Illumina 
MiSeq and 
HiSeq 
Reference 
mapping 
3 (MiSeq) plus 
77 (HiSeq) 
GII.4 (99%) MiSeq: median 
1.8% (0.12–1.90) 
HiSeq: 
median 2.7% 
(0.01–97.98%) 
 
MiSeq: 97–99% 
HiSeq: Mean 
97% (59 – 99%) 
MiSeq: Not 
stated 
HiSeq: Median 
100  (10–1,000) 
 
Wong 
(2013) 
[147] 
UK mRNA RNASeq  
 
Illumina 
MiSeq 
De novo 32 GII.4 (66%) Not stated 21/32 >97% Not stated 
Bavelaar  
et al. (2015) 
[189] 
Netherlands Whole 
transcriptome 
amplification with 
ribosomal RNA 
depletion 
Ion Torrent 
PGM (318 
chip) 
Reference 
mapping 
10 GI.1 (100%) 
GI.6 (100%) 
GII.4 (100%) 
GII.6 (100%) 
GII.21 (100%) 
GII.2 (100%) 
Median 28% 
(0.7–70.9%) 
100% Median 1309 
(25–3607) 
*>90% genome coverage 
** Not applicable for PCR amplicon sequencing 
† Success rate not reported 
†† Read depth not applicable for capillary sequencing 
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4.4.3 Comparison to PCR-based genotyping 
Target enrichment is shown in this chapter be superior to PCR capsid amplification for 
genotyping; all samples (164/164) that were processed in parallel successfully 
generated genome sequences by target enrichment, whereas 96% (158/164) were 
successfully amplified by capsid typing PCR. Four of the six samples that failed capsid 
genotyping but were sequenced by target enrichment had low norovirus titres (based 
on PCR Ct values), which suggests target enrichment is more sensitive than the 
conventional genotyping methods. The remaining two failed samples had primer 
mismatches that account for amplification failure. Target enrichment overcomes the 
limitations of primer design by allowing multiple baits with different sequences to target 
each region of the genome, thus accounting for sequence heterogeneity in a way that 
PCR primers cannot. 
Unlike classical genotyping, which requires sequential PCR and sequencing reactions 
yielding only fragments of the genome in return, full genome sequences can, in a single 
reaction, provide us with the RNA polymerase and capsid sequences, which are 
important for genotyping,  and in addition can identify recombination and reveal 
minority variants in the intra-host viral population.  
4.4.4 Quality assurance  
Despite good molecular practice, low level contamination does occur in the sequencing 
pipeline described in this chapter. Since negative extracts were RT-qPCR negative but 
target enrichment yielded reads that map to the norovirus genome, the suspected 
source of contamination is the automated equipment used for target enrichment and 
sequencing library preparation. In the context of norovirus-positive specimens, the 
contamination is low; reads are fragmented and only map to 9-12% of the genome with 
<100-fold read depth, which is significantly below the observed median % genome 
coverage and read-depth seen for norovirus-positive samples (100% and >12,000-fold, 
respectively) and below the 95% prediction intervals for % genome coverage (92–
100% for a sample with Ct <40). These findings support the proposed acceptance 
criteria for downstream analysis, which is >100-fold read depth and >90% genome 
coverage. Due to the potential for low level contamination, specimens for which 
norovirus RNA is not detectable by real-time PCR should not be sequenced.  
For robust quality assurance, which is required for diagnostic laboratory accreditation, 
a negative and positive control should typically be included in every run. The negative 
control should be a norovirus-negative specimen or buffer that has been co-extracted 
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and processed with the norovirus-positive specimens and the positive control a known 
norovirus-positive specimen. As described above, only norovirus positive samples 
should be processed for sequencing; these act as their own positive control therefore a 
separate positive control on every run is not strictly required. However a positive 
control with each batch would be necessary to ensure enrichment has performed as 
expected (for example expected read depth given the batch size). The positive control 
is of particular importance if one plans to identify minority variants; in this instance the 
control should include minority variants of known frequency. Implementation of 
acceptability criteria, as described here, overcomes problems of low-level 
contamination in the system, however this does not account for gradual accumulation 
of contamination in the system or gross contamination of reagents. For this reason a 
negative control should be included in sample processing. Ideally this should be with 
every batch; however in the context of low-throughput processing in a diagnostic 
laboratory the cost of this may be prohibitive.  
4.4.5 Cost of sequencing 
The cost of target enrichment whole genome sequencing is around £50 more 
expensive than PCR genotyping of the capsid and polymerase genes. Whole genome 
sequencing using overlapping amplicons is comparable in cost to target enrichment; 
therefore target enrichment is not more expensive than other whole genome 
sequencing methods. However there is an economy of scale with sequencing, 
including the library preparation reagents but in particular the sequencing run; an 
Illumina MiSeq sequencing cartridge costs £685 regardless of whether one or 100 
samples are sequenced. Therefore the costs discussed here were only achieved by 
sequencing in batches of 48 or 96 samples per run. This is achievable for a large 
study, or for a regional sequencing service which can fill a run with other samples, 
however is not realistic for an individual diagnostic laboratory.  
4.4.6 Turn-around times 
Once RNA is extracted, turnaround time for target enrichment is 6 days compared to 
three days for capsid and polymerase genotyping by PCR, including sequencing time. 
The semi-automated target enrichment hands-on-time is 4 hours more than 
conventional genotyping and comparable to RNASeq. It should be possible to 
synthesise cDNA, prepare the sequencing library and complete a sequencing run 
within 6 days, however in reality this took two weeks as cDNA synthesis was batched 
one week and library prep and sequencing batched the following week. In addition 
there is a one week lag between specimen collection and cDNA synthesis; this is due 
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to waiting for the diagnostic real-time PCR result to identify norovirus positive samples 
followed by weekly batching of RNA extraction for sequencing. Therefore, over all, 
there was a three week turn-around time from specimen collection to result. This three 
week turn-around time was only made cost-effective by topping up weekly batches to 
12 specimens with archived retrospective samples, and by filling MiSeq runs to 48–96 
samples using samples with other target pathogens from other studies. If other 
samples were not available, sequencing in real-time would either not have been cost 
effective, or turn-around times would have been extended by several weeks to enable 
a full run.   
The utility of norovirus full genome sequencing in real-time is currently limited by 
drawbacks of batch processing. These would be in part addressed by random-access 
processing and shortened library preparation hybridisation times, which are the subject 
of future work. In addition, to optimise turn-around times and cost-effectiveness, 
norovirus whole genome sequencing needs to occur in a laboratory with a high-
throughput of next generation sequencing. In time this may be individual diagnostic 
laboratories, but at the moment this would have to be a regional laboratory or 
sequencing service.  
4.4.7 Conclusions 
Target enrichment is a robust and sensitive method for sequencing norovirus full 
genomes that overcomes the limitations of other published methods, namely of primer 
design in PCR and of non-target sequencing in RNASeq. It is comparable in cost to 
other whole genome sequencing methods, and not significantly more expensive then 
PCR-based genotyping despite providing far greater amounts of data; however batch 
sequencing is necessary to achieve cost-savings, which has implications on turn-
around times and thus clinical utility. The read depth and breadth of genotypes that can 
be sequenced is superior to other published sequencing methods. 
Low level contamination occurs in the sequencing pipeline, however this is 
distinguishable from genuine data which has significantly greater genome coverage 
and read depth. Nevertheless only specimens for which norovirus is detectable by RT-
qPCR should be sequenced. 
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  CHAPTER 5
 
NOROVIRUS MOLECULAR EPIDEMIOLOGY IN A 
PAEDIATRIC HOSPITAL: UTILITY OF FULL GENOME 
SEQUENCING IN A CLINICAL SETTING 
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 INTRODUCTION 5.1
Molecular epidemiology allows us to compare either complete or partial viral genome 
sequences between infected cases; based on phylogenetic analysis one can infer 
shared ancestry between infecting viruses. This inference can allude to transmission 
events between linked infections or, conversely, exclude cases from an outbreak.  
Given that the number of cases of norovirus characteristically peaks during winter, it 
can be difficult to distinguish a true outbreak occurring in an institution, with introduction 
of a single strain and consequent spread, from multiple introductions of unlinked cases 
that happen to occur contemporaneously (Figure 5.1). It is important to distinguish 
between these two scenarios for purposes of infection control; the first scenario 
suggests a break-down in infection control practices and requires interventions to 
interrupt transmission, whist the second scenario suggests high rates of norovirus 
circulation but with effective infection control practice limiting transmission. 
Figure 5.1 Two scenarios of norovirus nosocomial epidemiology; (a) single introduction of one strain 
which spreads throughout the hospital thus causing the majority of detected cases, or (b) multiple 
introductions of several different strains with limited transmission of each strain 
 
Norovirus outbreaks in healthcare settings are characteristically dominated by a single 
genotype, typically GII.4 [128]. Genotyping of norovirus infections allows patients with a 
different genotype to be excluded from the outbreak; however it cannot confirm or 
exclude transmission between patients infected with the same genotype. In this 
instance molecular epidemiology using phylogenetic analysis may be informative; in 
influenza transmission studies phylogenetic analysis demonstrated that 
epidemiologically related cases, i.e. linked in time and place, did not always share 
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related viruses [193]. The lack of diversity in the polymerase and capsid shell domains 
used for norovirus genotyping means these regions provide insufficient information for 
tracking outbreaks [194]. Consequently these regions cannot be used to investigate 
transmission between infections caused by the same genotype.   
To date, reports of norovirus molecular epidemiology have largely utilised partial 
genome sequences, as these can be amplified by PCR and Sanger sequenced. In lieu 
of full genomes, due to its high level of diversity the P2 region of the capsid is the most 
informative region in norovirus outbreaks [145].  In immunocompetent people the P2 
region is expected to be 100% identical between patients in whom a transmission 
event has occurred [140, 143], with a 10% probability of 1–2 nucleotide changes in 
samples collected three weeks post-infection [142]. Therefore in acute norovirus 
outbreaks amongst immunocompetent persons P2 sequencing has been used to 
identify independent clusters of transmission among patients infected with the same 
genotype and identify transmission events which were missed based on traditional 
epidemiological data alone [139, 140, 142-144]. Reports of norovirus P2 domain 
sequencing used for nosocomial molecular epidemiology are summarised in Table 5.1.  
In immunocompromised patients, however, transmission may occur after in vivo 
evolution therefore single nucleotide polymorphisms (SNPs) are observed in the capsid 
sequence between linked patients [144]. Holzknecht et al. used PCR and Sanger 
sequencing to sequence the norovirus capsid sequence (1412 nt, including P2 domain) 
from 13 immunocompromised patients from an outbreak on a haematology ward in 
2008 in Denmark and found up to 13 SNPs between linked patients [144]. Diversity in 
the capsid region in immunocompromised patients has the potential to make 
interpretation of phylogenies based on P2 sequences alone challenging as the 
previously employed rule of identical P2 sequences between linked cases does not 
apply.  
To date, there are no comprehensive reports in the literature of norovirus molecular 
epidemiology in an immunocompromised population, neither using P2 sequences nor 
full genomes. This chapter aims to investigate the utility of norovirus whole genome 
sequencing in a nosocomial setting and to elucidate the transmission dynamics in a 
paediatric hospital with a large immunocompromised population.
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Table 5.1 Summary of published reports of nosocomial norovirus molecular epidemiology using capsid P2 domain sequences 
Authors Method  Genotype  Year and 
country 
Region 
analysed 
Number 
of 
patients 
Setting Results 
Xerry et al. 
2008 [143] 
PCR and 
Sanger 
sequencing 
GII.4 2006–2007, 
UK 
P2 (800 nt) 44 14 outbreaks in 2 hospitals 100% sequence identity within outbreaks 
 
Recommend ≥1 nt difference between patients 
suggests they are not linked 
Xerry et al. 
2010 [195] 
PCR and 
Sanger 
sequencing 
GII.3 2007, UK P2 2 Paediatric primary 
immunodeficiency unit; stool from 
two chronically infected patients 
on the same ward plus 116 
environmental swabs 
Longitudinal patient sequences 98.6–99.8% 
sequence identity (3 “strains”) 
 
3/18 environmental sequences identical to patient 
 
15/18 environmental sequences not identical to 
patients; conclude unrelated to patients (dismiss 
intra-host evolution) 
 
Sukhrie et al.  
2011 [140] 
PCR and 
Sanger 
sequencing 
GII.3 and 
GII.4  
2002–2007, 
Netherlands 
P2 (600 nt) 105 Nosocomial infections in one 
hospital 
100% sequence identity within clusters 
 
Clusters involved patients across several wards, 
previously not linked due to physical separation 
 
5 clusters involved outpatients 
Sukhrie et al.  
2013 [142] 
PCR and 
Sanger 
sequencing 
GII.4 2009–2011, 
Netherlands 
P2 (600 nt) 81 1 hospital outbreak and 3 nursing 
home outbreaks 
Identical P2 sequences (0 SNPs) within clusters in 
70/81 patients; 6/81 patients 1 SNP, 1/81 patients 2 
SNPs 
Holzknecht 
et al.  2015 
[144] 
PCR and 
Sanger 
sequencing 
GII.4  2007–2008, 
Denmark 
Capsid 
(1412 nt 
including P2) 
55 Nosocomial infections in one 
hospital 
7 distinct outbreaks identified, including 
interdepartmental transmission. 
 
3/7 clusters: 0 SNPs between patients; 1/7 clusters: 
1 SNP; 1/7 clusters: 2 SNPs; 1/7 clusters: 4 SNPs 
(suspect multiple introductions from community) 
 
1/7 clusters (immunocompromised patients): 13 
SNPs 
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 MATERIALS AND METHODS 5.2
5.2.1 Stool samples for molecular epidemiology 
The first positive stool sample of all new episodes of norovirus at GOSH Between 1st 
July 2014 and 17th February 2016 (19 months) were identified for inclusion in the study 
(n = 205). Ten patients had no residual stool sample and six were PCR negative on re-
extraction. The first norovirus-positive stool samples from the remaining 189 patients 
were included in this study. 
In addition, 71 samples were collected from Norfolk and Norwich University Hospital 
(NNUH) between January and April 2015. This represents a suspected norovirus 
outbreak over a two week period in March and April with 3 additional norovirus 
episodes from January and 3 from February 2015. Norfolk and Norwich University 
Hospital is a 1,200 bed general hospital mainly serving patients in Norfolk and North 
Suffolk. Whilst it provides paediatric services, it is not a paediatric hospital. 
5.2.2 Longitudinal stool samples 
94 longitudinal stool samples were sequenced from 25 patients, with two to seven 
samples per patient. Longitudinal samples were collected between November 2012 
and January 2016. 
5.2.3 Norovirus whole genome sequencing 
Whole norovirus genomes were sequenced from all study samples by SureSelect 
target enrichment, as described in Chapter 2.  
5.2.4 Sequence assembly 
Reads were assembled using a de novo assembly pipeline, as described in Chapter 2, 
to generate a consensus sequence to be used in downstream analysis. 
5.2.5 Phylogenetic analysis for molecular epidemiology 
A full genome alignment and maximum likelihood tree was reconstructed for each 
genotype. Maximum likelihood phylogeny was also reconstructed using the P2 domain 
sequence of norovirus GII.4 episodes. 
To assess the occurrence of recombination between genotypes, phylogenies were 
reconstructed for ORF1 sequences from samples with the same polymerase genotype 
but a different capsid genotype. 
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Details of all reconstructed phylogenies are described in Chapter 2.  
5.2.6 Longitudinal analysis 
A single maximum likelihood phylogeny was reconstructed for all longitudinal samples, 
as detailed in Chapter 2.  
5.2.7 Genotyping 
All full genome consensus sequences were submitted to the Norovirus Genotyping 
Tool (http://www.rivm.nl/mpf/norovirus/typingtool) [141] to determine the polymerase 
and capsid genotype. 
 RESULTS 5.3
5.3.1 Consensus sequences  
In total, 184/189, 62/71 and 86/94 samples that were sequenced for molecular 
epidemiology at GOSH, NNUH and longitudinal analysis, respectively, generated 
greater than 90% genome coverage and >100-fold read depth, therefore were taken 
forward for downstream analysis. Twenty-two samples that generated less than 90% 
genome coverage and/or <100-fold read depth were excluded from analysis. One 
sequence was excluded from the molecular epidemiology phylogenetic analysis and 
two from longitudinal phylogenetic analyses as infection with a mixture of genotypes 
was detected during sequence assembly; the assembly pipeline used in this study 
cannot generate reliable consensus sequences from samples with multiple genotypes 
(as demonstrated in Chapter 4).  
5.3.2 Patient immune statuses 
Of the 184 patients included in molecular epidemiology analysis from GOSH, 110/184 
(60%) are considered immunosuppressed based on the clinical specialty to which they 
were admitted (haematology, oncology, immunology, bone marrow transplant, solid 
organ transplant). The remaining 74/184 (40%) were medical or surgical patients, 
although some of these patients may have some degree of immunosuppression.  
5.3.3 Genotypes 
 Genotypes using full genome sequences 5.3.3.1
The 19 month sampling period in this study built on the 12 month sampling period 
described in Chapter 3; as expected the 19 month sampling in this chapter 
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demonstrates a broad range of genotypes, with a third of sequenced samples (62/184, 
34%) identified as norovirus capsid genotype GII.3 (Figure 5.2). Full genome 
sequences allow the polymerase and capsid genotype to be determined, identifying all 
of the GII.3 sequences as GII.P21_GII.3 (polymerase genotype II.21, capsid genotype 
II.3).  
Figure 5.2 Norovirus genotypes identified in paediatric tertiary referral hospital (GOSH), July 2014 – 
February 2016 (n = 184) 
 
Of the 73 samples with a GII.4 Sydney_2012 capsid only 40/73 (55%) had a GII.Pe 
polymerase as would typically be expected for a Sydney_2012 strain (GII.Pe_GII.4); 
30/73 (41%) had a GII.P4 New Orleans_2009 ORF1 and 3/73 (4%) a GII.P16 ORF1 
(GII.P4_GII.4 and GII.P16_GII.4, respectively). Multiple ORF1 genotypes were also 
identified with capsid sequences GI.3 (12/15 GI.P3_GI.3, 2/15 GI.Pd_GI.3, 1/15 
GI.Pf_GI.3), GII.2 (6/10 GII.P2_GII.2, 4/10 GII.Pe_GII.2) and GII.17 (1/2 
GII.P17_GII.17, 1/2 GII.P16_GII.17). 
 Recombination between genotypes 5.3.3.2
For each of the four ORF 1 maximum likelihood trees all of the ORF 1 sequences 
clustered according to their corresponding capsid genotype (Figure 5.3, Figure 5.4, 
Figure 5.5 and Figure 5.6). This suggests there has been no recombination between 
genotypes. 
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Figure 5.3 Maximum likelihood phylogeny of ORF1 sequences from norovirus episodes with a GII.P7 
ORF1 genotype 
 
 
 
Figure 5.4 Maximum likelihood phylogeny of ORF1 sequences from norovirus episodes with a GII.P16 
ORF1 genotype 
 
 
Figure 5.5 Maximum likelihood phylogeny of ORF1 sequences from norovirus episodes with a GII.Pe 
ORF1 genotype 
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Figure 5.6 Maximum likelihood phylogeny of ORF1 sequences from norovirus episodes with a GII.P21 
ORF1 genotype  
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 Genotyping for molecular epidemiology 5.3.3.3
Norovirus infections at GOSH occur throughout the year and throughout the hospital 
(Figure 5.7). However it is not known whether infections are occurring due to 
transmission between patients or from independent sources. 
Figure 5.7 Distribution of norovirus genotypes across wards in paediatric tertiary referral hospital 
(GOSH), July 2014 – February 2016. Each number on the y axis represents a different ward. Each point 
represents a new norovirus infection 
 
Genotyping shows that several norovirus genotypes are co-circulating throughout the 
hospital at any given time (Figure 5.8). In ten instances patients were closely linked by 
classical epidemiology, i.e. time and place, but were infected with different genotypes 
(Figure 5.8, circled episodes) thus genotyping can exclude cross-transmission 
between these patients.  
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Figure 5.8 Distribution of norovirus genotypes across wards in paediatric tertiary referral hospital 
(GOSH), July 2014 – February 2016. Each number on the y axis represents a different ward. Each point 
represents a new norovirus infection, colour-coded according to infecting genotype. Red circles indicate 
norovirus episodes closely linked in time and place, but shown to be different genotypes 
 
Genotyping using full genome sequences, as opposed to capsid sequences alone, 
increases the capacity to exclude cross-transmission in cases that share a capsid 
genotype but have a different polymerase genotype, as illustrated in Figure 5.8 and 
Figure 5.9. In these instances episodes would have been indistinguishable by capsid 
genotyping alone.  
Despite the utility of genotyping to exclude transmission in some instances, it is not 
possible with genotyping alone to ascertain whether norovirus episodes caused by the 
same genotype are linked. This is illustrated in Figure 5.9 a; the eight circled episodes 
highlight instances where transmission was possible as the episodes occurred on the 
same ward with identical genotypes. Similarly, there were eight instances where 
episodes caused by GII.P21_GII.3 occurred on the same ward at the same time, but 
cannot be differentiated by genotyping alone.  
 154 
 
Figure 5.9 Distribution of norovirus genotypes across wards, demonstrating utility of polymerase 
genotype to discern norovirus episodes caused by the same capsid genotype. Each number on the y axis 
represents a different ward. Each point represents a new norovirus infection, labelled according to 
infecting genotype. (a) GII.4 capsid episodes (orange circles highlight episodes occurring on the same 
ward with the same genotype); (b) GI.3 capsid episodes; (c) GII.2 capsid episodes; (d) GII.17 capsid 
episodes 
(a)                                                                       (b) 
  
(c)                                                                                              (d) 
   
 
5.3.4 Phylogenetic analysis 
 Phylogenies using full genomes 5.3.4.1
Phylogenetic analysis using full genome sequences is well supported, with 76% 
(133/174) of internal nodes in the whole genome trees supported by bootstrap values 
≥70 (Figure 5.10), which means the trees are very robust and reliable. Moreover the 
trees have defined clusters with distinct branching order. 
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Figure 5.10 Frequency histogram of internal node bootstrap support values in full genome maximum 
likelihood trees (all genotypes) 
 
Phylogenetic analysis using maximum likelihood trees identified 19 clusters of related 
sequences, with 2–17 sequences per cluster (median 3) (Table 5.2, Figure 5.11, 
Figure 5.12, Figure 5.13, Figure 5.14, Figure 5.15, Figure 5.16, and Figure 5.17). 
Sequence clusters were defined as a group of monophyletic sequences with no 
discernible horizontal branch length; i.e. a group of sequences derived from a common 
evolutionary ancestor, or a single founder, not shared with any other group and with 
minimal divergence between them. It is these sequence clusters which are the basis of 
all further analysis. 
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Table 5.2 Sequence clusters identified by maximum likelihood phylogeny using full genome sequences. All GII.4 capsid genotypes are Sydney_2012. GII.4 polymerase genotypes 
are GII.Pe Sydney_2012 or GII.P4 New Orleans_2009 
† expressed as the number of nucleotide differences across whole genome; * overlap in norovirus positive period and in-patient history; ** including one parent (NORO/51, father 
of NORO/52)
Cluster 
number Genotype 
Number 
of 
patients Date range 
Number 
of 
wards  Wards 
Number of clinical 
specialties involved 
Diversity 
within 
cluster † 
Identified 
by infection 
control 
Supported by 
classical 
epidemiology* 
1 GI.P3_GI.3 4 15 days – 5 months 4 Koala, Robin, MOP, Bumblebee 3 17–56 No No 
2 GII.P2_GII.2 2 2 months 2 Penguin, PICU 2 7 No No 
3 GII.P7_GII.6 2 3 months 2 Starfish, Fox 2 17 No No 
4 GII.P7_GII.6 3 7 days 1 Bear 1 0 Yes Yes 
5 GII.P21_GII.3 17 3 months 6 Elephant, Lion, Safari, Butterfly, Rainforest, Bear 3 0–22 Partially Yes (16/17) 
6 GII.P21_GII.3 2 3 days 1 Safari 1 14 No Yes 
7 GII.P21_GII.3 6 1 month 3 Eagle, Robin, Safari 2 0–10 Partially Yes 
8 GII.P21_GII.3 2 2 months 1 Fox 1 11 No Yes 
9 GII.P21_GII.3 2 2 days 1 Fox 1 12 No Yes 
10 GII.P21_GII.3 9 10 months 2 Butterfly (8/9) and Bumblebee (1/9) 1 19–149 Partially Yes 
11 GII.Pe_GII.4 8** 2 months 2 Robin (7/8) and Eagle (1/8) 2 1–24 Partially Yes 
12 GII.Pe_GII.4 2 6 days 1 Rainforest 1 3 No Yes 
13 GII.Pe_GII.4 2 3 days 1 Fox 1 0 No Yes 
14 GII.Pe_GII.4 4 11 days 2 Giraffe (3/4), Safari (1/4) 1 1–4 Partially Yes 
15 GII.Pe_GII.4 3 3 days 1 Squirrel 1 1–3 Yes Yes 
16 GII.P4_GII.4 7 3 months 2 Lion (6/7), Butterfly (1/7) 1 0–35 Partially Yes 
17 GII.P4_GII.4 2 25 days 2 Butterfly, Bumblebee 1 14 No Yes 
18 GII.P4_GII.4 3 10 days 1 Rainforest 1 0–1 No Yes 
19 GII.P4_GII.4 2 19 days 1 Elephant 1 6 No Yes 
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Figure 5.11 Maximum likelihood phylogeny of full genome sequences from norovirus episodes with a 
GI.2 capsid genotype. Individual sequences are labelled with a unique patient identifier (NORO/XX) and 
specimen collection date 
 
 
Figure 5.12 Maximum likelihood phylogeny of full genome sequences from norovirus episodes with a 
GI.3 capsid genotype. Individual sequences are labelled with a unique patient identifier (NORO/XX) and 
specimen collection date 
Cluster 
1 
 158 
 
Figure 5.13 Maximum likelihood phylogeny of full genome sequences from norovirus episodes with a 
GII.2 capsid genotype. Individual sequences are labelled with a unique patient identifier (NORO/XX) and 
specimen collection date 
 
 
 
Figure 5.14 Maximum likelihood phylogeny of full genome sequences from norovirus episodes with a 
GII.6 capsid genotype. Individual sequences are labelled with a unique patient identifier (NORO/XX) and 
specimen collection date 
Cluster 
2 
Cluster 
3 
Cluster 
4 
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Figure 5.15 Maximum likelihood phylogeny of full genome sequences from norovirus episodes with a GII.3 capsid genotype. Individual sequences are labelled with a unique 
patient identifier (NORO/XX) and specimen collection date  
Cluster 5 
Cluster 6 
Cluster 7 
Cluster 8 
Cluster 9 
Cluster 10 
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Figure 5.16 Maximum likelihood phylogeny of full genome sequences from norovirus episodes with a GII.4 capsid genotype. Individual sequences are labelled with a unique 
patient identifier (NORO/XX) and specimen collection date  
Cluster 11 
Cluster 12 
Cluster 13 
Cluster 14 
Cluster 15 
Cluster 18 
Cluster 19 
Cluster 16 
Cluster 17 
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Figure 5.17 Maximum likelihood phylogeny of full genome sequences from norovirus episodes with a 
GII.17 capsid genotype. Individual sequences are labelled with a unique patient identifier (NORO/XX) 
and specimen collection date 
 
 
 
Figure 5.18 Maximum likelihood phylogeny of full genome sequences from norovirus episodes with a 
GII.7 capsid genotype. Individual sequences are labelled with a unique patient identifier (NORO/XX) and 
specimen collection date 
 
 
 Phylogenies using P2 sequences 5.3.4.2
Maximum likelihood phylogeny of GII.4 episodes using the hyper-variable capsid P2 
domain sequences (427 nt) generates a tree with very low bootstrap support; only 34% 
(24/71) of internal nodes are supported by bootstrap values ≥70 (Figure 5.19), which 
means the branching order, and therefore the tree, is neither robust nor reliable.  
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Figure 5.19 Frequency histogram of internal node bootstrap support values in P2 domain maximum 
likelihood trees (GII.4 norovirus only) 
 
Since internal nodes with bootstrap values <70 are collapsed due to unreliability, the 
resulting tree has few clusters with the majority of sequences showing no branching 
order (Figure 5.20).  
P2 sequences within clusters are not identical, with up to 6 nucleotide differences 
between sequences within a cluster. Only clusters with no SNPs are identifiable by P2 
phylogeny (Table 5.3). 
Table 5.3 Diversity in P2 region of GII.4 clusters identified by whole genome phylogeny. Cluster number 
refers to clusters identified using full genome sequences (in Figure 5.16 on page 160) 
Cluster 
number Diversity in P2 region within cluster* Identified by P2 phylogeny** 
11 0—6 Partially (2/8 patients) 
12 0 Yes 
13 0 Yes 
14 0 Yes 
15 0 Yes 
16 0—5 No 
17 2 No 
18 0 Yes 
19 3 No 
*Expressed as number of nucleotide differences across P2 region; **as shown in Figure 5.20
  
 
1
6
3
 
Figure 5.20 Maximum likelihood phylogeny of hyper-variable capsid P2 domain sequences for norovirus GII.4 episodes at GOSH. Cluster numbers refer to clusters identified using 
full genome sequences in Figure 5.16 on page 160 
 
 
Cluster 12 
Cluster 11 
Cluster 13 
No cluster 
Cluster 15 
Cluster 14 
Cluster 18 
Cluster 16 
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5.3.5 Molecular and classical epidemiology 
 Verification of sequence clusters 5.3.5.1
All of the clusters identified by phylogenetic analysis of full genome sequences were 
verified by looking at the in-patient history and duration of norovirus positivity of each 
patient to determine whether transmission between the patients in each cluster would 
have been possible.  
Three of the 19 clusters identified by maximum likelihood phylogeny, Cluster 1 
(GI.P3_GI.3), 2 (GII.P2_GII.2) and 3 (GII.P7_GII.6), were not supported by classical 
epidemiology. In Cluster 1 (GI.P3_GI.3) all four patients were under the care of 
different clinical teams; three of the patients were admitted within 15 days of each other 
in 2014, the fourth five months later in 2015 from Portugal. All four patients were 
already norovirus positive on admission with no known contact between patients prior 
to admission; three patients had no prior outpatient appointments. In Cluster 2 
(GII.P2_GII.2), the two patients were under the care of different clinical teams. There 
was less than one day overlap in admission dates between the two patients; the index 
patient was norovirus negative for six weeks prior to the second patient becoming 
infected (illustrated in Figure 5.21). In Cluster 3 (GII.P7_GII.6) the two patients were 
also under the care of different clinical teams. Both patients were norovirus positive on 
admission, with no known contact between them prior to admission; neither patient had 
ever been seen in outpatients. Cluster 1, 2 and 3 were excluded from further analysis.  
Figure 5.21 Timeline of patients in Cluster 2. Classical epidemiology does not support the cluster as the 
first patient, NORO/96, was already norovirus-negative when the second patient, NORO/97, was 
admitted. NORO/97 has no prior outpatient history. Each was cared for by different clinical teams. Grey 
bars indicated the patient was an in-patient or outpatient and norovirus PCR negative; pink bars indicate 
the patient was an in-patient or out-patient and norovirus PCR positive 
 
The remaining 16 clusters were supported by classical epidemiology, i.e. there was an 
overlap between patient’s admissions whilst one of the patients was norovirus positive. 
As an example, this is illustrated for Cluster 11 in Figure 5.22. 
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Figure 5.22 Timeline of patients in Cluster 11, including an additional patient, Noro 113, who was 
norovirus positive on Robin ward at the same time as Cluster 11, but was infected with GII.P21_GII.3 
norovirus. Classical epidemiology supports the cluster, assuming NORO/50 was infected at an outpatient 
appointment on 21
st
 of July prior to admission. Grey bars indicated the patient was an in-patient or 
outpatient and norovirus PCR negative; pink bars indicate the patient was an in-patient or out-patient 
and was norovirus PCR positive 
 
Five of the 16 clusters involved likely transmission at outpatient appointments. In two 
clusters (Cluster 14 and 16) the index cases attended hospital as an outpatient whilst 
the next patient in the cluster to be infected was an in-patient. Conversely in three 
clusters (Cluster 11, 7 and 5) secondary transmission occurred at outpatient 
appointments; 1/8, 3/6 and 1/17 of the patients in each cluster, respectively, attended 
outpatient appointments whilst other patients in the cluster were already in-patients and 
norovirus positive. Since outpatient clinics are located on a separate floor to in-patient 
wards, transmission in these patients must have occurred indirectly; for example via 
staff movement or contaminated fomites. 
Classical epidemiology evidence does not support 1 of the 17 patients in Cluster 5; this 
patient was norovirus positive during the same time frame as the rest of the cluster, 
however he/she was a day-case admission, with no previous outpatient appointments 
or known contact with other patients in the cluster. For the purpose of on-going 
analysis this patient was excluded from the cluster. 
Cluster 10 has the greatest nucleotide diversity compared to other clusters (19–149 
compared to 0–35 SNPs) and spans the greatest time period (17 months compared to 
2 days–3 months in other clusters), which calls into question the validity of the cluster. 
However the cluster is distinctly monophyletic and all patients but one (8/9) are on the 
same ward; the remaining patient is on an adjoining ward under the same clinical team. 
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Epidemiological evidence supports this cluster, with an overlap in admission dates and 
norovirus positivity establishing a plausible link between all patients. 
 Comparison of molecular epidemiology and classical Infection Control 5.3.5.2
investigations 
During the study period there were eight outbreaks of norovirus identified by the 
infection control team at GOSH, with 2–12 patients per outbreak (median 3) (Table 
5.4).  
Table 5.4 Norovirus outbreaks identified by the Infection Control team using classical epidemiology 
(time and place) with details of corresponding sequence cluster 
Outbreak 
number Wards 
Number of 
identified 
patients 
Sequence 
cluster  
Extra patients in sequence cluster missed by 
infection control team 
14-06 L Butterfly 1 (plus 3 
staff) 
Cluster 16  N=6. All on Lion ward one month later (same CS) 
14-07 E Eagle 3 Cluster 7  N=3. Two Robin ward (different CS) 3 days and 
one month earlier; one outpatient (same CS). 
14-09 B Robin 8 Cluster 11  N=1. Eagle ward (different CS) same time. 
14-09 H Butterfly 5 Cluster 10  N=5. One Bumblebee ward (same CS) same time. 
Four same ward two and four months earlier and 
2 months later. 
15-01 O Giraffe 2 Cluster 14  N=2. One on same ward, same time; one 
outpatient (same CS) 
15-06 P Squirrel 3 Cluster 15  - 
15-12 H Bear 3 Cluster 4  - 
15-12 P Elephant 
and Lion  
12 Cluster 5  N=6. Two same ward same time; one Rainforest 
ward (same CS) same time; one Butterfly ward 
(same CS) same time; one outpatients (same CS) 
same time; one Bear ward (different CS) one 
month earlier.  
TOTAL number of 
patients 
37   
Median number of 
patients 
3   
CS, clinical specialty; -, none missed 
Four patients who were identified as being part of an infection control outbreak were 
not part of any sequence cluster (Table 5.5) therefore had been incorrectly assigned to 
an outbreak based on time and place (one patient in 14-09 B, one in in 14-09 H and 
two patients in 15-12 P). All four of these patients were infected with a different 
genotype compared to the other patients in that cluster.  
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Table 5.5 Comparison of norovirus transmission events identified by molecular epidemiology (this study) 
and classical infection control monitoring. Green indicates patients correctly identified by infection 
control monitoring; red indicates patients incorrectly identified by infection control monitoring 
 Part of infection control 
outbreak 
Not part of infection 
control outbreak 
TOTAL 
Transmission by 
molecular epi (part of 
verified sequence 
cluster) 
33 40 73 
No transmission by 
molecular epi (not part of 
sequence cluster) 
4 106 110 
TOTAL 37 146 183 
 
Overall, conventional infection control monitoring missed 40/73 (55%) of linked 
infections. Assuming molecular epidemiology sequence clustering corroborated by 
evidence of patient contact to be the gold standard, it follows that the negative 
predictive value of classical infection control is 73% (106/146); i.e. only 73% of patients 
were correctly identified as not linked to other patients. On the other hand, the positive 
predictive value for classical epidemiology (i.e. proportion of correctly identified linked 
cases) is high at 89% (33/37); if two patients are identified as linked by classical 
infection control investigations then this is likely to be true. This means that in this 
setting classical infection control investigations lack sensitivity (missing patients who 
are linked) but are specific (do not link patients who are not part of an outbreak). 
 Clusters fully or partially predicted by Infection Control 5.3.5.3
Two of the eight outbreaks identified by Infection Control correctly identified all patients 
involved in the transmission cluster.  
However for six of the eight outbreaks, extra linked cases were identified by molecular 
epidemiology that were missed by the Infection Control team, totalling 23 extra 
patients. The majority of these were norovirus infections that occurred at a similar time 
on different wards with a shared clinical specialty (7/23) or at a different time, either on 
the same ward or with shared clinical specialty (4/23 and 6/23, respectively) (Table 
5.6). 
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Table 5.6 Extra patients in sequence clusters that were partially recognised by Infection Control 
investigations (n=23 patients) 
 Same time Different time 
Same ward 3 4 
Different ward or outpatient but same CS 7 6 
Different ward and different CS 1 2 
CS, clinical specialty 
 Clusters missed by infection control 5.3.5.4
There are eight sequence clusters that were missed completely by the infection control 
team (Table 5.2 on page 156), totalling 17 patients. The majority (11/17) of these 
patients were infected on the same ward at a similar time; however each cluster only 
involved two or three patients. In addition, sequence clusters were not recognised as 
outbreaks by Infection Control if patients were on the same ward but separated by time 
(4/17) (Table 5.7). 
Table 5.7 Patients in sequence clusters that were not recognised by Infection Control investigations 
(n=17 patients) 
 Same time Different 
time 
Same ward 11 4 
Different ward or outpatient but same CS 0 2 
Different ward and different CS 0 0 
CS, clinical specialty 
5.3.6 Transmission dynamics at GOSH 
Overall, 73/183 (40%) of sequences from patients with norovirus at GOSH are part of a 
sequence cluster, suggesting they are involved in a transmission chain. Assuming that 
each of the 16 sequence clusters includes a source patient who, whilst transmitting to 
other patients were themselves not infected by another patient, only 57/183 (31%) of 
patients during this study period were infected by another patient (Table 5.8); 77% 
(44/57) of these patients were immunocompromised and 23% (13/57) were medical or 
surgical patients. Conversely 111/183 (60%) of cases were not linked to any others 
during the 18 month study period; 50% (55/111) of these patients were 
immunocompromised and 50% (56/111) were medical or surgical patients. A quarter of 
all patients (44/183, 24%) acquired a norovirus infection whilst an in-patient at GOSH 
during the study period but were not part of any sequence cluster or they were the 
index patient therefore were infected from an unknown source; 59% (26/44) of these 
were immunocompromised and 41% (18/44) were medical or surgical patients. 
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Table 5.8 Summary of sources of infection at GOSH during study period, July 2014–February 2016 
Source of infection Number of 
patients (n=183) 
Proportion of patients 
immunocompromised 
Another patient (part of a transmission cluster) 57 (31%) 44/57 (77%) 
Outside of the hospital (norovirus positive on 
admission) 
82 (45%) 39/82 (48%) 
Unknown (hospital acquired infection but not 
transmission from another patient) 
44 (24%) 26/44 (59%) 
 
Only 4/16 clusters had an index patient who was norovirus positive on admission 
(POA) with a source of infection outside the hospital; in the remaining 12/16 clusters 
(75%) the index patient had a hospital acquired infection for which the source of 
infection is unknown.  
With the exception of one GII.6 cluster involving two patients, all transmission events 
involved norovirus genotypes GII.3 or GII.4. Sequence clustering from maximum 
likelihood phylogenies identified clusters of transmission within genotypes and, 
conversely, excluded transmission between patients infected with the same genotype 
(Figure 5.23).  
Of the eight instances where norovirus occurred on the same ward, at the same time 
and caused by the same GII.4 genotype (circled in Figure 5.9 on page 154), 7/8 were 
confirmed as linked by phylogenetic analysis. Similarly, 7/8 instances involving 
GII.P21_GII.3 infection on the same ward at the same time were confirmed as linked 
by phylogenetic analysis. 
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Figure 5.23 Distribution of norovirus episodes across wards, July 2014–February 2016, separated by genotype and colour coded by sequence cluster (identified by full genome 
maximum likelihood phylogeny). Black points indicate no cluster. Each line on the y axis represents a different ward. X axis indicates the date of infection.  
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5.3.7 Molecular epidemiology in a non-paediatric general hospital (NNUH) 
Of the 62 norovirus stool samples sequenced from NNUH, 60 (97%) were GII.4 
Sydney_2012 strains; 12/60 (20%) were GII.Pe_GII.4 (Sydney_2012 ORF1) and 48/60 
(80%) were GII.P4_GII.4 (New Orleans_2009 ORF1). 
Maximum likelihood phylogeny of the GII.4 infections using whole genome sequences 
shows that norovirus infections at NNUH fall into four clusters, labelled A–D in Figure 
5.24. The majority of GII.4 infections (46/60) are part of Cluster A which is a GII.P4 
New Orleans_2009_GII.4 Sydney_2012 strain. In total, 53/60 (88%) of patients were 
infected from another patient. Diversity within each cluster is very limited, with a 
maximum of 6 SNPs across the whole genome within a single cluster (Table 5.9).  
Phylogenetic analysis using the P2 domain sequences from NNUH correctly identifies 
all of the clusters seen using full genome sequences (Figure 5.25). All of the 
sequences within a cluster have identical P2 sequences (0 SNPs), with the exception 
of one sequence pair which has 1 SNP (Table 5.9). 
Table 5.9 NNUH sequence clusters identified by whole genome and P2 maximum likelihood phylogeny. 
All clusters were identified by both analyses 
Cluster Number of 
sequences 
Date 
range 
Within cluster 
diversity in full 
genome* 
Within cluster 
diversity in P2 region* 
A 46 1 week 0–6†  0–1 
B 2 2 weeks 0 0 
C 2 2 days 9 0 
D 7 10 days 0–2 0 
*expressed as number of nucleotide differences; †up to 34 if include NOR_2191 (all SNPs occur in 100 nt 
region at 5’ end) 
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Figure 5.24 Maximum likelihood phylogeny of NNUH GII.4 full genome sequences. Sequences are 
labelled with the specimen collection date 
 
Figure 5.25 Maximum likelihood phylogeny of NNUH GII.4 P2 domain sequences. Sequences are labelled 
with the specimen collection date 
 
Cluster A 
Cluster B 
Cluster C 
Cluster D 
Cluster A 
Cluster B 
Cluster C 
Cluster D 
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5.3.8 Persistence vs. re-infection in longitudinally sampled patients 
 Continuously positive patients 5.3.8.1
Eighteen of the 25 longitudinally sampled patients were continuously norovirus PCR 
positive in between collected samples (median 129 days from first to last sequenced 
sample, range 7–466) (Table 5.10). 3/16 (19%) of these patients were infected with a 
different genotype by the last sample, including two (Px 101 and Px 65) who were co-
infected with two genotypes. Two of the patients who were re-infected with a different 
genotype were chronically infected for a long time (321 and 466 days), however for one 
patient only 58 days had passed. The remaining 15/18 patients (83%) remained 
infected with the same genotype. All longitudinal samples which remained the same 
genotype cluster together by patient in the phylogenetic tree (Figure 5.26). This 
suggests on-going infection is caused by persistence with the same virus, rather than 
re-infection with a new virus of the same genotype. 
The median duration of infection was 322 days (range 58–738 days) in patients who 
had a super-infection and 215 days (range 14–711 days) in those who did not. The 
difference in duration of infections was not statistically significant (P = 0.360). 
 Chronically infected patients with undetected period 5.3.8.2
Nine of the 25 longitudinally sampled patients had a period of norovirus PCR negative 
stools in between the first and last sequenced samples (median 153 days undetected, 
range 9–466) (Table 5.10). 5/9 patients (56%) were infected with a different genotype 
after the negative period. 4/9 (44%) remained infected with the same genotype. One of 
the patients who remained infected with the same genotype (Px 63) is identified as a 
new infection based on phylogenetic analysis (Figure 5.26), in which the latest sample 
does not cluster with earlier samples.  Those who remained infected with the same 
genotype (3/9, 33%) had the shortest interval during which norovirus was not detected; 
less than two months compared to 5–15 months for those who were re-infected.  
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Table 5.10 Summary of longitudinally sampled norovirus infections 
Patient 
ID 
Number 
of 
samples 
Days between 
first and last 
sample 
Negative in 
between 
samples Genotype 
Re-
infection 
(Yes/No) 
63 3 1006 
No (135 days) GII.P21_GII.3  No 
Yes (466 days) GII.P21_GII.3 Yes 
101 2 466 No 
GII.P21_GII.3 to mixed 
GII.P21_GII.3/ GII.P7_GII.6 
Yes 
50 2 446 No GII.Pe_GII.4 No 
58 2 445 No GII.P4_GII.4 No 
65 5 321 No 
GII.P21_GII.3 to mixed 
GII.P21_GII.3/GII.Pe_GII.4 
Yes 
64 2 243 No GII.P4_GII.4  No 
67 7 197 No GII.P21_GII.3  No 
177 2 190 No GII.P21_GII.3 No 
174 2 163 No GII.P7_GII.6 No 
61 5 123 No GII.P21_GII.3  No 
66 2 35 No GII.P7_GII.6  No 
74 4 28 No GII.P21_GII.3  No 
71 3 14 No GII.P21_GII.3  No 
70 4 13 No GII.P21_GII.3  No 
62 2 7 No GII.P4_GII.4  No 
54 2 7 No GII.Pe_GII.4 No 
40 2 7 No GII.Pe_GII.4  No 
147 2 339 Yes (11 months) GII.P4_GII.4 to GII.P21_GII.3 Yes 
68 5 202 Yes (6 months) GII.P4_GII.4 to GII.P7_GII.6 Yes 
34 2 178 Yes (5 months) GII.P21_GII.3 to GII.Pe_GII.2 Yes 
176 2 157 Yes (5 months) GII.P2_GII.2 to GII.P7_GII.6 Yes 
73 6 152 
No (58 days) GII.Pe_GII.4 to GII.P16_GII.17  Yes 
Yes (57 days) GII.P16_GII.17 to GII.P21_GII.3 Yes 
31 7 123 Yes (56 days) GII.Pe_GII.4  No 
72 5 73 Yes (23 days) GII.P21_GII.3  No 
75 6 62 Yes (9 days) GII.P7_GII.6  No 
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Figure 5.26 Full genome maximum likelihood phylogeny of longitudinal norovirus sequences. Px, patient number 
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 DISCUSSION 5.4
5.4.1 Full genomes for norovirus genotyping 
In Chapter 3 PCR and Sanger sequencing of the capsid shell domain identified the 
circulating genotypes at GOSH over a 12 month period (July 2014–July 2015) and 
showed a broad range of circulating genotypes.  This study uses full genome 
sequences to determine the norovirus genotype, thus identifying both the polymerase 
and capsid genotypes over a 19 month period (July 2014 – February 2016). The 
breadth of genotypes is replicated, with a third (34%) of sequences identified as 
GII.P21_GII.3 and a third (27%) identified as non GII.4 genotypes. 39% of sequences 
are identified as having a GII.4 Sydney_2012 capsid sequence, however only half 
(55%) of these sequences have a GII.Pe Sydney_2012 polymerase; with the remaining 
41% a GII.P4 New Orleans_2009 polymerase and 4% a GII.P16 polymerase.  
The Sydney_2012 norovirus variant emerged globally in the winter of 2012/2013, 
causing an early norovirus season in the UK between October and December 2012, 
instead of the usual season of January to March. By the 2013/2014 season 
Sydney_2012 had replaced the previously circulating New Orleans_2009 variant, 
however both variants were in circulation during the 2012/13 winter season. Our study 
shows that at GOSH 45% of circulating GII.4 norovirus episodes during 2014–2016 are 
recombinant strains with non-Sydney_2012 polymerases. The same is seen at Norfolk 
and Norwich, in which 77% of GII.4 sequences have the New Orleans_2009 
polymerase (GII.P4_GII.4), confirming that recombinant GII.4 genotypes are not unique 
to our population at GOSH.  
This New Orleans_2009/Sydney_2012 GII.4 recombinant strain has previously been 
described in the literature using PCR to sequence partial or full genomes however all, 
but one, of these reports are from the 2012/2013 winter norovirus season [147, 192, 
196, 197] during which the two strains were co-circulating. There has been only one 
report of this recombinant strain since, by Bruggink et al. in 2016 [198]. Bruggink et al. 
report that this strain was in circulation at low frequency in Victoria, Australia in 2015, 
causing 3/64 (5%) reported outbreaks in the region; in 2016 it was reportedly 
responsible for the majority (17/23, 74%) of their outbreaks. Bruggink et al. suggest this 
may be a novel epidemic strain, however this suggestion is disputed by Fonager et al. 
[199] who oppose the novelty of the strain since it was detected in 2012/13. The data 
presented in this chapter supports Fonager et al.’s stance since at GOSH the New 
Orleans_2009/Sydney_2012 recombinant was already in circulation, at high frequency, 
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in 2014. It is likely that these recombinant genotypes have been in circulation since the 
2012/2013 season however, due to a tendency to capsid genotyping alone, they have 
not previously been recognised.  
Norovirus infections caused by GII.P16_GII.4, causing three infections in this study, 
were until very recently unknown. In 2016, nine infections in an outbreak in Kawasaki, 
Japan, were also caused by GII.P16_GII.4 [200]. There are currently no other reports 
of this recombinant genotype therefore it is not known how widespread or common it is, 
however given that it has now been detected in Japan and the UK it is likely to have a 
global distribution. Despite sampling for this study spanning almost two years, it was 
not detected in our population until January 2016 which suggests it could be a newly 
emerging genotype.  
Genotyping using the full genome has revealed co-circulation of multiple GII.4 lineages, 
which provides potential insight into the global epidemiology of norovirus. However 
genotyping using the full genome is also useful at a local level; determining the 
polymerase and capsid genotype has allowed identification of multiple GI.3, GII.2, GII.4 
and GII.17 lineages. Capsid typing alone would have falsely assumed circulation of a 
single lineage for each genotype. A combination of the polymerase and capsid 
genotype provides extra information to exclude the occurrence of a transmission event.  
5.4.2 Full genomes vs. P2 region for outbreak investigation 
Whilst in immunocompetent patients the P2 region between linked patients is expected 
to be identical [140, 143], in vivo evolution of norovirus in immunocompromised hosts 
introduces single nucleotide polymorphisms (SNPs) between the P2 region of linked 
patients [144]. Consequently, as demonstrated in this chapter, in the context of an 
immunocompromised population the P2 region is insufficient for outbreak 
investigations. The short sequence (427 nt) combined with SNPs occurring between 
linked patients, results in phylogenetic trees with very poor bootstrap support and very 
limited ability to detect transmission clusters. Consequently in the context of an 
immunocompromised population using only the P2 sequence for phylogenetic analysis 
is not informative.  
Conversely in the context of an immunocompetent population such as at NNUH, in 
which limited or no viral evolution is expected to occur prior to transmission, 
sequencing the P2 region alone appears to be sufficient to identify transmission 
clusters. However there are limitations in comparing the two datasets to draw 
conclusions about immunocompetent and immunocompromised populations. 
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The NNUH population was chosen for comparison to GOSH as it represents a largely 
immunocompetent population, compared to GOSH’s largely immunocompromised, for 
which specimens were collected for outbreak investigation. However there are other 
differences between the two populations which could account for the differences seen 
in norovirus molecular epidemiology. The first is that NNUH patients are adults (median 
sampled age 84 years, range 20–97) whereas GOSH patients are children (median 
sampled age 2 years, range 5 weeks to 16 years). This may explain the difference in 
breadth of genotypes between the two populations, with 3% of infections caused by 
non-GII.4 norovirus at NNUH compared to 60% at GOSH during the same sampling 
period. Additionally, at GOSH patients are screened for norovirus on admission 
whereas at NNUH they are not, which may also have resulted in a greater breadth of 
genotypes at GOSH since patients with community acquired norovirus infections are 
reported to have a higher proportion of non-GII.4 than those which are hospital 
acquired [130].  
At GOSH 60% of the beds are in isolated rooms, whereas at NNUH the majority of 
beds are on open wards. It has previously been shown that norovirus outbreaks are 
poorly controlled in hospitals with nightingale style wards compared to isolated rooms 
[96] therefore this is likely to account for the difference in cluster sizes between the two 
populations (largest cluster in GOSH was 17 patients, compared to 46 patients at 
NNUH). 
Lastly a confounding factor which would account for the difference in within cluster 
diversity seen between GOSH and NNUH populations is that whilst the GOSH 
population was sampled over a 19 month period, the NNUH population was 
predominantly sampled over 2 months. It is possible that over a longer sampling period 
the molecular epidemiology at NNUH could reveal clusters of norovirus infections with 
greater diversity than is seen in this study; consequently a more extensive sampling 
period, encompassing at least one calendar year to account for changes in norovirus 
seasonality, should be performed to confirm the findings observed in this study.  
Full genome sequencing is critical to identify transmission in an immunocompromised 
population; full genomes allow phylogenetic reconstruction with very high bootstrap 
support, and thus reliable branching order, despite SNPs occurring between linked 
sequences. This allows reliable identification of sequence clusters. Whilst the full 
genome sequence may not be required for phylogenetic analysis in an 
immunocompetent population, it will nonetheless add value by identifying the 
polymerase genotype of the infecting virus.   
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5.4.3 Classical and molecular epidemiology to identify transmission 
events 
All of the outbreaks identified by the infection control team, based on the occurrence of 
multiple norovirus episodes connected by time and place, were corroborated by 
molecular epidemiology using full genome sequences. The only exception to this was 
four patients who were included in outbreaks but were shown to be infected with a 
different genotype, therefore were not actually linked to the outbreak. Nevertheless in 
these instances transmission was occurring between other patients on the same ward 
therefore infection control efforts were not wasted by misidentifying these patients. 
Conversely, many instances of transmission were missed by the Infection Control 
team. These largely fall into two categories. First, patients part of a recognised 
outbreak but not identified because they are on a different ward, albeit with shared 
clinical teams. Second, patients in clusters that occur on the same ward, but are 
completely missed by Infection Control because only two patients are involved.  
The high PPV (89%) of classical epidemiology investigations suggests that cases 
linked by classical Infection Control monitoring are likely to be truly linked based on full 
genome sequences. However, the low NPV (73%) suggests that it is possible that 
cases that are not linked by infection control monitoring investigations are in fact linked 
by molecular epidemiology. The implication of this is that the true extent of an outbreak 
may not be recognised and therefore the outbreak not brought under control. 
Phylogenies should not be interpreted in isolation; to determine whether the 
sequencing data represents transmission between patients it is necessary to determine 
whether there has been any contact between patients. In three of the nineteen clusters 
identified by full genome phylogeny there was no plausible link between patients. There 
is a possibility that there has been unidentified contact between patients, either via 
undocumented hospital attendance at GOSH, contact at another hospital or in the 
community. However in Cluster 1 in particular this is unlikely since one of the patients 
was admitted from Portugal. It may be that unrelated sequences in these genotypes 
(GI.P3_GI.3 for Cluster 1, GII.P2_GII.2 Cluster 2 and GII.P7_GII.6 for Cluster 3) are 
less variable compared to unrelated sequences in GII.3 and GII.4 infections; this will 
make phylogenetic analysis for outbreak investigation less useful where these 
genotypes are concerned as similar sequences do not necessarily indicate 
transmission. Extensive analysis of sequence diversity between unrelated sequences 
of the same genotype will aid with interpretation of phylogenies in this scenario, 
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however there is currently only one publically available full genome sequence for 
GI.P3_GI.3 and one for GII.P2_GII.2 therefore at present this analysis is not possible. 
5.4.4 Indirect transmission of norovirus 
Data presented in this chapter suggests that out-patients are both a source of infection 
and at risk of infection from in-patients; 5/16 clusters included an out-patient who 
visited hospital but was not admitted. This corroborates earlier findings by Sukhrie et al. 
[140] who demonstrated that out-patients were involved in 5/14 clusters identified with 
P2 sequence phylogenies. 
These out-patients did not come into direct contact with the other patients in the cluster 
therefore transmission must have occurred indirectly, either via an intermediate person 
or via contaminated fomites. Sukhrie et al. [140] reached the same conclusion, 
although neither their or our study included environmental sampling nor sampling from 
staff.  
One of the clusters described in this chapter, Cluster 11 (GII.Pe_GII.4), was at the time 
suspected to be an outbreak by classical Infection Control investigations (14-09 B). 
This outbreak occurred on a bone marrow transplant ward; patients are in isolated 
rooms and have no direct contact (Figure 5.27). Indirect transmission was suspected, 
prompting a request for stool samples from parents on the ward. Of the three parents 
that submitted stool specimens, one was norovirus positive and part of Cluster 11 
(NORO/51, father of the index patient NORO/52). It is not known whether the father 
contributed to the transmission chain; however it demonstrates that transmission does 
occur beyond the affected patients and provides a potential route for indirect 
transmission via visitors.  
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Figure 5.27 Layout of bone marrow transplant ward at GOSH in which norovirus outbreak occurred 
(Cluster 11). Each room is in isolation with its own bathroom facilities and positive pressure ventilated 
lobby. Blue arrows indicate direction of airflow, designed to prevent airflow from room to corridor and 
vice-versa. 
 
Another potential source of indirect transmission between patients is infected staff; be it 
clinical or auxiliary. It is well documented that staff are affected during norovirus 
outbreaks; over a seven year period in five hospitals in England, on average the ratio of 
affected staff to affected patients was 1:1.75 (staff:patients), ranging from 1:7 in 2007/8 
and 2008/9 to 1:1.15 in 2010/11 when almost as many staff were affected as patients 
[201]. Exclusion of affected staff can reduce transmission to patients [97] which is why 
national guidelines recommend symptomatic staff are excluded from work for 48 hours 
after resolution of symptoms [88].  
An alternative route of indirect transmission is fomites contaminated with norovirus, 
which are a recognised source of infection that does not require direct contact between 
affected persons [202]. Contamination can occur in the environment immediately 
surrounding the patient, such as the bedside and in bathroom facilities, but also on 
patient notes trolleys, computer keyboards and portable medical equipment such as 
blood pressure equipment, pulse oximeters and tympanic thermometers [95]. During a 
norovirus outbreak in a long-term care facility, norovirus was also detected on an 
elevator button which was only accessed by staff [203]. Furthermore it is predicted that 
the transfer of norovirus is possible even after the virus has dried on hands or 
contaminated surfaces [204]. In the context of out-patients in a transmission chain 
fomites may become contaminated which are then touched by staff who return to the 
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wards, or the contaminated fomites themselves, such as patient notes or portable 
equipment, may be taken to the ward.  
5.4.5 Utility of full genome sequencing and phylogeny for outbreak 
investigations 
Full genome sequencing has proven in this study to be useful both by discriminating 
between infected patients based on genotype, for which both polymerase and capsid 
genotypes are critical, and by using phylogenetic analysis to link patients that were 
missed by classical Infection Control investigations. 
Based on this, real-time sequencing of all new norovirus cases to support infection 
control investigations is useful and worthwhile. However currently the fastest 
achievable turn-around time for full genome sequences is one week and due to 
batching requirements often closer to 3 weeks (described in more detail in Chapter 4); 
whilst this is an excellent turn-around time for generating the associated volume of 
data, it is of limited use in the context of norovirus outbreaks which have incubation 
times as short as 12 hours. Therefore at this time infection control decisions must often 
be made in the absence of sequencing data; however newer and faster sequencing 
technologies are on the horizon which could provide data in a clinically useful time-
frame. For instance the Oxford Nanopore Technologies MinION claims a sequencing 
speed of 500 bases per second; theoretically this could generate a norovirus full 
genome with 100-fold read depth in 25 minutes. The compatibility of platforms such as 
the MinION with SureSelect target enrichment is yet to be assessed.  
To this end the data from this study should be used to improve and inform best practice 
when investigating norovirus transmission using classical epidemiology, for instance by 
considering norovirus positive patients on different wards during outbreak 
investigations, in particular if there are shared clinical teams. Sequencing data going 
forward should be used to confirm the findings of the infection control team and to 
identify gaps, as has been the case in this study, for the benefit of future investigations. 
In the case of outbreaks that last longer than a week or two, sequence data may be 
able to provide information in real-time. 
5.4.6 Persistence vs. re-infection 
Patients for longitudinal sampling were chosen at random, with a bias towards those 
who appeared to be chronically infected or who were norovirus PCR positive following 
a period during which norovirus could not be detected in stool, thus suggesting a new 
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infection. This was not a comprehensive collection of all such patients; consequently an 
accurate rate of re-infection vs. persistence cannot be determined. Nonetheless our 
results do suggest that patients are more likely to be re-infected with a new genotype if 
a period of negative stools occurs compared to those who were continuously PCR 
positive (67% and 17% re-infected, respectively), however re-infection can occur in as 
little as 58 days with no negative period in between (Px 73). This demonstrates super-
infection with a different genotype is possible, as is seen in the last sequenced sample 
for Px 65, in whom a mixed infection with GII.3 and GII.4 is detected despite 
continuously PCR positive stools. As this was a retrospective study data is not 
available to determine whether super-infection is associated with worsening symptoms. 
However super-infection is not associated with a longer duration of infection therefore 
may not be clinically significant. As there were only three patients who had super-
infections, a larger sample size is required to verify the clinical significance.  
All, but one, patients who remained infected with the same genotype were shown by 
phylogenetic analysis to have persistence with the same virus, not re-infection with 
another strain of the same genotype. In the only patient to be re-infected with a 
different strain of the same genotype (Patient 63, genotype GII.P21_GII.3) over a year 
(466 days) had passed between the two norovirus episodes. 
These results suggest that recent or current norovirus infection is not necessarily 
protective against re-infection with a different genotype. Norovirus animal and human 
vaccine studies to date have only included one or two genotypes, most commonly GI.1 
and GII.4 [101], therefore this could have implications for vaccine development, 
especially considering the breadth of genotypes seen in our paediatric population. The 
population described in this chapter includes patients with immunosuppression and/or 
other co-morbidities, therefore the findings cannot be extrapolated to a general 
paediatric population; however it is these at-risk patients to whom vaccination 
programmes should be targeted, therefore the findings are of interest.  
5.4.7 Conclusions 
Classical epidemiology alone, i.e. linking patients in time and place, is not sensitive 
enough to identify all transmission events. The majority that are missed are either on a 
different ward, spread over time or the clusters are small (2 patients) therefore do not 
raise alarm bells. Conversely, molecular epidemiology is able to identify many 
transmission events that are missed using classical epidemiology, including small 
clusters of two patients with limited onward transmission and clusters with rumbling 
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transmission over several months. Moreover sequence analysis reveals the true extent 
of outbreaks which are only partially recognised by classical epidemiology, primarily 
due to episodes occurring on separate wards. In these instances transmission is likely 
to be indirect via staff, visitors or fomites.  
Both capsid and polymerase genotyping are required as an adjunct to classical 
epidemiology; norovirus episodes linked in time and place and caused by the same 
genotype are likely to be linked. However phylogenetic analysis is necessary to confirm 
or exclude transmission between patients infected with the same genotype, in 
particular when separated in time or place. The polymerase and capsid shell domain 
sequences used for genotyping are not discriminatory enough for outbreak 
investigations [145]; in an immunocompetent population sequences of the P2 domain 
may suffice, however in an immunocompromised population full genome sequences 
are required. It is important however to take into account whether a plausible link 
between patients exists to confirm the occurrence of transmission; this must include 
attendance at outpatient clinics and other recent admissions.  
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  CHAPTER 6
 
ORAL RIBAVIRIN THERAPY FOR CHRONIC 
NOROVIRUS INFECTION IN IMMUNOCOMPROMISED 
PATIENTS 
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 INTRODUCTION  6.1
Norovirus infections are self-limiting in immunocompetent hosts, with limited morbidity 
aside from dehydration. In immunocompromised patients however, there is a risk of 
chronic infection with significant associated morbidity. Chronic infections are bi-phasic 
[177] with an acute phase of vomiting and diarrhoea, followed by chronic viral shedding 
and diarrhoea lasting weeks to years. The stool volume can amount to several litres a 
day, which is comparable to that observed with cholera infections [205]. The majority of 
case reports describe patients to be symptomatic during this extended period of 
shedding, with up to 24 bowel movements per day [206], however chronic norovirus 
infections can experience intermittent symptoms of diarrhoea [116] or be asymptomatic 
[207].  
Chronic infection can lead to dehydration, malnutrition, dysfunction of intestinal barrier 
[80, 207-209], dramatic weight loss [54, 81, 82, 118, 120, 207, 210-217] and a 
requirement for nutritional support [54, 120, 208, 209, 211, 212, 215-217]. The 
requirement for nutritional support may be proportional to the duration of infection, as 
suggested by a cohort of hematopoietic stem cell transplant (HSCT) recipients in whom 
patients that excreted virus for more than 100 days required nutritional support for 165 
days on average compared to those who excreted virus for less than 100 days required 
intravenous nutritional support for a shorter period, on average 46 days [54]. Prolonged 
norovirus infections can lead to worse outcome of underlying disease [80] or graft 
rejection in solid organ transplant recipients [218]. In extreme cases, norovirus in 
immunocompromised patients can be fatal; one third of fatal norovirus cases are 
reported to occur in organ transplant recipients or in patients receiving chemotherapy 
for malignancy [219]. 
The prevalence of norovirus infections in immunocompromised patients is not formally 
established, however a small number of case reports suggest it is around 20%. In a 
cohort of 61 haematopoietic stem cell transplant (HSCT) recipients, 21% developed 
norovirus infections [54]. In a cohort of 78 renal transplant recipients, 17% were 
infected with norovirus [116]. In cohorts with mixed causes of immunodeficiency, 22% 
of 116 patients with a history of bone marrow transplant (BMT) or HSCT developed 
norovirus infection [118] and 23% of 47 patients who had undergone BMT, solid organ 
transplant or who were immunosuppressed due to an oncological diagnosis [117] had 
norovirus infections. 
Severe, protracted diarrhoea caused by norovirus has been reported in several 
immunocompromised populations, including HSCT recipients [54, 80, 120, 176] who 
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remain immunosuppressed until immune reconstitution post-transplant. Solid organ 
transplant recipients [218], namely intestinal transplant [220], pancreatic transplant 
[221], combined liver, pancreas and bowel transplant [209, 222], kidney transplant [81, 
116, 207, 210, 223], lung transplant [224, 225] and heart transplant [211-213], remain 
on life-long maintenance immunosuppression to prevent graft rejection. Consequently 
solid organ recipients are at risk of chronic norovirus infections at any time post-
transplant, with reported infections occurring anywhere from one month to 10 years 
post-transplant. In HSCT recipients on the other hand, immunosuppression is largely 
temporary therefore the majority of reported infections occur within the first year post-
transplant. Severe norovirus infections are also described in patients with malignancy 
[82, 206, 208, 226-228] who are immunosuppressed either as a direct consequence of 
the malignancy or as a consequence of therapy, and in acquired immune deficiency 
syndrome (AIDS) due to HIV infection [214]. Patients with primary immunodeficiencies 
are also described as at risk of chronic and debilitating norovirus infections [84, 195, 
215-217, 229]; these patients are permanently immunosuppressed due to genetic 
abnormalities. These case reports are summarised in Table 6.1. 
Viral clearance is reportedly associated with immune reconstitution and T cell recovery 
in animal models [55] and human case reports [54, 228]. Reducing or withholding 
immunosuppression has been shown to improve clinical symptoms caused by 
norovirus in 2 days to 5 weeks [116, 120, 207, 220, 230], however in a renal transplant 
cohort the intensity of immunosuppression correlated with diarrhoeal symptoms but not 
with viral shedding [116]. In an HIV infected patient symptoms caused by norovirus 
infection improved once CD4+ count increased [214]. However, reduction of 
immunosuppression to promote norovirus clearance is not always possible; in solid 
organ transplant recipients it risks graft rejection, in bone marrow transplant recipients 
one has to wait for immune reconstitution and in primary immunodeficiencies 
immunosuppression is not an induced state therefore cannot be changed. In these 
scenarios specific antiviral therapies to clear chronic norovirus infections and aid 
recovery of gut function would be desirable and possibly reduce chronic norovirus-
associated morbidity. 
  
 
1
8
8
 
Table 6.1 Summary of chronic norovirus cases in immunosuppressed patients in the literature 
Reason for 
immunosuppression Reference N  
Adult 
or 
paed. 
Time 
since 
transplant  
Duration 
of 
shedding 
Bowel 
movements 
per day Associated morbidity (additional to diarrhoea) Treatment 
Malignancy Ghosh et al. 
(2016) [206] 
8 A and 
P 
N/A 46–270 
days 
1–24 Not stated Treated 17 norovirus cases (including 
non-chronic) with nitazoxanide. Mean 
duration of diarrhoea in treated (n=17) 7 
days (3–30), untreated (n=32) 12 (2–32) 
(P=0.09) 
Knoll et al. 
(2016) [228] 
1 A N/A Not stated 10–15 Not stated Nitazoxanide for 7 days ineffective. IVIG 
ineffective. Recovery associated with 
immune reconstitution 
Bruggink et al. 
(2015) [226] 
1 A N/A >241 days Not stated No sequence changes in ORF1 and ORF 2 over 241 
days 
None 
Ronchetti et 
al.(2014) [227] 
1 A N/A 12 weeks 4–7 Not stated Parenteral and oral immunoglobulin (one 
day of each) unsuccessful 
Ludwig et 
al.(2008) [82] 
9 P N/A 22–433 
days 
(median 
46) 
Not stated Two patients with excretion >100 days had weight loss, 
one with severe growth retardation 
None 
Simon et al. 
(2006) [208] 
5 P N/A 37–140 
days 
Not stated 35% required parenteral nutrition (7/20 infected patients) 
1 patient: life-threatening bleeding from lower 
gastrointestinal tract 
1 patient: failure to thrive, dehydration, transient lactose 
malabsorption. Several months of protracted diarrhoea 
requiring parenteral nutrition. Mucosal biopsies showed 
flattened mucosa with patchy haemorrhagic areas 
None 
  
 
1
8
9
 
Reason for 
immunosuppression Reference N  
Adult 
or 
paed. 
Time 
since 
transplant  
Duration 
of 
shedding 
Bowel 
movements 
per day Associated morbidity (additional to diarrhoea) Treatment 
Lung transplant Gairard-Dory 
et al. (2014) 
[224] 
12 A 25 months 
(±18) 
Not stated Mean 7 ±3 52% had diarrhoea-induced renal impairment All treated with oral immunoglobulin for 2 
days; 11/12 success, 1/12 mildly 
improved. NB success = resolution of 
clinical symptoms, no follow-up norovirus 
testing 
Boillat Blanco 
et al. (2011) 
[225] 
1 A 2 weeks 
post-lung, 
5 years 
post-
HSCT 
6 months Not stated Not stated Resolved with switch from sirolimus to 
tacrolimus 
Pancreatic 
transplant 
Echenique et 
al. (2016) 
[221] 
1 A 841 days 2543 days 20 Hospitalised for intravenous rehydration None 
Renal transplant Coste et al. 
(2013) [210] 
15 A 9.5 years 
(±7.7) 
Not stated Mean 6 (±3) Greater weight loss compared to other causes of 
diarrhoea 
None 
Roos-Weil et 
al. (2011) [81] 
15 A 37 months 
(±37) 
Median 
289 (107–
581) 
Not stated Greater weight loss compared to other causes of 
diarrhoea 
9-fold longer duration of symptoms compared to other 
causes of diarrhoea 
Diarrhoea-associated acute renal failure in 81% 
None 
Schorn et al. 
(2010) [116] 
9 A Median 42 
months 
(1–136) 
97–898 
days 
Not stated 5/9 had intermittent symptoms 
5/9 had to be hospitalised 
Decrease in renal function in all (reversible) 
Treated with cautious reduction in 
immunosuppression. Intensity of 
immunosuppression correlated with 
diarrhoeal symptoms but not with viral 
shedding (all patients improved clinically 
but only 3/9 stopped shedding) 
  
 
1
9
0
 
Reason for 
immunosuppression Reference N  
Adult 
or 
paed. 
Time 
since 
transplant  
Duration 
of 
shedding 
Bowel 
movements 
per day Associated morbidity (additional to diarrhoea) Treatment 
Chagla et al. 
(2013) [223] 
1 A 5 years 
post-
pancreatic
, 15 years 
post-renal 
18 months 
(79 days 
confirmed 
by PCR) 
5–10 Hospital admission for diarrhoea 
Diarrhoea required placement of a rectal tube 
Parenteral immunoglobulin unsuccessful 
Enteral Immunoglobulin for 2 days 
successful 
Westhoff et al. 
(2009) [207] 
2 A  3 months 
and 14 
years 
5.5 
months 
and 3 
months 
Not stated Both admitted to hospital due to diarrhoea 
1 patient: Intermittent diarrhoea for 3 months, >5 kg 
weight loss, shortened and broadened villi on biopsy 
1 patient: spontaneous resolution  
1 patient: symptom resolution and cleared 
virus once withheld tacrolimus 
Heart transplant Ebdrup et al. 
(2011) [211] 
1 A 3 years 56 days 10–15 Administered intravenous fluids 
Parenteral nutrition for 12 days 
Severe weight loss (9 kg) 
Required renal dialysis (severe metabolic acidosis) 
Immunoglobulin via duodenal tube 
successful 
Nilsson et al. 
(2003) [212]  
1 A 6 years >3 years 4–8 Admitted to hospital for intravenous rehydration 
Severe weight loss 
Parenteral nutrition 5 days per week for > 3 years 
Longitudinal sampling showed one permanent amino 
acid change and one transient amino acid change in 
polymerase after 1 and 4 months, respectively. 
 
Breast milk (three times per day) for 3 
weeks, oral immunoglobulin for 15 days, 
IV immunoglobulin for 5 days and 
reduction of immunosuppression; all 
unsuccessful.  
  
 
1
9
1
 
Reason for 
immunosuppression Reference N  
Adult 
or 
paed. 
Time 
since 
transplant  
Duration 
of 
shedding 
Bowel 
movements 
per day Associated morbidity (additional to diarrhoea) Treatment 
Engelen et al. 
(2011) [213] 
1 A 14 months 365 Not stated 10 kg weight loss Symptom and virus resolution when 
everolimus added to immunosuppressive 
regimen   
Intestinal transplant Kaufman et al. 
(2003) [220] 
1 P 178 days >120 days Not stated Intravenous fluid therapy required Recovery associated with reduction in 
immunosuppression 
Combined liver, 
pancreas and small 
bowel transplant 
Lee et al. 
(2008) [209] 
1 P 61 days 114 days Not stated 
(high 
ileostomy 
losses) 
Haemorrhagic necrosis of small bowel 
Total parenteral nutrition required 
 
Florescu et al. 
(2008) [222] 
2 P 4 months 
and 7 
months  
2–8 
months 
Not stated 
(increased 
ileostomy 
output) 
Aggressive fluid replacement required  Oral human serum immunoglobulin for 2 
days successful 
Mixed solid organ 
transplants (kidney, 
liver, pancreas, 
small bowel  or 
heart) 
Lee et al. 
(2016) [218] 
67 A Median 
2.82 years 
(12–5945 
days) 
Median 
135 days 
(1–2569 
days) 
Not stated Duration of diarrhoea significantly longer compared to 
non-norovirus causes (median 135 vs. 25 days), 88% 
developed chronic diarrhoea 
39/67 patients hospitalised for diarrhoea 
1 diarrhoea-related death, 2 diarrhoea-related graft 
failures 
2 kg weight loss at 1 month 
None 
Mixed solid organ 
transplants 
Avery et al. 
(2017) [231] 
31 A 37 months 
(<1–312) 
4 months 
(<1–20) 
Not stated Wasting (>10% of body weight) (35%) 
Acute kidney injury (23%) 
All resolved, unclear which therapy 
responsible (16% spontaneous; 84% on 
nitazoxanide,  reduced 
immunosuppression and/or IVIG) 
  
 
1
9
2
 
Reason for 
immunosuppression Reference N  
Adult 
or 
paed. 
Time 
since 
transplant  
Duration 
of 
shedding 
Bowel 
movements 
per day Associated morbidity (additional to diarrhoea) Treatment 
Hematopoietic stem 
cell transplant 
(HSCT) 
Saif et al. 
(2011) [54] 
13  P −80–63 
days 
Median 
150 days 
(60–380) 
Not stated All required nutritional support 
Patients excreting >100 days: required combined 
nutritional support for 165 days (35–416) 
Patients excreting <100 days required nutritional support 
for 46 days (26–71) 
Weight loss 
Viral clearance correlated with T cell 
recovery 
 
Roddie et al. 
(2009) [120] 
6 A Median 
10.5 
months 
(0.25–60 
months) 
Median 7 
months 
(3–14 
months) 
Not stated All chronically infected (6/12) required enteral or 
parenteral nutrition 
1 patient 14 kg weight loss (25% of body weight) 
1 patient died of malnutrition 
26–108 days hospitalisation (median 73) 
2 patients responded to withdrawal of 
immunosuppression  
Mixed case series: 
solid organ and 
HSCT (not specified) 
Ye et al. 
(2015) [118] 
11 P Median 
137 days 
(−3–1962) 
Median 
12.5 (1–
324) 
Median 9 
(3–16) 
55% hospitalised for diarrhoea 
27% required ICU admission (compared to 0% non-
norovirus; P=0.02) 
Median 1.6 kg weight loss (vs. 0.6kg non-noro P<0.01) 
 
HIV positive Wingfield et al. 
(2010) [214] 
1 A N/A 7 months 20 Weight loss 3 stone 3 days IVIG unsuccessful 
Clearance associated with increase in 
CD4 count 
  
 
1
9
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Reason for 
immunosuppression Reference N  
Adult 
or 
paed. 
Time 
since 
transplant  
Duration 
of 
shedding 
Bowel 
movements 
per day Associated morbidity (additional to diarrhoea) Treatment 
Primary 
immunodeficiency - 
CVID 
Woodward et 
al. (2015) 
[215] 
8 A N/A Up to 22 
months 
Up to 10–20 Weight loss, 5/8 required long-term parenteral nutrition 5/8 treated with ribavirin; 2/5 successfully, 
3/5 unsuccessfully 
Duraisingham 
et al. (2015) 
[216] 
3 A N/A 9–30 
months 
3–4 (only 
stated for 1 
patient) 
All severe weight loss, 1 patient malnutrition and long 
term parenteral nutrition 
1 patient nitazoxanide (10 days) 
unsuccessful 
1 patient 2 weeks ribavirin unsuccessful  
2 patients oral immunoglobulin, 1 with 
symptom improvement but not viral 
clearance 
Van de Ven et 
al. (2011) 
[217] 
1 P N/A >2 years Not stated Severe enteropathy with 19% weight loss, required 
parenteral nutrition 
Unsuccessful IVIG, duodenal 
immunoglobulin, duodenal breast milk, 
ribavirin (10 days),  
Primary 
immunodeficiency -
other 
Frange et al. 
(2012) [84] 
11 P N/A Up to 10 
months 
Not stated Mild to severe dehydration and denutrition, exacerbation 
of immune-mediated enteropathy 
IVIG (3/11 patients ) and oral 
immunoglobulin (1 patient) unsuccessful 
Gallimore et 
al. (2004) 
[229] 
1 P N/A 156 days Not stated None reported None 
Xerry et al. 
(2010) [195] 
2 P 
 
N/A 48–69 
days 
Not stated Not stated None 
N, number of patients; A, adults; P, paediatric; N/A, not applicable; ±, standard deviation 
CVID, common variable immunodeficiency; Other, SCID (severe combined immunodeficiency), cartilage hair dysplasia, Wiskott-Aldrich syndrome, MHC Class II deficiency, 
agammaglobulinaemia, chronic granulomatous disease 
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The development of specific antivirals against norovirus infections has been somewhat 
neglected in comparison to other viral pathogens, primarily due to the acute short-lived 
nature of infection in immunocompetent hosts, and thus the majority of people. 
However norovirus is increasingly recognised as a major cause of morbidity, and in 
rare cases mortality, in immunocompromised patients, stimulating research activity to 
develop an effective antiviral therapy; nonetheless these studies remain few and on a 
small scale. Several compounds have been shown to have some degree of antiviral 
activity against murine norovirus or human norovirus replicon systems [232]. Of these 
there are two that are already licenced for the treatment of other infections in humans 
and therefore available to use clinically. These are nitazoxanide, licenced for 
Cryptosporidium and Giardia infections, and ribavirin, licenced for the treatment of 
respiratory syncytial virus (RSV) in infants and children and Hepatitis C virus (HCV) 
infections. In HCV infections ribavirin is given by mouth with peg interferon alpha or 
interferon alpha. In RSV bronchiolitis ribavirin is administered by inhalation, although 
there is no evidence that ribavirin produces clinically relevant benefit in RSV 
bronchiolitis [233].   
Ribavirin is a purine mimic synthetic nucleoside analogue that resembles guanosine 
[234]. First synthesised in 1972 [235, 236] it is a broad range antiviral with activity 
against RNA and DNA viruses; in vitro activity has been demonstrated against 36 virus 
species across 18 genera and ten families [237].  
Ribavirin has been shown to have in vitro dose dependent antiviral activity against 
murine norovirus and norovirus replicon-bearing cells [238]. More recently successful 
treatment with ribavirin has been reported in two adult Common Variable 
Immunodeficiency (CVID) patients with chronic norovirus infection, in whom 6 and 14 
months of ribavirin therapy resulted in clearance of norovirus, complete resolution of 
clinical symptoms, improved nutritional status and almost complete recovery of 
duodenal villous morphology. Conversely, three patients from the same CVID cohort 
were treated with ribavirin for 9, 20 and 21 months without clearance of norovirus [215]. 
A possible side-effect or ribavirin is reversible haemolytic anaemia caused by the 
accumulation of ribavirin in erythrocytes.  
There are several postulated mechanisms of action of ribavirin [239], which are 
summarised in Table 6.2. One which is measurable in vivo is the accumulation of 
mutations leading to lethal mutagenesis. RNA viruses lack proof-reading enzymes, 
resulting in a high mutation frequency of 10−3 to 10−5 substitution per nucleotide per 
replication cycle [21, 51]. Intra-host viral populations consequently exist as a 
heterogeneous population with a consensus sequence and minority variant sequences, 
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known as quasispecies. This high mutation frequency is advantageous as it allows 
rapid evolution and adaptation, however there is an upper limit of genome variability, 
known as the error threshold, beyond which errors become deleterious to the 
population. RNA viruses exist at the edge of the error threshold [240-242]; an increase 
in mutation frequency forces the population beyond the error threshold [242] thus is 
detrimental (Figure 6.1).  
Table 6.2 Mechanisms of action of ribavirin against RNA viruses, as reviewed by Graci & Cameron [239] 
GTP, guanosine triphosphate; RMP, ribavirin monophosphate; IMPDH, inosine monophosphate 
dehydrogenase; RdRp RNA dependent RNA polymerase; ATP; adenosine triphosphate; RTP, ribavirin 
triphosphate; CTP cytosine triphosphate; UTP, uracil triphosphate 
Mechanism of action Outcome 
REDUCTION OF CELLULAR GTP POOLS 
RMP binds to the active site of IMPDH, the cellular enzyme involved 
in the first step of guanosine nucleotide synthesis, thus 
competitively inhibiting cellular GTP synthesis. 
 
Inhibits translation, 
transcription and 
replication  
IMMUNOMODULATORY EFFECT 
Mechanisms not understood 
 
Enhances T-cell 
response 
INHIBITION OF RNA CAPPING (7-METHYL GUANOSINE) 
Competitive inhibition of capping enzymes 
or 
Incorporated as a cap analogue 
 
RNA not competent for 
translation 
INHIBITION OF RNA POLYMERASE 
Competition with GTP and ATP pools so RTP incorporated into RNA  
or 
Binds to RdRp close to active site and changes conformation 
 
Reduced elongation 
activity if RBV in 
template 
 
MUTAGENESIS 
RTP has equal binding efficiency with cytidine or uridine  
Potential for mutagenesis due to incorporation of RTP during 
replication, compounded by ambiguous base pairing with CTP or UTP 
during next round of replication 
 
Accumulation of 
mutations leading to 
lethal mutagenesis 
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Figure 6.1 Model of viral quasispecies at the error threshold of lethal mutagenesis. The majority of 
viruses, having fewer mutations, are viable. Some viruses, with a greater number of mutations, are non-
viable. A small increase in mutation frequency is predicted to push the virus population into lethal 
mutagenesis (mutagenized population), where the number of errors per viral genome is sufficiently high 
to lethally mutate the majority of the virus populations. Figure reproduced, with permission, from 
Vignuzzi et al. [237] 
 
Lethal mutagenesis has been demonstrated to be the primary mechanism of action of 
ribavirin against Hantaan virus, Hepatitis C virus, foot and mouth disease virus and 
poliovirus [237]. In poliovirus, an increase in mutation frequency beyond the error 
threshold results in reduced virus infectivity [237], demonstrating  that the accumulation 
of deleterious mutations due to lethal mutagenesis caused by ribavirin ultimately leads 
to loss of fitness. To date, virus mutation frequencies have been determined by PCR 
amplification of a region of the genome followed by cloning and capillary sequencing of 
70 or more colonies [158]. 
Since ribavirin is a purine mimic which binds with equal efficiency to cytidine or uridine, 
ribavirin driven mutations are expected to be transitions rather than transversions 
(Figure 6.2). 
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Figure 6.2 Schematic of transition and transversion nucleotide substitutions 
 
This chapter reports the use of ribavirin treatment in two child recipients of organ 
transplants in whom chronic norovirus infection was associated with malnutrition and 
weight loss. In order to determine whether ribavirin was acting on norovirus, deep 
sequencing was used to look for signatures of ribavirin mutagenesis in virus sampled 
pre– and post–treatment in relation to the clinical outcome following treatment.     
 MATERIALS AND METHODS 6.2
6.2.1 Case history and ribavirin therapy 
Patient A was a six year old girl who had a heart transplant at one month of age, 
following enteroviral myocarditis (coxsackie virus). She remained on long-term 
immunosuppressive therapy with sirolimus following transplant. In August 2012 she 
developed severe diarrhoea, which was diagnosed by routine real-time RT-PCR as 
norovirus GII in September 2012. By November 2012 she was malnourished, had lost 
a third of her body weight (from 17.5 kg in July 2012 to 12.8 kg in November) and was 
unable to attend school due to the severity of diarrhoea.  
Three months after norovirus was first detected, oral ribavirin therapy for Patient A was 
commenced at 2.5 mg/kg BD for 4 weeks, with no evidence of adverse effects. The 
dose was increased to 5 mg/kg BD for a further 4 weeks. Therapy was stopped after a 
total of 2 months. Four weeks prior to starting Ribavirin therapy, Patient A’s sirolimus 
dose (immunosuppressant used to prevent organ rejection) was decreased from 1 to 
0.5 mg OD and further reduced to 0.2 mg OD ten days prior to starting ribavirin 
therapy. 
 198 
 
Patient B was a three year old boy with congenital nephrotic syndrome who received a 
kidney transplant at 22 months of age, following which he remained on long term 
immunosuppressive therapy with tacrolimus. He developed chronic diarrhoea a few 
days after transplant which was diagnosed at the time as norovirus GII.  
Oral ribavirin therapy for Patient B was commenced 7 months after norovirus was first 
detected at 2.5 mg/kg BD for 5 weeks; the dose was then increased to 5 mg/kg BD and 
to 7.5 mg/kg seven weeks after that.  Ribavirin was well tolerated and he remained on 
treatment for a total of 5 months. Patient B’s tacrolimus (immunosuppressant) dose 
was not changed throughout the study period. 
Stool frequency and consistency was recorded daily by parents commencing from 
before and continuing for a few weeks after ribavirin treatment and weight was 
measured weekly.  Stool samples were collected once to twice weekly to monitor 
norovirus detection; blood samples were collected once weekly to monitor for anaemia 
associated with ribavirin therapy and every two weeks to monitor plasma ribavirin 
levels. 
6.2.2 Viral load monitoring 
Stool samples from each patient were collected and tested for norovirus once to twice 
per week using real-time PCR, the methods for which are described in Chapter 2. Copy 
number was determined using a standard curve, as described in Chapter 2. To 
generate a viral load in copies/gram, the amount of stool used to make the stool lysate 
was weighed.  
6.2.3 cDNA synthesis 
cDNA was prepared using universal norovirus GII.4 primers, as described in detail in 
Chapter 2.  
6.2.4 Method to determine mutation frequencies: cloning vs. deep 
sequencing 
Fragments of the RNA polymerase (NS7, 782 nucleotides) and capsid (VP1, 694 
nucleotides) genes (Figure 6.3) were amplified from cDNA by PCR from samples 
collected from Patient A before and during ribavirin therapy. In parallel, VP1 and NS7 
amplicons were cloned, with 96 colonies capillary sequenced, and deep sequenced on 
an Illumina MiSeq. Methods for cloning and MiSeq library preparation are described in 
Chapter 2. 
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Figure 6.3 Schematic of norovirus genome with NS7 (green) and VP1 (red) PCR target regions 
highlighted. Nucleotide numbering is based on a GII.4 genome 
 
A norovirus GII.4 full length clone, constructed by the Goodfellow lab, was used as a 
control throughout the process.  
6.2.5 Norovirus mutation frequencies pre- and post-ribavirin therapy 
To estimate the mutation frequency of the total norovirus population in each sample, 
NS7 and VP1 amplicons were generated from longitudinal samples collected before 
and during ribavirin therapy from Patient A, Patient B and from a third and fourth child, 
Patient C and Patient D who were chronically infected bone marrow transplant 
recipients who were not treated with ribavirin. All amplicons were sequenced by 
capillary sequencing to determine the consensus sequence and deep sequenced on an 
Illumina MiSeq to determine the mutation frequency, as described in Chapter 2. A GII.4 
full length clone, constructed by the Goodfellow lab, was used as a control throughout 
the process.  
6.2.6 Calculation of mutation frequency 
The mutation frequency is expressed as number of mutations per 10,000 nucleotides. 
Details of how this was calculated are described in Chapter 2.  
6.2.7 Statistical analysis 
All statistical analysis was undertaken in SPSS v23, as described in Chapter 2.  
6.2.8 Full genome sequencing 
Pre- and post-ribavirin samples for Patient A and Patient B were sequenced using 
SureSelect target enrichment to generate full genome consensus sequences (methods 
described in Chapter 2). Genomes were assembled using the de-novo pipeline 
described in Chapter 2. Full genome sequences were used to determine the full 
polymerase and capsid protruding domain sequences, as the NS7 and VP1 amplicons 
only provide partial sequences for these regions.  
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6.2.9 Mapping amino acid changes 
Known epitopes were identified in the capsid protruding (P) domain amino acid 
sequences from Patient A and Patient B ten and 27 days into ribavirin therapy, 
respectively, as described in Chapter 2. Residue changes seen during ribavirin therapy 
were highlighted. 
6.2.10 Phylogenetic analysis of capsid nucleotide sequences 
A maximum likelihood tree was reconstructed for the VP1 PCR capsid sequences, as 
described in Chapter 2.  
 RESULTS 6.3
6.3.1 Viral load, weight and diarrhoea  
During ribavirin therapy the stool viral load for Patient A decreased and became 
undetectable 6 weeks after start of therapy. During this time Patient A’s weight steadily 
increased from 13.3 kg at the start of ribavirin to 16 kg two months after ribavirin was 
stopped. The patient was followed up for a further nine months during which time her 
weight continued to increase to 21.2 kg (11 months after start of therapy) and norovirus 
remained undetectable (Figure 6.4a).  
Patient A’s stool output remained unchanged during ribavirin therapy with 6-10 liquid 
stools per day.  Diarrhoea improved significantly two months after norovirus was 
eradicated and stopped completely after seven months (Figure 6.4b).
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Figure 6.4 Patient A a) norovirus viral load and weight; b) clinical timeline  
a) 
 
 
 
Prior to norovirus infection Patient B’s weight was in the 91st centile. During norovirus 
infection Patient B suffered significant weight loss to 12.7 kg, on the 25th centile. During 
5 months of ribavirin therapy Patient B also gained weight, from 12.7 kg to 16.5 kg, 
returning to the 91st centile. Patient B was followed up for a further three months during 
which time he continued to gain weight to 18.4 kg (Figure 6.5). 
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Figure 6.5 Patient B a) norovirus viral load and weight; b) clinical timeline 
a) 
 
Patient B’s viral load fluctuated during ribavirin therapy, but his stool output remained 
unchanged, with 1–9 liquid stools per day. Two months after the end of therapy 
diarrhoea had improved significantly and norovirus was no longer detectable. However 
2 months later norovirus was once again detectable and two weeks later severe 
diarrhoea, with up to 13 stools a day, re-started, coinciding with an acute astrovirus 
infection. Once the astrovirus infection resolved spontaneously, norovirus remained 
detectable for a further 6 months however diarrhoea did not return.   
6.3.2 Ribavirin levels 
Ribavirin levels in plasma for Patient A peaked at 782 ng/ml and 1,252 ng/ml for 
Patient B (Figure 6.6). 
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Figure 6.6 a) Norovirus viral load, plasma ribavirin level and sirolimus dosage for Patient A; b) Norovirus 
viral load and plasma ribavirin level for Patient B (dosage of immunosuppressant unchanged) 
a) 
 
b)  
 
 
Red blood cell counts for Patients A and B stayed within normal limits therefore there 
was no indication of anaemia during therapy, suggesting that ribavirin accumulation 
had no adverse effects. 
6.3.3 Consensus sequences 
 Whole genome sequences and genotypes 6.3.3.1
Whole genomes sequences, used to derive the full RdRp and capsid protruding 
domain sequences, were successfully determined for Patient A and Patient B (Table 
6.3).  
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Table 6.3 Assembly details of norovirus full genome sequences used to derive capsid P domain and 
polymerase sequences 
Sample name Assembly 
method 
Assembled 
genome size 
Estimated genome 
coverage 
Average 
read depth  
Patient A pre-ribavirin De novo 7408 97.99% 20,548 
Patient A 10 days post-ribavirin De novo 7495 99.14% 10,388 
Patient B pre-ribavirin De novo 7466 98.76% 491 
Patient B 27 days post-ribavirin De novo 7499 99.19% 153 
 
Genotyping using the Norovirus genotyping tool [4] and full genome sequences 
showed all norovirus positive samples from Patient A and Patient B to be GII.P4_GII.4 
New Orleans_2009. The positive control used throughout this study was a GII.P4_GII.4 
Farmington Hills_2002. 
Genotyping using the Norovirus genotyping tool [4] and NS7 and VP1 amplicon 
sequences showed all samples from Patient C were GII.Pe_GII.4 Sydney_2012 and 
from Patient D were GII.P4 New Orleans_2009_GII.4 Sydney_2012. 
 Consensus sequence changes in RdRp  6.3.3.2
The second and subsequent samples collected from Patient A, seven days after 
starting ribavirin treatment, showed five coding changes in the RNA polymerase gene 
(Figure 6.7, Table 6.4).  Although most substitutions did not alter the predicted protein 
properties, one (M231K) corresponds to a change from a very hydrophobic to a 
hydrophilic amino acid near the RdRp palm domain.  
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Figure 6.7 Coding changes in RNA polymerase gene of Patient A mapped onto RNA polymerase protein 
structure of Norwalk virus RdRp. Blue indicates residues known to be involved in catalysis. Red indicates 
changes selected with ribavirin treatment (figure prepared by Lucy Thorne, University of Cambridge) 
 
 
Table 6.4 Coding (non-synonymous) nucleotide changes in norovirus RNA polymerase gene from Patient 
A 
 Nucleotide position 
Sample collection date 3973 4202 4263 4710 4943 
29/11/12 (pre ribavirin) G G T C A 
05/12/12 (pre ribavirin) G G T C A 
16/12/12 (during ribavirin) T A A T G 
07/01/12 (during ribavirin) T A A T G 
13/01/12 (during ribavirin) T A A T G 
Amino acid change E134D V211I M231K A380V I458V 
 
The emergence of this RdRp variant coincided with a log reduction in norovirus viral 
load and subsequent clearance of the virus (Figure 6.8). Neither Patient B nor patient 
C or D showed consensus level coding changes in the RdRp gene.  
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Figure 6.8 Norovirus viral load in Patient A, with emergence of RdRp variant 
 
 Consensus sequence changes in capsid 6.3.3.3
Patients A and B had 10 and 11 amino acid substitutions (non-synonymous changes 
with SNP frequency >50%), respectively, between the first and last sample in the 
capsid (VP1) sequences compared to 1 and 6 in patients not treated with ribavirin 
(Patient C and Patient D). 
All of the amino acid substitutions in the capsid protruding domain of Patients A and B 
correspond to surface exposed sites of the capsid P2 subdomain (Figure 6.9, Table 
6.5 and Table 6.6). 
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Figure 6.9 Patient A and B protruding (P) domain amino acid changes seen 10 and 27 days, respectively, into ribavirin therapy mapped onto GII.4 protein crystal structure (2OBT 
[2]); a) right to left rotation; b) top to bottom rotation. Dark Brown (top), P2 subdomain; Beige (bottom), P1 subdomain; Yellow, Dimer interface; Dark pink, HBGA binding site; 
pale pink, Indirect role in HBGA binding; Violet, Binding pocket predicted by Tan et al. 2003; Teal, Immunogenic epitopes; Green, Residue changes associated with ribavirin (dark 
green, in epitope; light green, not in epitope); Extra molecule, HBGA B trisaccharide. Protruding domain sequences derived from full genome sequences 
Patient A 
 
Patient B 
 
a) b) 
a) b) 
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Table 6.5 Patient A capsid protruding (P) domain amino acid changes seen 10 days into ribavirin therapy 
(protruding domain sequences derived from full genome sequences) 
Amino acid 
change 
Known epitopes Change to amino acid 
properties 
Val 298 Asp 
Asn 372 Thr 
Immunogenic epitope A in P2 Hydrophobic  Acidic 
No change (neutral) 
 
Ser 393 Gly 
Lys 395 Thr 
 
Immunogenic epitope D and  binding pocket 
indirectly involved in HBGA binding in P2 
 
Neutral  Unique 
Basic  Neutral 
 
Asn 413 His 
 
Immunogenic epitope E in P2 
 
Neutral  Basic 
 
Unknown epitopes 
 Phe 375 Leu Next to HBGA binding site in P2 Hydrophobic (aromatic)  
Hydrophobic (aliphatic) 
Ile 410 Arg 
Asn 411 Asp 
Next to immunogenic epitope E in P2 Hydrophobic  Basic 
Neutral  Acidic 
 
Asp 354 Asn 
 
Not known epitope in P2 
 
Acidic  Neutral 
 
Table 6.6 Patient B capsid P domain amino acid changes seen 27 days into ribavirin therapy (protruding 
domain sequences derived from full genome sequences) 
Amino acid 
change 
Known epitopes Change to amino acid properties 
Thr 291 Ile Speculative binding 
pocket in P2 
Neutral  hydrophobic (aliphatic) 
Asn 297 Arg 
Ser 298 Asn 
Asn 372 Asp 
 
Immunogenic epitope A 
in P2 
Neutral  Basic 
No change (neutral) 
Neutral Acidic 
Asp 393 Ser Immunogenic epitope D 
and  binding pocket 
indirectly involved in 
HBGA binding in P2 
Acidic  Neutral 
 
Unknown epitopes 
 Ser 310 Asn 
Ser 352 Tyr 
Asn 357 Asp 
 
Not known epitope in P2 No change (neutral) 
Serine  Hydrophobic (aromatic) 
Neutral  acidic 
Thr 293 Ile 
Asp 341 Asn 
Leu 375 Phe 
Ala 396 Pro  
 
Next to HBGA binding site 
in P2 
Neutral  hydrophobic (aliphatic) 
Acidic  neutral 
Hydrophobic (aliphatic) hydrophobic (aromatic) 
Hydrophobic (aliphatic)  Unique 
Ala 377 Thr Next to speculative 
binding pocket in P2 
Hydrophobic (aliphatic)  Neutral 
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 Phylogenetic analysis of capsid nucleotide sequences 6.3.3.4
Phylogenetic analysis of the capsid gene fragment, VP1, showed the sequence 
amplified from the sample from Patient B after norovirus was undetectable and 
diarrhoea had improved, clustered with other samples from Patient B, but in a separate 
cluster to samples from Patient A and a GII.4 variant Farmington Hills 2002 (Figure 
6.10). Sequences within each cluster were 97-99.8% identical at the nucleotide level, 
whereas sequences between clusters, but still of the same variant type (GII.4 New 
Orleans_2009), had 92-93% sequence identity. GII.4 variant Farmington Hills 2002 had 
85-88% sequence identity to the GII.4 New Orleans_2009 sequences.  
Figure 6.10 Phylogenetic tree of Patient A and Patient B VP1 (capsid) nucleotide sequences. All 
sequences are genotype GII.4 variant New Orleans_2009, with the exception of the outgroup GII.4 
variant Farmington Hills 2002.  indicates samples collected before ribavirin therapy was started. Scale 
bar represents the number of substitutions per site 
 
 
6.3.4 Method to determine mutation frequencies: cloning vs. deep 
sequencing 
Each cloned amplicon generated 64–88 colony sequences for mutation frequency 
analysis. Deep sequencing generated a median of 835–4,763 reads per amplicon. 
The mutation frequencies determined by cloning were up to ten-fold higher than by 
deep sequencing (Table 6.7), suggesting cloning considerably over-estimates the 
mutation frequency. Consequently deep sequencing was used to investigate the effect 
of ribavirin on norovirus intra-host mutation frequency. 
 210 
 
Table 6.7 Comparison of mutation frequencies obtained by cloning and deep sequencing method 
 
Region 
Cloning 
Mutation frequency 
per 10,000 nt 
Deep Sequencing 
Mutation frequency 
per 10,000 nt 
GII.4 full length clone control 
NS7 
VP1 
15 
12 
3 
1 
Patient A 29/11/12 (pre-ribavirin) 
NS7 
VP1 
36 
35 
3 
11 
Patient A 16/12/12 (during ribavirin) 
NS7 
VP1 
32 
26 
4 
1 
NS7, region of RNA polymerase gene; VP1, region of capsid gene 
 
6.3.5 Mutation frequencies and ribavirin  
 Fold-changes in mutation frequency 6.3.5.1
The mutation frequency of the GII.4 full length clone control was <1 mutation per 
10,000 nt.  
One month after start of treatment, the mutation frequency in Patient A and Patient B 
increased by 3.4-fold and 1.9-fold, respectively, compared to pre-ribavirin samples. 
During the same time period the mutation frequency in control patient C reduced by 
0.9-fold and in Patient D increased 1.4-fold. Three months after the start of treatment, 
the mutation frequency in Patient B increased 4.2-fold compared to the pre-ribavirin 
sample; over the same time frame the mutation frequency in control patient C 
increased by 1.4-fold and in Patient D decreased 3.2-fold (Figure 6.11). The difference 
in mutation frequency between pre-and post-ribavirin samples in Patient A and Patient 
B was not significant (P = 1.0 and 0.5, respectively). The P values are exceptionally 
high due to the small sample number, in particular only one sample in the pre-ribavirin 
group. When the data for Patient A and Patient B is grouped together, so there are 
more data points in each group, the outcome is unchanged (P = 0.371). 
In all patients the mutation frequencies in the capsid region (median 21.0 mutations per 
10,000 nt) are significantly higher than in the RdRp region (median 5.4 mutations per 
10,000 nt) (P = 0.005). 
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Figure 6.11 Mutation frequencies for ribavirin treated Patient A and Patient B and untreated Patient C 
and Patient D in longitudinal samples (excluding consensus level changes). GII.4 FLC is a norovirus GII.4 
(Farmington Hills) control. Day number is relative to start of ribavirin therapy. (a) Transitions only; (b) 
Transversions only 
a) 
 
b) 
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 Transitions and transversions 6.3.5.2
The majority of mutations in Patients A and B were transitions, rising from 96% and 
93% pre-ribavirin, respectively, to 98% and 95% during treatment. The proportion of 
transitions in un-treated patients C and D ranged between 78-91% and 36–81%, 
respectively. Therefore the proportion of transitions in Patients A and B was higher 
than in the un-treated patients, but this was already the case pre-ribavirin (Figure 
6.11). 
 Non-synonymous and synonymous mutations (dN/dS ratios) 6.3.5.3
All patients had wavering dN/dS ratios in the capsid over time (Table 6.8), suggesting 
the selection pressure on the capsid is frequently changing. 
The polymerase in Patient B and Patient C had a dN/dS ratio consistently below one 
(0.0–0.5). Conversely Patient D consistently had a dN/dS ratio near or above one (0.9–
3.6). Patient A had a dN/dS ratio of 3.0 before the commencement of ribavirin therapy, 
and below one (0.5-0.7) during treatment (Table 6.8).  
Table 6.8 Intra-host dN/dS ratios in RdRp (NS7) and capsid (VP1) in ribavirin treated Patients A and B 
and chronically infected un-treated Patients C and D, determined by deep sequencing of NS7 and VP1 
amplicons (excluding positions with SNP frequency >50%) 
 
dN/dS ratio 
NS7 VP1 
Patient A 
Day -2 (pre-ribavirin) 3.0 1.7 
Day 17 (during ribavirin) 0.7 0.3 
Day 31 (during ribavirin) 0.5 0.3 
Patient B 
Day -15 (pre-ribavirin) 0.0 3.2 
Day 27 (during ribavirin) 0.1 2.8 
Day 48 (during ribavirin) 0.0 2.7 
Day 91 (during ribavirin) 0.0 1.2 
Patient C 
Day 0 0.1 1.2 
Day 32 0.2 1.0 
Day 44 0.3 0.5 
Day 100 0.5 2.6 
Patient D 
Day 0 1.7 5.7 
Day 23 3.6 0.4 
Day 40 3.4 4.4 
Day 75 0.9 2.5 
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 Frequency distribution of mutations 6.3.5.4
The distribution of low frequency mutations differs between patients. Patients A and B 
had non-synonymous mutations with <50% frequency at 3 and 2 positions across the 
NS7 amplicon sequence, whereas Patients C and D, who were not treated with 
ribavirin, had low frequency mutations at 15 and 12 positions (Figure 6.12). This 
difference between treated and untreated patient is not mirrored in the capsid (VP1) 
amplicon, for which low frequency mutations are seen at 13, 19 and 29 positions for 
Patients A, B and C and only 5 positions in Patient D (Figure 6.13). 
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Figure 6.12 Mutation frequency spectrum in RdRp (NS7) of longitudinal samples from ribavirin treated Patients A, B and chronically infected un-treated Patients C and D, 
determined by deep sequencing of NS7 amplicon. Vertical axis indicates the number of positions across the region sequenced; X axis indicates the frequency of the mutation at a 
given position. Day number is relative to start of ribavirin therapy 
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Figure 6.13 Mutation frequency spectrums in capsid (VP1) of longitudinal samples from ribavirin treated Patients A, B and chronically infected un-treated Patients C and D, 
determined by deep sequencing of VP1 amplicon. Vertical axis indicates the number of positions across the region sequenced; X axis indicates the frequency of the mutation at a 
given position. Day number is relative to start of ribavirin therapy 
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 DISCUSSION 6.4
This chapter describes the compassionate treatment with oral ribavirin of two paediatric 
solid organ transplant recipients chronically infected with norovirus. Ribavirin was well 
tolerated by both patients, with no noted side effects or anaemia. Whilst only one of the 
two patients cleared norovirus during treatment both gained weight, thereby avoiding 
the need for parenteral nutrition. However, notwithstanding clearance of norovirus in 
patient A, both cases continued to have diarrhoea for several months suggesting on-
going gut dysfunction following norovirus infection.  
6.4.1 Amino acid substitutions in RdRp with ribavirin therapy 
Patient A, who is the only patient to have cleared norovirus whilst on ribavirin therapy, 
is the only patient in this study to have developed amino acid substitutions in RdRp, 
and their appearance corresponded with a log reduction in viral load and viral 
clearance. The functional consequence of these mutations is unknown, however one 
possible mechanism is that the mutations code for a higher-fidelity RdRp which, whilst 
potentially minimising incorporation of ribavirin into the RNA template during 
replication, may also infer lower fitness therefore contributing to the elimination of 
norovirus in this patient. Poliovirus with a high fidelity RNA polymerase has previously 
been shown to have an attenuated phenotype and restricted tissue tropism [237] and 
high-fidelity RNA polymerase in murine norovirus, caused by a single amino acid 
change, has been shown to result in lower transmissibility [243]. Therefore it is 
plausible that reduced viral fitness in Patient A is caused by consensus-level mutations 
that reached fixation under selection pressure from ribavirin treatment, however 
functional experiments are required to assess the impact of the mutations seen in 
Patient A on the function of RdRp. 
Whilst coding mutations were not seen in the RdRp of any other patients in this study, it 
has previously been described in a heart transplant recipient with chronic norovirus 
infection, in whom a single amino acid change was seen after 1 month of longitudinal 
sampling [212]. Nilsson et al. do not describe the position of the RdRp coding changes 
therefore they cannot be compared to those seen in Patient A in this study.  
6.4.2 Norovirus viral loads 
Whilst Patient B did appear to clear norovirus several weeks after the end of ribavirin 
therapy, phylogenetic analysis of the capsid confirmed that detection of the virus two 
months later was not a new norovirus infection, but the resurgence of the existing 
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infection which must have remained sequestered in the patient at an undetectable level 
whilst the patient was asymptomatic. Nevertheless Patient B appeared to recover gut 
function whilst on ribavirin therapy, which suggests attenuated virulence associated 
with ribavirin therapy.  
As is seen in Figure 6.6 (a) on page 203, the reduction of viral load in Patient A is 
preceded by reduced immunosuppression with a lowered sirolimus dose, which could 
account for viral clearance due to improved immune function. However viral clearance 
due to reduced immunosuppression, as opposed to ribavirin, might result in a different 
pattern in mutation frequencies to Patient B, in whom immunosuppression (tacrolimus) 
was not reduced, which is not the case. Nevertheless reduced immunosuppression in 
Patient A may have had a synergistic effect with ribavirin to clear norovirus, which did 
not occur in patient B. Alternatively viral clearance in Patient A and not B could be 
explained by a synergistic effect between ribavirin and sirolimus, which has previously 
been shown to have moderate antiviral effects [225]. This is supported by the dramatic 
drop in viral load leading to viral clearance when the sirolimus dose was increased to 
0.4 mg OD and the plasma ribavirin level reached 400 ng/ml. This was not seen in 
Patient B who was managed post-transplant with tacrolimus instead of sirolimus.  
6.4.3 Next generation sequencing for investigation of mutation 
frequencies 
Mutation frequencies were over-estimated by up to 10-fold when determined by cloning 
and capillary sequencing, compared to deep sequencing, including in the full length 
clone (FLC) control, which one would expect to have little or no mutations. The high 
error rate seen in the cloning method may be due to replication errors in Eschericia coli 
during colony growth or, most likely, the small number of sequenced clones. Although 
96 colonies were capillary sequenced for each sample, only 64-88 generated high 
quality sequences. Even though Beaucourt et al. [158] suggest a minimum of 70 
colonies for an accurate estimation of the mutation frequency, deep sequencing 
provides an average read depth of over 800 which is effectively equivalent to 
sequencing over 800 clones. The extra data will provide a more accurate estimate of 
the mutation frequency. 
Deep sequencing of amplicons is also more cost effective than sequencing multiple 
clones. The cost of cloning, sub-culturing and sequencing 96 clones in a single 
direction is approximately £350 per sample, whereas the cost of paired end deep 
sequencing is only £57 per sample for sequencing library preparation plus £685 for a 
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MiSeq run, for which up to 1,700 samples can be multiplexed with 5000-fold read depth 
per sample. 
The mutation frequency range for the GII.4 full length clone (FLC) in this study using 
deep sequencing is only 0–0.64 mutations per 10,000 nucleotides, suggesting that the 
in vivo mutation frequencies seen in Patients A, B, C and D are genuine, rather than 
PCR or sequencing artefacts. 
6.4.4 Mutation frequencies are higher in the capsid 
In ribavirin-treated Patients A and B the mutation frequencies in the capsid region 
(VP1) were significantly higher than in RdRp (NS7) and several capsid amino acid 
substitutions occurred at the consensus level. By contrast, no or few amino acid 
substitutions were seen in untreated patients sampled over a similar timeframe. All the 
substitutions localised to the surface exposed-sites of the capsid P2 subdomain, and 
may therefore represent escape mutations in response to host immune pressure. Since 
Patients C and D were bone marrow, rather than solid organ, transplant recipients, the 
immune pressures acting on the norovirus capsid may be different to Patients A and B. 
The mutation frequency in RdRp was significantly lower than in the capsid for all 
patients. This likely reflects functional constraints on the polymerase protein; viruses 
with mutated polymerase genes may not be able to replicate. This is reflected in the 
lack of consensus level changes in the RdRp of Patients B, C and D.  
6.4.5 dN/dS ratios 
dN/dS ratios, obtained from deep sequencing mutation frequency data, suggest that 
the norovirus capsid in chronically infected patients is under frequently changing 
selection pressure. Conversely, distinct patterns are seen in the dN/dS ratios of the 
polymerase (RdRp, NS7). 
In Patients B and C RdRp is under purifying selection (<1) at all times, suggesting all 
mutations are disadvantageous. Conversely in Patient A, who is the only patient with 
polymerase amino acid changes, RdRp was under positive selection (>1) pre-ribavirin 
but under purifying selection (<1) once on treatment. Patient D, who wasn’t treated with 
ribavirin, had a polymerase evolving under positive selection (>1) throughout sampling. 
Given than Patient A’s RdRp was under positive selection prior to commencement of 
ribavirin therapy and similar dN/dS ratios are seen in Patient D, the positive selection 
pressure on RdRp seen in Patient A is likely not due to ribavirin. 
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However a naturally occurring positive selection pressure on Patient A’s RdRp may 
have allowed selection of a ribavirin-associated mutation. Although Patient D’s RdRp 
appears to be under positive selection, with several low frequency coding mutations, 
none of these reached fixation.  
6.4.6 Changes in mutation frequency with ribavirin therapy 
An increase in mutation frequency is one of several mechanisms of action described 
for ribavirin [239] (Table 6.2 on page 195). Whilst high mutation frequencies in RNA 
viruses, which lack proof-reading enzymes, provide an adaptive advantage, it has been 
shown in polio virus that a ribavirin-induced increase in mutation frequency beyond the 
error threshold is deleterious [237]. 
A three-fold increase in mutation frequency has been described in ribavirin treated 
murine norovirus in vitro [244], with an associated, albeit limited, reduction in infectivity; 
however the same effect has not been reported in vivo in mice infected with murine 
norovirus, in which the observed mutation frequencies were comparable to placebo-
treated mice [244]. This is the first investigation of in vivo mutation frequency analysis 
in human norovirus infection, showing a 1.9–4.2-fold increase in mutation frequency in 
ribavirin-treated patients and ranging from a 3.2-fold decrease to a 1.4-fold increase in 
un-treated patients. This study shows an increase in mutation frequency in ribavirin 
treated patients beyond that seen in un-treated patients; however the baseline mutation 
frequencies of one un-treated patient (Patient C) were comparable to that seen in 
ribavirin-treated patients. Due to the small sample size the increases in mutation 
frequency in ribavirin-treated patients did not reach significance.  
6.4.7 Suitability of untreated patients as controls 
Patients C and D were chosen as controls in this study because they were 
immunocompromised patients chronically infected with GII.4 norovirus during the study 
period. However the underlying causes of immunosuppression differ; Patients A and B 
are solid organ transplant recipients, whereas Patients C and D are bone marrow 
transplant recipients therefore are likely to be more profoundly immunosuppressed. 
The observed mutation frequencies for Patient C were higher than in all other patients 
across the majority of time points, whereas the mutation frequencies in Patient D were 
considerably lower than the mutation frequencies seen in all other patients. The 
fluctuating, and in the case of Patient C high baseline, mutation frequencies suggest 
that the mutation frequency in chronically infected immunocompromised patients is not 
constant. The rate of mutation frequencies may be a function of underlying 
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immunosuppression or duration of infection, although it is not known how long Patients 
C and D had been infected at the time of sampling.  
Patient C, who had the highest baseline mutation frequency, was infected with a 
different ORF1 genotype compared to the other patients; Patient C’s virus had a GII.Pe 
ORF1 whereas Patients A, B and D’s viruses had a GII.P4 ORF1. It is possible that 
these different polymerases have different replication properties, with GII.P4 being 
higher fidelity and thus resulting in a lower mutation frequency compared to GII.Pe. If 
this were to be the case, it lends greater significance to the rise in mutation frequency 
seen in Patients A and B who were treated with ribavirin, as this is not seen in Patient 
D who is infected with the same ORF1 genotype but was not treated.  
In vitro experiments, in which ribavirin has been shown to cause an increase in 
mutation frequency in murine norovirus [244], are controlled situations with a 
standardised inoculum, duration of infection, sampling time and genotype. In an 
observational study such as this one, on the other hand, there is variability in inoculum 
size, duration of infection, immune status, and even genotype, all of which may cause 
changes in mutation frequencies. The difference between patients makes it very 
difficult to draw conclusions; whilst changes in mutation frequency are seen in Patients 
A and B, in the context of naturally fluctuating mutation frequencies one cannot 
definitively say that these are caused by ribavirin therapy. For definitive conclusions, a 
placebo-controlled trial with controls matched for immunodeficiency cause and status, 
time post-infection and infecting genotype must be performed. 
6.4.8 Ribavirin levels in the blood 
We took a cautious approach to dosing due to concerns of toxicity in our paediatric 
patients; consequently neither patient sustained plasma ribavirin levels above 1000 
ng/ml, which is the recommended therapeutic dose for HCV and has been associated 
with norovirus clearance in adult CVID patients [215]. These CVID patients remained 
on treatment for 6 and 14 months to achieve clearance of norovirus, which calls into 
question the potency of ribavirin against norovirus. However the authors did observe an 
inverse relationship between ribavirin plasma levels and viral load excretion in stool, 
suggesting ribavirin therapy was indeed responsible for viral clearance. 
Since no side effects were seen in either of our patients it is likely that higher dosing 
would be achievable and that dosing in this study was possibly sub-optimal. 
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6.4.9 Other treatment options for norovirus 
This is not the first attempt to treat chronic norovirus infections, although unequivocal 
and reproducible success is yet to be reported with any agent. Treatment with breast 
milk, which one would expect to contain anti-norovirus IgA, had no impact on viral load 
or symptoms [212, 217]. Human immunoglobulin has shown mixed results; cases 
treated with intravenous immunoglobulin (IVIG) have been unsuccessful [212, 214, 
223, 227, 228] as have cases treated with oral immunoglobulin [212, 222, 227, 245]. 
The exception to treatment with oral immunoglobulin is reported by Gairard-Dory et al. 
in a case series of 12 lung transplant recipients with norovirus infection, in whom 11/12 
had full symptom resolution and 1/12 mild symptom improvement when treated for 2 
days with oral immunoglobulin [224]. However the norovirus status of these patients 
was not verified after treatment, therefore it is not known whether virus clearance 
accompanied clinical recovery.  
The limited success of immunoglobulin treatment may be due to inconsistent levels of 
norovirus-specific antibodies in immunoglobulin preparations. However it could also be 
due to the mode of delivery, since two cases of severe chronic norovirus infection were 
successfully treated when immunoglobulin was delivered via the enteral route [211, 
223]. 
Nitazoxanide, an anti-protozoal agent with additional activity against anaerobic bacteria 
and viruses, resolved clinical symptoms in an immunosuppressed hematopoietic stem 
cell transplant (HSCT) recipient with a ten day history of diarrhoea [246] and is the only 
agent to have been the subject of a randomized double-blind placebo controlled trial 
(RCT). The RCT saw a significant reduction in the duration of illness in 
immunocompetent patients from 2.5 days in the placebo arm to 1.5 days in the 
treatment arm [247]. This was a small trial, with 6–7 patients in each arm and only 
included immunocompetent patients with acute infections; the utility of nitazoxanide in 
chronic infection in immunocompromised patients is yet to be determined. In a case 
series of 17 norovirus infected patients in a cancer centre treated with nitazoxanide, the 
mean duration of diarrhoea was reduced to 7 days compared to 12 days in untreated 
patients, however this was not statistically significant [206]. An additional case report in 
a single immunocompromised patient showed that treatment with nitazoxanide for 7 
days was not effective [228]. 
Favipiravir is a new broad range nucleoside analogue with some homology to ribavirin 
which is currently in Phase 3 clinical trials for the treatment of influenza in adults. As it 
is not yet a licenced drug it has not been used against norovirus infections in patients 
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but so far shows promise against murine norovirus in vitro and in vivo in mice. 
Compared to ribavirin, favipiravir showed a greater fold-change in mutation frequency 
(6-fold compared to 3-fold) in cell culture [244] and all mice infected with murine 
norovirus (5/5) had reduced viral titres in stool when treated with favipiravir, compared 
to only 2/5 mice with ribavirin. The increased mutagenic activity of favipiravir may have 
a greater effect on norovirus infectivity and thus may be a superior agent to ribavirin.  
6.4.10 Conclusions  
There is likely a complex combination of mechanisms of action involved in the in vivo 
treatment of chronic norovirus infection with ribavirin. The evidence presented in this 
chapter suggests it is possible that lethal mutagenesis is playing a role, however in light 
of differing immune pressures, durations of infection at time of treatment and fluctuating 
mutation frequencies also seen in untreated patients, it is difficult to make firm 
conclusions. There are three scenarios that may be occurring with regards to mutation 
frequency. First, ribavirin did not have activity against norovirus in the two patients that 
were treated in this study. Second, ribavirin did act directly against norovirus, but not 
via lethal mutagenesis. Third, ribavirin acted directly against norovirus via lethal 
mutagenesis, but the effect is masked by the naturally occurring changes in norovirus 
mutation frequency in chronic infections.  
More data is required on the intra-host mutation rate in chronically infected patients and 
how this is affected by immune status, duration of infection and genotype. There is also 
a need for bigger sample sizes of ribavirin-treated patients and matched controls; 
ideally in the context of a randomised controlled trial or, at the very least, greater 
numbers of patients with comparable immune statuses.  
This pilot data shows a potential role for ribavirin in treatment of chronic norovirus 
infections but further studies are required to increase evidence of efficacy, optimise 
treatment regimens and compare new alternative agents such as favipiravir. 
Deep sequencing is a useful tool for analysis of mutation frequencies, with improved 
accuracy and cost effectiveness over conventional cloning and Sanger sequencing. At 
the time of specimen processing for this study norovirus full genome sequencing was 
not yet available; therefore this study used partial genome sequences amplified by 
PCR followed by deep sequencing. Future studies should assess the utility of full 
genome sequencing, such as described in Chapter 4, for the analysis of mutation 
frequencies across the norovirus genome.  
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 NOROVIRUS IN IMMUNOCOMPROMISED CHILDREN 7.1
The data presented in this thesis shows norovirus to be a leading cause of 
gastroenteritis in children, with the greatest burden falling on immunocompromised 
patients. Immunocompromised patients have the highest prevalence of infection 
compared to general medical and surgical patients, transmission clusters are 
dominated by immunocompromised patients which means they are involved in patient-
patient transmission more frequently than medical and surgical patients (Chapter 5) 
and they are the most likely to develop chronic infections (Chapter 3). 
Norovirus infections are associated with the highest viral titres and the highest rate of 
chronic infections compared to other gastrointestinal viruses (Chapter 3). It is 
interesting to note though that adenovirus, rotavirus and sapovirus are also associated 
with chronic infections, which anecdotally is seldom realised. Despite suggestions that 
B cells may be important for norovirus replication [24], immunocompromised children 
who lack B cells are equally susceptible to norovirus infection as those with B cells, 
albeit with a lower viral load (Chapter 3). 
There is an observed difference in the prevalence of infections caused by GII.3 in 
children and adults (Chapter 3 and Chapter 5), however the reason for this is not 
known. One possibility is that the two genotypes circulate in equal numbers in children 
and adults in the community, but GII.4s are more transmissible and thus are seen most 
frequently in nosocomial outbreaks, which are dominated by adults. The data 
presented in this thesis does not support this hypothesis; there is no difference in the 
number of patients involved in transmission clusters caused by GII.3 and by GII.4 
(Chapter 5). In fact, the number of patients involved in GII.3 clusters was slightly higher 
(38 and 33, respectively) despite observing fewer GII.3 clusters (6 clusters caused by 
GII.3 compared to 9 by GII.4) which suggests GII.4 is not more transmissible than 
GII.3. 
A genuine difference in the prevalence of GII.3 in children and adults could alternatively 
be explained by longer lasting immunity to GII.3 or differences in the presence of GII.3 
cellular receptors or co-factors between children and adults. Either possibility would 
result in fewer GII.3 infections in adulthood. For this to hold true one would expect to 
see a difference in the prevalence of GII.3 between children and adults in the 
community; since the distribution of norovirus genotypes in the community is not known 
this remains to be determined.  
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 CHRONICALLY INFECTED PATIENTS 7.2
The majority (79%) of chronically infected patients are immunocompromised (Chapter 
3). Given that some of the medical/surgical patients may also have some degree of 
immunosuppression, the exact proportion is probably higher.  
There is no difference in the viral titre between norovirus infections in 
immunocompromised and immunocompetent patients, nor is there a difference in the 
genotypes between acute and chronic infections (Chapter 3). Both of these 
observations suggest the establishment of chronicity in immunocompromised patients 
is host, not virus, mediated.  
Until now it has not been certain whether chronically infected patients are continuously 
infected with the same virus or whether re-infection occurs, especially in instances 
where there are periods of undetectable norovirus by real-time PCR. Full genome 
genotyping and phylogenetic analysis shows that re-infections do occur, especially 
following a period of undetectable real-time PCR. Nonetheless a relatively short period 
of undetectable norovirus (less than 2 months) can indicate persistence with the same 
virus (Chapter 5); in this instance the virus must persist in the stool at a very low level 
(below the limit of detection of PCR) or elsewhere.  
Although chronically infected patients who are continuously PCR positive are most 
likely to remain infected with the same virus (Chapter 5) super-infections do occur, 
leading to a period of mixed infection that can be detected during sequence data 
assembly (Chapter 4). Without regular genotyping of chronically infected patients these 
super-infections would not be recognised. The full clinical implication of super-infection 
is unknown however they do not appear to increase the duration of infection (Chapter 
5); this is perhaps unsurprising given that the establishment of chronicity in norovirus 
infections is not genotype mediated (Chapter 3). Regardless of the clinical implication 
to an individual patient, super-infections represent a breach of infection control. 
 SOURCES OF INFECTION IN A PAEDIATRIC HOSPITAL 7.3
Norovirus is notorious as a cause of nosocomial outbreaks during winter, dominated by 
GII.4 norovirus [128]. In the community we see a breadth of genotypes causing 
infection [130]; although the exact distributions of genotypes in the community is 
unknown the diversity seen in waste water contaminated with sewage [248-250] 
suggests that, unlike nosocomial infections, community infections may not be 
dominated by GII.4. 
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The occurrence of norovirus infections at GOSH, a paediatric tertiary referral hospital, 
is not seasonal. Instead the number of new infections correlates with the number of 
admissions, estimated to account for 50% of the variability in the number of new 
infections per month (Chapter 3). Given that community norovirus outbreaks do not 
follow a seasonal trend [119], this begins to suggest a community source of infection.  
Genotyping reveals a breadth of genotypes causing infection at GOSH, with only 39–
52% of infections caused by GII.4 (Chapter 5 and Chapter 3). Furthermore full genome 
phylogenetic analysis suggests that 69% of new norovirus infections are not acquired 
from another patient (Chapter 5). This points to a model of transmission in which there 
are frequent introductions of multiple strains, with limited onward transmission of each 
(Figure 7.1). 
Figure 7.1 Proposed transmission dynamics at paediatric tertiary referral hospital (GOSH), with multiple 
introductions of several different strains with limited transmission of each 
 
Combined with the lack of seasonality, the breadth of genotypes at GOSH suggests a 
community source of infection. A substantial proportion of this (45%) represents 
patients who were norovirus positive on admission (POA) thus represent infection prior 
to hospital admission, most likely whilst in the community or at another healthcare 
facility. Of the remaining 54% which were hospital acquired infections (HAI), the 
distribution of genotypes more closely resembles community norovirus infections 
(Chapter 3, Chapter 5). Half of the HAIs (57/101) are explained by nosocomial patient-
patient transmission; however the remaining HAIs, making up a quarter of all norovirus 
infections during the study period, have an unknown nosocomial source. This begs the 
question, what is the source of these infections? 
One explanation is transmission from staff with norovirus infections, since their 
infection will have been acquired in the community. However staff are unlikely to be the 
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main source of infection since they are present in all healthcare institutions, yet the 
epidemiology seen at GOSH differs to other healthcare settings (Chapter 5). 
Norovirus is an extremely diverse species, yet the reservoir in which the broad 
genotypes are maintained and from which new epidemic and pandemic strains arise is 
currently not known. Since there is no evidence of zoonotic transmission [16] an animal 
reservoir is deemed unlikely; current opinion is that the reservoir of norovirus diversity 
is within the human population [251].  The high level of intra-host norovirus diversity 
reported in immunocompromised patients, but not seen in immunocompetent 
infections, has led to suggestions that immunocompromised people may be a reservoir 
for norovirus diversity [52]. In particular a weak immune response, which fails to 
completely shut down viral replication (as in an immunocompetent person) but 
simultaneously provides selective pressure for escape mutants (unlike in profoundly 
immunocompromised people), is postulated to result in maximal intra-host virus 
adaptation and thus a reservoir of diversity [252]. An extension of this is the suggestion 
that malnourished and elderly individuals, with consequent weakened immune 
response, are a potential reservoir [251]. 
Another plausible reservoir for viral mixing is children in the community, who are 
estimated to experience four episodes of diarrhoeal disease per year [106] and in 
whom over 20% of under-five year olds experience sub-clinical norovirus infections 
[83]. Due to a maturing immune system, the immune response to a pathogen is weaker 
in a child than in an adult [253]. This comparatively weak immune response could 
maximise intra-host virus adaptation, creating a reservoir for norovirus infection and 
diversity.  
GOSH is a paediatric hospital, therefore the vast majority of visitors are patients’ 
parents, who may have other children at home or also visiting their sibling. If children in 
the community are a reservoir of norovirus infections and diversity they are a probable 
source of infection in a paediatric hospital such as GOSH, either directly or via their 
parents, thus accounting for the breadth of genotypes causing infection. Good hand 
hygiene is critical for control of norovirus [88], however adherence to hand hygiene in 
hospital visitors is estimated to be extremely low [254-256]. Even when alcohol hand 
sanitizers are placed in convenient locations in hospital lobbies, only 7% of visitors are 
observed using them when entering a hospital [254]. Randle et al. investigated hand 
hygiene (either with alcohol sanitizer or soap and water) on two paediatric wards; one 
oncology ward and one general medical/respiratory ward. Whilst hand hygiene rates 
were higher than was observed in hospital lobbies, they reported that only 38% of 
visitors adhered to hand hygiene, compared to 74–84% of healthcare professionals 
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[257]. This data, combined with less awareness of personal hygiene in children [258], 
supports parents and children as plausible vectors of infection in a paediatric hospital.   
Indirect transmission of norovirus, most likely via staff, visitors or contaminated fomites, 
plays an important role in norovirus nosocomial transmission (Chapter 5). To 
definitively identify the routes of indirect transmission sampling of staff, the environment 
and visitors is required, although this is unlikely to be practicable on a routine basis. 
Instead infection control efforts should be focused on hand hygiene by staff and visitors 
moving between wards but also careful consideration should be given to the movement 
of portable objects and equipment between wards.  
 FULL GENOME SEQUENCING IN CLINICAL PRACTICE 7.4
The advancement of sequencing techniques, from PCR with capillary sequencing to 
target enrichment with deep sequencing, has facilitated the use of norovirus full 
genomes in clinical practice. In conjunction with growing expertise, lower costs and 
faster turn-around times, full genomes can be sequenced for under £100 in less than a 
week (Chapter 4); this makes full genome sequencing a reality not just in academic 
settings but for informing public health practice in real time. The utility of generating full 
genome sequences is demonstrated in Chapter 5, in particular to identify transmission 
between patients who are separated by time, are on different wards, or who have not 
had direct contact, such as out-patients.  
The requirement for full genome sequencing is limited to immunocompromised 
populations, as in immunocompetent populations sequences between affected patients 
are conserved enough to allow phylogenetic analysis using partial sequences, namely 
the capsid P2 domain (Chapter 5). 
Despite the potential for affordable sequencing of full genomes, low sequencing costs 
can only be achieved by sequencing large batches of samples (48–96 samples) at a 
time. This is not feasible for individual hospitals that do not see such high numbers of 
new infections simultaneously; instead batch sequencing is better suited to a regional 
service. The limitation of a regional service is that turn-around times may be extended 
due to specimen transport time. Even so, the short incubation time for norovirus (12-48 
hours) means that sequencing, which at best takes 6 days, is unlikely to be informative 
in the context of an acute outbreak. Results from whole genome sequencing, or simply 
genotyping for that matter, can be acted upon in the context of an on-going 
uncontrolled outbreak to identify unrecognised routes and sources of infection. In the 
context of a fast-spreading outbreak the results may not be timely enough, however 
they will still be useful to retrospectively identify outbreaks. This retrospective 
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information will be useful to better focus infection control resources and practices and 
thus prevent future outbreaks from occurring.  
 TREATMENT OF CHRONIC INFECTIONS 7.5
Anti-viral treatment for norovirus has not been a priority due to the self-limiting nature of 
most infections, typically with limited sequelae. However immunosuppressed patients 
are at risk of chronic infections (Chapter 3) with significant associated morbidity 
(Chapter 6), therefore the development of effective antiviral treatment is important for 
this patient population. Reports to date of treatment with various agents have shown 
mixed success and often small patient numbers. Often these are case series reports, 
rather than randomised controlled trials (with the exception of nitazoxanide) therefore it 
is difficult to determine whether the treatment successes are directly due to the agent 
that was used. The use of ribavirin for treatment of two chronic norovirus infections 
presented in this thesis (Chapter 6) presents a similar picture; whilst it resulted in 
symptom resolution in both patients and viral clearance in one, it is difficult to ascertain 
whether this was directly due to the action of ribavirin. Deep sequencing data could be 
a useful technique to determine a direct effect due to lethal mutagenesis; however the 
small number of patients and fluctuating mutation frequencies in untreated patents 
makes the results difficult to interpret. Favipiravir appears to be a more promising 
candidate for the treatment of chronic norovirus infections, but the effectiveness in 
human infections is yet to be determined. 
Vaccination of vulnerable patients could be an effective way to prevent chronic 
infections in immunocompromised patients. Unlike the development of a specific 
antiviral agent, for which there is limited economic incentive due to the relatively small 
number of patients affected by chronic infections, a norovirus vaccine can also be used 
in immunocompetent people to reduce the global burden of acute infectious 
gastroenteritis as has been done successfully for rotavirus [259]. However vaccine 
development is hampered by short-lived immunity and antigenic variability. Current 
vaccine candidates only contain two genotypes, GI.1 and GII.4 [101]. Published in vitro 
data suggests these vaccine candidates elicit the production of cross-reactive 
antibodies, however the data presented in this thesis suggests this may not be the 
case in vivo in immunocompromised hosts. Patients for whom longitudinal norovirus 
positive samples were sequenced showed that whilst re-infection with the same 
genotype was not detected during the sampling period (with the exception of one 
patient with over a year in between infections), re-infection and super-infection with a 
different genotype did occur (Chapter 5). This suggests the immune response raised by 
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a norovirus infection may not be cross-protective across genotypes in this patient 
population; given the breadth of genotypes seen in a paediatric population (Chapter 3 
and Chapter 5) this is likely to be problematic for the control of norovirus in 
immunosuppressed patients; the extent to which this applies to immunocompetent 
hosts, and therefore the control of norovirus globally, is yet to be determined. Future 
vaccine candidates will require careful consideration of the choice and number of 
genotypes to be included, as well as the immune status of vaccine recipients.  
 DIRECTION OF FUTURE WORK 7.6
7.6.1 Genotyping of community infections  
Current estimates of diversity in community acquired norovirus infections are based on 
patients presenting to healthcare facilities, therefore have a presentation bias. To 
determine the role of community infections in norovirus transmission and nosocomial 
epidemiology, unbiased estimates of circulating genotypes are required. This could be 
achieved by genotyping archived norovirus positive stool samples from the Infectious 
Intestinal Disease Study 2 (IID2), a prospective population-based study in which people 
in the community were sampled longitudinally [113], or the MAL-ED study multi-country 
birth cohort with two-year longitudinal sampling [175]. The only limitation of the IID2 
study is that samples were collected in 2008 and 2009 therefore the circulating 
genotypes will likely have changed. Nevertheless the genotypes identified could be 
compared to retrospective data from Public Health England surveillance of nosocomial 
outbreaks during the same time period.  
7.6.2 Model for identification of transmission 
There are several factors to consider when investigating possible nosocomial 
transmission of norovirus; the relatedness of norovirus genome sequences from each 
patient (evaluated by phylogenetic analysis) and the in-patient histories of each patient 
(Chapter 5). The in-patient histories are important; if there is no plausible link between 
two patients, either in time or by location, then it may be that they are coincidently 
infected with the same virus rather than a transmission event having occurred. 
Conversely indirect transmission must be considered, such as attendance at out-
patient clinics or shared clinical teams across wards. A model that incorporates all of 
these pieces of information could be used by infection control teams to ascertain the 
likelihood of transmission between two patients having occurred and so is the focus of 
future work.  
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7.6.3 Chronic Viral Gastroenteritis study 
A study is currently underway at GOSH called the Chronic Viral Gastroenteritis Study, 
set up by myself and approved by the Brent NRES committee. The aim of the study is 
to assess the gut pathology in acute and chronic norovirus infections, including factors 
that may predispose patients to chronic infections. The study has recruited 59 patients 
undergoing bone marrow or solid organ transplant. Each patient has stool and urine 
specimens collected pre-transplant and monthly for one year following transplant. Gut 
inflammation, gut epithelial cell damage and stool microbial community diversity will be 
assessed to determine how these differ in acute and chronic norovirus infections. 
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